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Abstract 
 
Mosquito transmitted viruses (arboviruses) cause significant burden in much of the 
developing world.  Little is known about mosquito responses to viral infection, and 
how these responses could be utilised to prevent spread of viral disease.  Anopheles 
gambiae, the principal vector of human malaria, unusually transmits virtually no 
arboviruses, with one known exception - O’nyony-nyong Virus (ONNV).  In this thesis 
the interactions between ONNV and the A. gambiae immune system were studied.  
Initially ONNV infection in A. gambiae mosquitoes and an A. gambiae derived cell 
line were characterised.  The in vivo transcriptional responses of A. gambiae to viral 
infection were profiled using full genome microarrays, describing the global 
response to ONNV infection.  This thesis demonstrates that the A. gambiae immune 
system does respond to viral infection, with genes covering all aspects of immunity 
being differentially regulated, from pathogen recognition to modulation of immune 
signalling, complement-mediated lysis/opsonisation and immune effector 
mechanisms. 
 
Furthermore, this study identified four immune genes (a galectin, an MD2-like 
receptor and two lysozymes) regulated by ONNV infection that are capable of 
limiting virus during infection.  These genes have novel roles in anti-viral immunity, 
and suggest previously uncharacterised mechanisms for targeting viral infection.  
Additionally, it is shown that A. gambiae uses a combination of core conserved anti-
viral mechanisms, including RNAi, but does not utilise some signalling pathways 
reported to be anti-viral in other insects.  This indicates that species specific 
mechanisms target viral infection.  Finally this study demonstrates that foreign RNA 
acts as a Pathogen Associated Molecular Pattern (PAMP) in A. gambiae derived cells, 
and triggers transcriptional responses that dramatically reduce viral infection.  In 
conclusion the data presented in this thesis demonstrate that A. gambiae responds 
to and is capable of limiting viral infection through conserved and novel immune 
mechanisms triggered by recognition of viral infection and foreign RNA.      
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1.1 The importance of mosquitoes to human health 
 
Mosquitoes belong to the order of the two winged flies called the Diptera, Suborder 
Nematocera, Family Culicidae, where some 3000 or so species have been 
painstakingly grouped and ordered.  Mosquitoes have been living alongside, and 
biting, man for around one million years [1].  Though studied by many people for 
centuries, it is only in the past 100 years that research into mosquitoes has been 
intensified and become of great importance to human health.  This explosion of 
work was brought about by “the discovery that these flying visits could be the 
prelude to sickness and death; the realisation that this lowly creature, this 
insignificant gnat could be responsible for whole epidemics, epidemics that in the 
past had helped shape the course of human history” [1].  The idea that mosquitoes 
were responsible for disease transmission has arisen through a number of early 
observations; the first reference is from a Brahmin priest called Susruta, in 500 BC 
India, who declared that malaria was spread by mosquitoes[1].  More recently, in 
1572 Henry Hawkes wrote a report from Mexico in which he said that bites from 
mosquitoes inflicted newcomers to the area with sickness [1].  In 1848 Josiah Nott, 
an American doctor, suggested that both Yellow Fever and Malaria were spread by 
mosquitoes.  In a world where the concept of disease was based on miasmas or bad 
air, and where germ theory had yet to be developed, these ideas were largely 
forgotten.  In 1878 Sir Patrick Manson showed that the filarial worm Wuchereria 
bancrofti (the causative agent of elephantiasis) lived part of its life cycle in the 
mosquito, however he attributed the transmission of the disease to contaminated 
water from mosquito egg laying rather than direct transmission by the mosquito 
itself [1].   It was not until the discovery, and proof, by Ronald Ross in 1897 that 
mosquitoes were responsible for the transmission of malaria, a disease that has 
infected and killed people numbering hundreds of millions, that the study of 
mosquitoes changed forever.  In parallel, in 1881 a series of papers by Carlos Finlay 
on the spread of yellow fever by Aedes aegypti, and in 1900 a series of experiments 
by Sir Walter Reed proved that the transmission of yellow fever was carried out by 
mosquitoes alone[1].  Since the turn of the last century, mosquitoes have been 
  
 20 
shown to transmit more than 100 viruses, and dozens of parasitic infections, making 
them among the most important vectors of disease known to man (see Table 1).       
Table 1.  Examples of the human disease burden of mosquito species across the 
world 
 
Disease Infectious agent Mosquito vectors 
Parasites   
Malaria Protozoa; 
Plasmodium falciparum 
Anopheles spp 
 Plasmodium vivax Anopheles spp 
 Plasmodium ovale Anopheles spp 
 Plasmodium malariae Anopheles spp 
Elephantiasis Helminth; 
Wuchereria bancrofti 
Anopheles, Culex  and Aedes spp. 
Viruses   
Eastern Equine 
Encephalitis (EEEV) 
Virus Culiseta melanura Culex Melanoconion 
Venuzuelan Equine 
Encephalitis (VEEV) 
Virus Culex Melanoconion spp 
Western Equine 
Encephalitis (WEEV) 
Virus Culex tarsalis, Culex quinquefasciatus 
Chickungunya (CHICKV) Virus Aedes spp 
O’nyong-nyong 
(ONNV) 
Virus Anopheles gambiae/funestus 
Ross River (RRV) Virus Culex annulirostris Oculerotatis vigilax, 
Dengue Fever 1-4 
(DENV1-4) 
Virus Aedes aegypti, 
Aedes albopictus 
Japanese Encephalitis 
(JEV) 
Virus Culex tritaeniorhynchus, Culex spp 
St Louis Encephalitis 
(StLEV) 
Virus Culex quinquefasciatus 
West Nile  (WNV) Virus Culex spp 
Yellow Fever (YFV) Virus Aedes, Sabethes and Haemagogus spp. 
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1.2 Arboviral disease 
  
Viruses comprise the majority of infectious agents transmitted by mosquitoes.  
Arthropod-borne viruses (arboviruses) are defined as those multiplying within 
arthropod tissues after ingestion of infected vertebrate blood and transmitted by 
subsequent bites to other susceptible vertebrates [2]. Arboviruses mainly impact 
upon the developing world causing disease in humans, animals and livestock.  They 
represent an emerging and resurgent group of pathogens, increasing in both 
prevalence and geographical distribution [3]. Of those, many are mosquito-borne, 
including Chikungunya virus (CHIKV), Dengue virus (DENV), West Nile virus (WNV) 
and Yellow fever virus (YFV).  There are two main mosquito transmitted groups of 
arboviruses that are important for human health; the Flaviviruses and the 
Alphaviruses.   
1.2.1 Flaviviruses  
 
The flavivirus genus contains over 70 viruses, including DENV, Japanese encephalitis 
(JEV), WNV and YFV [4].  The name flavivirus is derived from the word yellow, 
referring to the jaundice caused by YFV [5].  The flaviviruses have a positive sense 
single stranded (+ss) ribonucleic acid (RNA) genome, encoding 10 genes; 3 structural 
proteins (capsid, envelope and membrane) and 7 non-structural proteins essential 
for genome replication [5].    
 
YFV is widespread across Africa, and since the introduction of the disease believed to 
have happen during the slave trade, in South America.  Sylvatic (jungle) cycles of 
transmission from primates are the sources of current epidemics, with multiple 
mosquito vectors being involved.  Urban cycles of YFV are transmitted by Ae. aegypti 
from person to person.  Ae. aegypti control programmes, as proposed by Finlay and 
Reed were successful in the eradication of urban cycles of YFV in Cuba, in Panama 
allowing the completion of the panama canal, in Rio de Janerio and subsequently in 
much of South America [1, 4].             
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Although an effective vaccine is available, developed in the 1930’s by Max Theiler[1], 
only 32 of 44 countries where YFV is endemic use the vaccine, and in many of these 
countries vaccine coverage is less than 50% [4].  Currently no effective anti-viral 
treatment exists, and although the majority of cases are mild, fatality rates from 
severe YFV are around 50% [4].  The WHO data indicates that 15-20% of reported 
cases of YFV are fatal.  The presence of capable mosquito vectors in much of Asia 
raises concerns that epidemics may arise from imported cases of the disease.       
        
Dengue Fever, caused by a group of 4 DENV flaviviruses, is among the most 
important emerging infectious diseases: estimates range from 50-100 million [6] to 
70-500 million [7] cases each year with more than 20,000 deaths, mainly in children 
[6-7]. Currently, DENV can be found in almost all tropical and sub-tropical regions, 
with regular epidemics in South-East Asia, the Caribbean and South America; no 
cases have been reported in temperate European countries in recent years [8]. DENV 
is predominantly transmitted by Ae. aegypti, however, Ae. albopictus is believed to 
be responsible for outbreaks in Japan, Indonesia, the Seychelles, Thailand, Malaysia, 
Indian Ocean Islands, Hawaii and China [9]. It is predicted that indigenous DENV 
transmission in Europe should be expected soon due to the presence of competent 
vectors and the frequent import of the disease [8].   To date no vaccine exists for 
DENV.  One of the complicating factors is the presence of 4 distinct serotypes within 
the DENV group.  Severity of disease often increases upon secondary infection with 
another DENV serotype, believed to be caused by antibody-dependent 
enhancement; antibodies bind to, but are unable to neutralise the virus, forming 
non-neutralizing antibody-virus complexes that bind to the Fc receptors of 
circulating mononuclear cells.  This facilitates virus uptake and results in higher viral 
loads than in primary infection [4].  Thus a vaccine must provide long term immunity 
to all 4 DENV serotypes to be effective.  Currently 5 DENV vaccines are in clinical or 
pre-clinical trials [7], and there are hopes that one of these will be widely availably 
by the mid-2010’s [4].   
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A number of other flaviviruses impact upon human health, mainly from the Japanese 
encephalitis serogroup.  Viruses from this serogroup share clinical and ecological 
features such as maintenance in enzootic cycles, usually between birds and Culex 
mosquito species [4].  Humans are ‘dead end’ hosts of these viruses i.e. human-
mosquito-human transmission is not observed, and infection often results in 
encephalitic disease [4, 10].  JEV is endemic to parts of Asia, where most of the 
50,000 annually reported cases orginate [10].  WNV is endemic in much of Africa, 
Europe, the Middle East, Central Asia, and has expanded across North America 
within the last decade[4].  Other members of the group can be found throughout 
Australia (Kunjin Virus, Murray Valley encephalitis, Alfuy viru), Africa (Usutu virus, 
Koutango virus, Yaounde virus) and South America (Cacipacore virus, St Louis 
encephalitis)[10].  The Flaviviruses represent an important group of diverse human 
pathogens, with a health burden across much of the world.                
1.2.2 Alphaviruses 
 
The alphaviruses are a genus of 30 enveloped RNA viruses that cause disease in 
human and domestic animals.  They are transmitted by mosquitoes or other 
haematophagous insects (Table 1)[11].  Similarly to the Flaviviruses, the Alphavirus 
genome consists of +ssRNA, encoding 4 non-structural proteins essential for genome 
replication, capsid and 2 envelope glycoproteins [11].  Viruses from this group with 
particular interest in terms of human health are CHIKV, Ross River virus (RRV), 
Sindbis virus (SINV), Eastern equine encephalitis (EEE), Venezuelan encephalitis (VEE) 
and O’nyong-nyong (ONNV).   
 
CHIKV was first isolated in the 1950s in East Africa [12]. Sporadic outbreaks were 
reported during the 1960’s-1980’s throughout much of Asia and in countries of 
Southern and Central Africa [13]. The primary vector was thought to be Ae. aegypti, 
while Ae. albopictus (the Asian tiger mosquito) acted as a secondary vector [14]. The 
Asian tiger mosquito has been spreading in geographical range rapidly; first 
identified in America in 1983, it invaded 36 States and several South American 
countries within 25 years, and currently is spreading through parts of Africa and 
Europe [9]. A huge epidemic of CHIKV occurred in the Indian Ocean in 2005-2006, 
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with over 3 million cases being reported in India and surrounding islands [15]. In 
2006, around 35% of the population in the French island La Reunion was infected 
[13].  Unusually during this epidemic, very few asymptomatic infections, and a 
relatively high mortality rate for CHIKV (1:1000) were observed, likely due to the fact 
that infected population had little or no immunity [4].  Fears emerged for outbreaks 
of CHIKV and other arboviral diseases in North America and Europe, as the Asian 
tiger mosquito (found in many parts of Europe) was identified as the major vector 
[13].  With increased tourism and the existence of local mosquito populations 
capable of transmitting arboviruses, we may expect epidemics with high morbidity in 
non-immune populations.  One year after the epidemic of CHIKV in Asia, around 200 
cases were reported in 2 small Italian towns on the Adriatic coast, demonstrating the 
first example of locally transmitted CHIKV by the Asian Tiger mosquito in Europe [16-
17]. This mosquito was introduced in Italy in 1990 through the importation of used 
tyres and has subsequently become endemic and widespread [18].  The most 
important feature of the 2005-2006 epidemic was a single amino acid substitution in 
the envelope protein of CHICKV that allows efficient transmission by both Ae. 
aegypti and Ae. Albopictus [4].  It was this variant that was locally transmitted in Italy 
in 2007, and it is believed this strain could cause further outbreaks in Europe and the 
Americas where Ae. albopictus is becoming widespread [4].          
1.2.2.1 ONNV epidemics – 1959 to the present day  
 
ONNV (family Togaviridae, genus Alphavirus, species O’nyong-nyong) is an unusual 
and rather elusive arthropod-borne virus [19].  Literally translated as ‘weakening of 
the joints’ or ‘joint breaker’, the disease causes fever, acute joint pain, 
lymphadenitus and rash [20].  In 1959 ONNV caused a huge epidemic beginning in 
north-west Uganda, and spreading to Kenya, throughout Tanzania, Malawi and 
Mosambique [21] infecting over 2 million people between 1959 and 1962 in East 
Africa alone [22-23].  Interestingly the disease affected all age groups with the same 
ferocity, indicating that no natural immunity was present in the population from 
previous infections [1].  Initially the disease was believed to be CHIKV [22] (a closely 
related alphavirus) that was responsible for an epidemic in Tanzania 6 years 
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previously [1], however serological tests confirmed the outbreak to be a different 
virus, named ONNV (Gulu strain)[24].  The principal vectors of the epidemic were 
determined as either Anopheles gambiae or Anopheles funestus mosquitoes [25] 
making ONNV the first and only discovered virus that is naturally transmitted by 
Anopheline mosquitoes.  Curiously the disease all but vanished for 37 years, re-
emerging in Uganda in 1996 [26-28].  During this time ONNV was sporadically 
identified in a small number of people [26, 28-29].  No animal reservoir of the 
disease could be found, and isolation of ONNV has only ever been possible from 
humans or mosquitoes [30].  An epidemiology study of ONNV carried out in Kenya by 
Marshall et al 1982 [31] declared that ONNV ‘transmission had virtually or actually 
ceased’.   
 
In 1996 ONNV suddenly re-appeared in Uganda.  The SG650 strain of ONNV was 
isolated during this epidemic.  Mosquito collections during the outbreak indicate A. 
funestus as the principal vector of the virus however only a small number of 
mosquitoes were found to be ONNV positive, and only 2 A. gambiae mosquitoes 
were caught during the study [26].  All modern research on ONNV derives from this 
1996 outbreak strain.  The virus was sequenced [27], and was found to be the same 
as Igbo ora virus, identified in a small number of people since the 1959 outbreak 
[28].  The virus is closely related to CHICKV, and is placed in the same seriological 
group as Semliki Forest virus (SFV) and RRV [27, 32].            
 
1.2.2.2 Virion structure, replication and transmission of ONNV 
 
The alphaviruses have been well characterised, primarily based on SINV, RRV and 
SFV, with high conservation across the Alphavirus family.  Thus the virion structure, 
replication and transmission of ONNV are based on that of the Alphavirus family, 
although some unknown differences may occur.  The virion consists of a single copy 
of the genome complexed with multiple copies of capsid protein, forming the 
nucleocapsid core [11].  The nucleocapsid core is surrounded by a host derived lipid 
bilayer embedded with multiple dimers of two glycoproteins; E1 and E2.  E1 and E2 
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dimers are arranged in trimers, each forming a spike on the surface of the virion [11].  
The replication cycle of the alphaviruses in vertebrate cells has been extensively 
studied and is reviewed by Strauss and Strauss [11].  The general replication cycle 
begins with entry to a cell, either via receptor mediated endocytosis, or direct fusion 
of the virus with the plasma membrane [33].  Virus particles in endocytic vesicles are 
believed to fuse with the endosomal membrane after exposure to the acidic pH of 
the vesicle.  Once free in the cell cytoplasm, viral replication begins [11].  The +ss 
viral RNA encodes 4 non-structural proteins (called nsP1-4) and 5 structural proteins 
(capsid, E1 and E2, E3 and 6K).  The genome is organised as a single open reading 
frame (ORF) that generates one of two possible polypeptides (see figure 1) in most 
alphaviruses.  This ORF comprises the 5’ two thirds of the genome.  P123 is believed 
to function as a proteinase that acts in trans (acting on other proteins) to process 
polypeptides involved in the replication process.  P1234 is formed by read-through 
of an opal stop codon used to produce P123, and forms the active replicase.  P1234 
is cleaved to form nsP1-4, as well as a series of intermediates all with distinct 
important functions in replication [11].  ONNV does not have an opal stop codon 
between nsP3 and nsP4, and produces only a single P1234 polypeptide [27].  A 
minus strand copy of the genome is produced, and is transcribed into the 26S 
subgenomic RNA, in which the structural ORF resides.  P130 polypeptide is translated 
and is cleaved in cis (cleaved by itself) to produce capsid protein, a precursor of E2 
later cleaved into E2 and E3, the small 6K protein and E1 (see figure 1).  In the early 
stages of infection, the non-structural genes are translated, and genome replication 
begins.  This process occurs in the cytoplasm of the infected cell, although replication 
complexes are associated with internal membrane structures within the cell [11].  
 
Each non-structural protein has a distinct function, along with their polypeptide 
intermediates[34].  nsP1 is required for the initiation or continuation of minus strand 
RNA synthesis.  It is also believed to be responsible for capping genomic and 
subgenomic RNAs during transcription, having been shown to have both 
methyltransferase and guanyltransferase activity [11].  The nsP2 gene is believed to 
be an RNA helicase, belonging to the same superfamily as the DEAD box helicases, 
with a role in RNA unwinding during replication and transcription [11].  nsP2 is also 
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thought to be the proteinase responsible for cleaving the non-structural 
polypeptides.  During SFV infection, around half the nsP2 produced is localised to the 
nucleus, where it’s function is unknown [11].  The nsP3 gene has a poorly 
understood function in viral replication [35].  It has two  
  
  
 
 
Figure 1. Genome organisation of the Alphaviruses – adapted from Strauss and 
Strauss [11].  The 49S genomic RNA is illustrated schematically in the centre, with its 
translated ORF shown as a medium blue box.  Small dark blue boxes are conserved 
sequence elements; the open diamond denotes the leaky opal termination codon.  
The non-structural polyproteins and their processed products are shown above.  
Termination at the opal codon produces P123, whose major function in replication is 
believed to be as a proteinase that acts in trans to process the polyproteins in active 
RNA replicases; this proteinase domain is found in the nsP2 region.  Readthrough of 
the opal stop codon produces P1234, which can form the active replicase.  The 26S 
subgenomic mRNA is expanded below to show the structural ORF (light blue box) 
and its translation products.  Structural polypeptides present in the virion are shaded 
purple.  Viral complementary (vc)RNA is the minus strand compliment of genomic 
RNA [11].    
 
   
  
 28 
domains; a highly conserved N-terminal macro domain with unknown function, and 
a highly variable and heavily phosphorylated C-terminal domain also with an 
unknown function [35].  nsP4 is the RNA-dependent RNA polymerase (RDRP) of the 
virus and is required for replication [11].  In vertebrate cells, early in infection, 
positive strand RNA (destined to be new genome copies) and negative strand RNA 
(the template for generation of the 26S subgenomic RNA and thus the structural 
genes) are generated, however minus strand synthesis ceases after a short time, and 
only positive strand RNA is generated throughout the rest of the infection.  It has 
been suggested that the switch from minus to positive strand synthesis may be 
regulated by the cleavage of polyproteins, with P123 + nsP4 generating negative 
strand RNA, and nsP1, nsP2, nsP3 and nsP4 generating positive strand RNA with both 
replication complexes requiring host factors [11].                     
 
The structural proteins are transported via the golgi to the plasma membrane [36].  
New viral cores assemble in the cytoplasm which then either diffuse to the plasma 
membrane, associate with the structural proteins, and bud from the membrane [11], 
or viral cores may fuse with secretory vesicles, forming new virus particles which are 
released when the secretory vesicle fuses with the plasma membrane [37].  Figure 2 
depicts the replication cycle of the Alphaviruses.     
 
Infection of insect cells differs in several ways to infection of mammalian cells. Most 
notably, several alphaviruses induce apoptosis of infected mammalian cells; 
however, this is not the case in insect cells [38]. It has been suggested that entry of 
the virus particles into the insect cells may occur via direct fusion with the plasma 
membrane rather than receptor mediated endocytosis [33]. Several studies on 
alphavirus infection of insect cells suggest that release of virus particles from cells 
may also differ; nucleocapsid cores in the cytoplasm are thought to form virus 
particles in internal membrane bound vesicles, subsequently being release during 
exocytosis [37, 39-40]. 
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Figure 2. Model of Alphavirus infection and replication in insect cells.  1) Mature 
infectious virions attach to the surface of the cell and enter either by receptor 
mediated endocytosis (clatherin-dependent or clatherin-independent) or by direct 
fusion with the plasma membrane. After receptor mediated endocytosis, the acidic 
environment of the endosome induces a conformational change in viral E1 and E2 
surface glycoproteins resulting in fusion with the endosomal membrane. The 
nucleocapsid core is released into the cytoplasm and capsid protein dissociates from 
the RNA genome. 2) Translation of the positive strand RNA genome produces the 
viral genes essential for genome replication. 3) Transcription (generating the 
negative strand RNA genome) and (4) subsequent translation produces the 
subgenomic RNA from which the structural genes are translated. 5) Viral proteins E1 
and PE2 are modified in the ER. E1 and E2 form hetero-dimers and are transported 
via the secretory pathway to the surface of the cell (7). Nucleocapsid cores form in 
the cytoplasm of the cell. Interactions between the E1/E2 hetero-dimers and capsid 
protein in the nucleocapsid core result in the budding of new mature virions (8). 
Alternatively assembled nucleocapsid cores may bud into vesicles containing E1/E2 
heterdimers, forming mature virions that are released from the cell when these 
vesicles fuse with plasma membrane (6).  
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1.2.2.3 Alphaviruses in the laboratory: a model group for molecular biology 
studies 
 
Several alphaviruses have been made into Alphavirus Transducing systems (ATSs).  
ATSs use a complementary deoxyribonucleic acid (cDNA) copy of the viral genome to 
generate a plasmid containing the full length cDNA copy of the viral genome flanked 
with a promoter sequence, such as T7 or SP6.  The first nucleotide of the viral 
sequence is modified to allow for the addition of a cap analogue [19].  The advantage 
of using a cDNA copy of the viral genome for genetic manipulation and amplification 
is the reduction in error rate gained from using a DNA polymerase compared to an 
RDRP.  The plasmid is lineraised using a unique restriction enzyme site, and is subject 
to in vitro transcription.  The resulting infectious clones of the virus are capped and 
then either electroporated or transfected into cultured cells (see figure 3)[19].  ATSs 
typically have very similar tissue tropism and replication rates as wild-type viruses 
[41-42].  They offer the advantage of being able to produce ‘fresh’ virus without 
serial passage of wild-type viruses, which results in quick adaptation to the 
conditions of culture and alterations in the original sequence of the virus.  ATSs have 
been generated for SINV, CHICKV, ONNV, SFV, RRV and VEEV [19, 41-47].  The 
plasmid containing the cDNA infectious clone of the virus can be easily manipulated 
genetically.  Two manipulations are common, one is the insertion of a gene of 
interest (GOI) and the second is the insertion of an RNAi cassette that can be used to 
silence GOIs.  Both require the insertion of a multiple cloning site, usually under the 
control of a duplicated viral subgenomic promoter [19].  There are many examples of 
ATSs that have been used to introduce genes, including: a SINV ATS expressing 
scorpion toxin [43]; a SINV ATS expressing an anti-circumsporozoite protein antibody 
which successfully prevents Plasmodium gallinaceum sporozoites from invading the 
salivary glands of infected mosquitoes [44]; GFP expressing chimeric viruses used to 
study viral components essential for different vector/virus combinations [45].  
Additionally ATSs have been used to silence GOIs, including a SINV ATS expressing 
dsRNA against the luciferase reporter gene [46], and a SINV ATS expressing dsRNA 
against DENV virus successfully preventing DENV infection in SINV infected 
mosquitoes [47].  Brault et al 2004 [42] have generated several ATSs encoding 
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infectious clones of ONNV, including p5’dsONNVic-Foy, containing a full length cDNA 
clone of the SG650 strain of ONNV, a multiple cloning site and a duplicated viral 
subgenomic promoter.  This plasmid has been used to generate infectious clones 
that express enhanced GFP (p5’dsONNVic-eGFP).  Studies in this thesis have 
predominantly been carried out using this infectious clone of ONNV.   
 
 
 
 
 
Figure 3. Generation of ATSs and production of infectious clones.  Taken from Foy 
et al 2006 [19].  The full sequence of an Alphavirus is used to generate a full length 
cDNA copy of the viral genome (non-structural ORF is represented by the blue box, 
the structural ORF is represented by the yellow box).  The full length cDNA copy is 
cloned into a plasmid (pX) and a unique restriction site is introduced.  Additional 
markers, genes of interest or RNAi probes can be cloned into the viral genome 
(green box).  Plasmid is linearised using the unique restriction site.  In vitro 
transcription is performed and the resulting RNA is capped.  Capped RNA is either 
electroporated or transfected into cells where the RNA clone replicates, eventually 
releasing recombinant infectious clones of the Alphavirus, which will go on to infect 
and replicate in other cells [19].   
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1.3 Mosquito innate immunity 
 
Insects are exposed to a wide variety of pathogens both from within their natural 
habitats, and through their life cycles.  In order to combat a barrage of microbial 
attack, insects have evolved a multifaceted innate immune response including 
physical barriers to infection  (the thick and strong chitin cuticle) and a number of 
cellular and humoral innate immune effector mechanisms [48].  Invading pathogens 
are subject to attack from potent anti-microbial peptides (AMPs), the majority of 
which function by attacking the membrane surface of the pathogen causing lysis.   
Pathogens are recognised by pattern recognition receptors (PRRs) and are 
subsequently lysed by complement-like factors or phagocytosed by hemocytes - the 
insect equivalent of white blood cells.  Additionally pathogens can be melanised 
(captured within a network of cross-linked proteins) or undergo cellular 
encapsulation by hemocytes.  Recognition of pathogens also triggers immune 
signalling cascades, resulting in the up-regulation of immune genes, including anti-
microbial peptides.  The immune response of insects can be both systemic and/or 
localised [48].   
 
1.3.1 Vector immune responses to Arboviruses 
 
Insect immunity is a research field largely developed in the last two decades 
providing advanced understanding of anti-bacterial, anti-fungal and, more recently, 
anti-parasitic immune responses [49]. Considering the immense health and 
economic burden caused by viruses transmitted by insect vectors [3], it is perhaps 
surprising that anti-viral immunity has not received similar attention.  The majority 
of studies on anti-viral immunity in insects have been conducted in the model insect 
Drosophila melanogaster.  To date three immunity pathways have been implicated in 
D. melanogaster anti-viral responses (reviewed in [50-53]).  The Toll pathway, known 
for its involvement in responses to Gram-positive bacteria and fungi [54], is activated 
by viral infection, and Toll or Dif loss-of-function mutants exhibit increased 
susceptibility to the infection [55]. It has been proposed that the function of the Toll 
pathway during a viral infection is to signal to the fat body and hemocytes, thus 
  
 33 
enhancing the innate immune response. In response to a viral infection, specific 
genes are also up-regulated via the JAK/STAT (Janus kinase/signal transducers and 
activation of transcription) pathway, such as vir-1 (viral induced RNA 1)[56]. Loss-of-
function of JAK/STAT signalling leads to increased susceptibility to infection. Finally, 
the RNA interference (RNAi) pathway has been shown to modulate the replication of 
RNA viruses in D. melanogaster. Loss-of-function of several components of the RNAi 
pathway including Dicer-2, Argonaute-2 (Ago2) and Armitage increases the 
susceptibility of flies to arboviruses [57-61]. 
The power of genetics and the generated extensive knowledgebase in Drosophila 
were invaluable in establishing the foundations for insect anti-viral immunity 
research. However, the biology of arboviruses is tightly linked to the physiology of 
haematophagous arthropods, and as such research in model organisms may not be 
fully relevant to the transmission of viruses and the associated vector defence. The 
immune responses of mosquitoes to malaria parasites can serve as a very good 
example. Several A. gambiae genes have been identified to date, which confer 
resistance to the rodent malaria parasite, P. berghei. However, the majority of these 
genes have no orthologs in Drosophila, e.g. Leucine rich repeat immune protein 1 
(LRIM1) and APL1C [62-64], the thioester-containing protein 1 (TEP1) and numerous 
clip-domain serine proteases (CLIPs) and their inactive homologs, serpins (SRPNs) 
and C-type lectins (CTLs), which are implicated in parasite melanisation [65-67] 
Therefore, a forward research approach is required to effectively study the vector 
responses to arboviruses, utilising findings in Drosophila as guidance. Such early 
studies are reviewed below, which ought to be intensified in the future.  
 
1.3.2 Responses of the JAK/STAT pathway 
 
The JAK/STAT pathway was first identified in Drosophila via its role in embryo 
segmentation [68]. It begins with the circulating ligand Unpaired (Upd) that binds to 
the transmembrane receptor Domeless (Dome). Upd-bound Dome forms dimers 
activating the tyrosine kinase Hopskotch (or JAK), which in turn phosphorylates the 
transcription factor STAT92E leading to its nuclear translocation and up-regulation of 
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STAT-regulated genes [69]. In mammals, the homologous signal transduction 
cascade regulates the expression of over 30 cytokines and growth factor signals 
important during viral infection [70].   
 
 
 
Figure 4. The JAK/STAT pathway in A. gambiae.  The pathway begins with a ligand 
(currently not identified in A. gambiae, dUpd refers ligand of the D. melanogaster 
JAK/STAT pathway) that binds to the receptor DOME.  Bound DOME activates the 
kinase Hopskotch (HOP), which in turn phosphorylates and activates the 
transcription factor STAT.  Phosphorylated STAT translocates to the nucleus and 
switches on expression of STAT responsive genes.  PIAS is a negative regulator of the 
JAK/STAT pathway.     
 
In mosquitoes, orthologues of Dome, Hopskotch, and STAT92E have been identified.  
The ligand of the pathway, UPD, has yet to be discovered, likely due to the variable 
nature of receptor ligands, their small size, and the little sequence level homology.  
Figure 4 outlines the JAK/STAT pathway in A. gambiae.  Recent evidence suggests 
that the JAK/STAT may have a conserved function in mosquitoes.   
 
 In a study characterising two mosquito STATs it was observed that infection of an 
Ae. aegypti C6/36 cell line with JEV led to decreased STAT activity in nucleus extracts.  
Experiments using a phosphatase inhibitor suggested that in the JEV-infected cells, 
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STAT phosphorylation is inhibited, probably through the induction of cellular 
phosphatase(s) or inactivation of JAK or other tyrosine kinase(s) by viral products 
[71].  The inhibition of the JAK/STAT signalling suggests that this pathway exerts 
enough evolutionary pressure on the virus to result in a possible inhibitory 
mechanism during infection.     
 
A study by Xi et al 2008 [72] investigated the genome-wide transcriptional responses 
of Ae. aegypti midguts and carcasses 10 days after natural DENV infection. It showed 
that a large proportion of the differentially regulated genes (~1/3) were known or 
putative immune genes belonging to multiple immune pathways and effector 
mechanisms, with a bias towards genes involved in the Toll pathway and the 
JAK/STAT pathways. In the carcass of DENV infected mosquitoes, DOME was up-
regulated as well as an ortholog of the D. melanogaster SOCS36E. The latter cytokine 
is known to be a downstream target of the JAK/STAT pathway in D. melanogaster 
and functions to suppress further activation of the pathway [73]. A hypothetical 
protein, with a JAK/STAT related ortholog in D. melanogaster was down-regulated in 
both infected midgut and carcass tissues.  Additionally a metabotropic glutamate 
receptor was up-regulated in infected carcasses; an ortholog of D. melanogaster mXr 
that was shown to have an inhibitory role in the JAK/STAT pathway in a genome 
wide RNAi screen [74].  The increase in transcripts of DOME and a gene putatively 
downstream of the JAK/STAT pathway indicate that viral infection triggers JAK/STAT 
signalling in the carcass of the mosquito.  The increase in transcripts of two negative 
regulators of the pathway indicates that by 10dpi, negative feedback of the JAK/STAT 
pathway is in effect.  Souza-Neto et al 2009 [75] subsequently showed that Ae. 
aegypti can be made more, or less susceptible to DENV infection by silencing a 
positive (DOME) and negative (PIAS) regulator of the JAK/STAT pathway, thus 
demonstrating that the JAK/STAT pathway regulates DENV infection in Ae. aegypti 
mosquitoes.  In order to dissect the downstream targets of the JAK/STAT pathway 
that have anti-viral effects, the authors carried out microarray analysis of PIAS 
depleted mosquitoes, and compared the differentially regulated genes to those 
regulated by DENV infection in Ae. aegypti mosquitoes.  They found 18 genes that 
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were transcriptionally regulated in the same direction by DENV infection, and 
JAK/STAT activation.  A selection of these genes were silenced in Ae. aegypti 
mosquitoes to see if they had an anti-viral function, of which two genes tested so far 
are demonstrated to be anti-DENV factors [75].  One of these genes has a 
transmembrane domain, possibly suggesting a receptor function.  The other gene 
shares homology with the A. gambiae cuticular proteins (CPF) 1 and 2.  How these 
genes function to reduce viral infection in the mosquito is not known.   
 
In a study of SFV in an Ae. albopictus derived cell line (U4.4), activation of the 
JAK/STAT pathway, as well as the Toll and IMD pathways, was investigated [76].  It 
was shown that viral infection of cells did not induce any STAT dependent immune 
signalling.  However putative activation of STAT (and IMD) signalling, by heat treated 
bacteria, prior to infection reduced viral gene expression from both the genomic and 
subgemonic promotors by around half (as demonstrated using recombinant viruses 
encoding luciferase), and also inhibited genome replication by 40-60% (as 
demonstrated by real time quantitative PCR (qrt-PCR)).  It is not clear from this study 
which signalling pathway induced by treatment with heat-inactivated bacteria is 
responsible for the decrease in viral gene expression and replication.  Numerous 
immune mechanisms have a role in targeting gram negative bacteria, including the 
IMD pathway regulated AMPs, TEP1 and CLT1 in conjuction with CTLMA2[49].    
However, it is possible that STAT signalling is responsible for the reduction in viral 
replication.  In summary, to date there is evidence that the JAK/STAT pathway 
regulates the expression of anti-viral immune effectors in Ae. aegypti, however no 
evidence in A. gambiae has been published. 
     
1.3.3 RNAi pathway 
 
The RNAi pathway is triggered by double stranded (ds) RNA molecules of various 
lengths. It begins with the cleavage of dsRNA, either by Dicer 1 (endogenous dsRNA) 
or by Dicer 2  (other dsRNA) (figure 5) complexed with R2D2[77] .  Dicer 1 and Dicer 
2 belong to the RNase III gene family, and contain an N-terminal helicase domain, 
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two RNase III like domains and a C-terminal RNA binding domain [59].  Processed 
dsRNA can take one of several forms – short interfereing (si) RNAs, repeat associated 
short RNA’s (rasiRNAs) and micro RNA’s (miRNAs).  dsRNA generated by virus 
replication or by hybridisation of overlapping transcrips (e.g transposons) leads to 
the production of rasiRNAs and siRNAs, which generally target homologous mRNA 
for degradation [78].  Endogenous transcripts that contain homologous regions 
forming dsRNA hairpains lead to the production of miRNAs, which generally target 
homologous mRNA for translational silencing [78].  RNAi was quickly recognised as a 
mechanism to prevent or slow the replication of RNA viruses; however it also has an 
important role in the regulation of gene expression [78].      
 
After processing, the small RNA fragments are incorporated into complexes (RNA 
induced silencing complex (RISC) or mi ribonucleoprotein (miRNP) complex).  
miRNAs are incorporated into miRNP and function in gene regulation whereas 
siRNAs are incorporated into RISC which targets transposon, and virus, replication.  
RISC contains several proteins; Ago2, which targets and destroys homologous RNAs; 
tudor-SN (TSN), which cleaves non-specific ssRNA, cleaves hyper-edited dsRNA 
substrates and has an undefined role in anti-viral defence;  Vasa Intronic Gene (Vig), 
which binds RNA but has a poorly defined role in anti-viral defence and endogenous 
gene regulation [79] and other unidentified proteins [77].  Figure 5 summarises the 
model of the RNAi pathway in D. melanogaster.       
 
The first evidence of RNAi mediated anti-viral mechanisms in mosquitoes came from 
Keene et al 2005 [80]. In this study the role of RNAi in response to ONNV infection in 
A. gambiae mosquitoes was investigated. A recombinant virus that expresses GFP 
(ONNVic-eGFP) was used during investigations as a marker of infection.  Initially it 
was demonstrated that RNAi was capable of modulating virus replication through 
dsRNA mediated silencing of the viral nsP3 gene, which efficiently reduced viral 
replication and titres in A. gambiae mosquitoes. Several components of the RNAi 
pathway, belonging to the Argonaute family, were silenced during infection by co-
injection of dsRNA homologous to these genes and ONNVic-eGFP. AGO2 silenced  
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Figure 5.  The RNAi pathway.  Primary miRNA transcripts are processed to miRNA 
precursors in the nucleus by the RNase-III-like enzyme Drosha. The miRNA precursor 
is subsequently exported to the cytoplasm by means of the export receptor exportin-
5. The miRNA precursor is further processed by Dicer to siRNA-duplex-like 
intermediates. The duplex is unwound while assembling into miRNP/RISC. Mature 
miRNAs bind to Ago proteins, which mediate translational repression or cleavage of 
target mRNAs. Other sources of long dsRNA in the cytoplasm of a cell are viral RNAs, 
artificially introduced dsRNA, dsRNAs generated by RdRPs, and genomic sense and 
antisense transcripts. Like miRNA precursors, long dsRNA is processed by the RNase 
III enzyme Dicer into 21–23 nucleotide dsRNA intermediates. Assisted by the RNA 
helicase Armitage and R2D2, the single-stranded siRNA-containing RISC is formed. 
The stability of the dsRNA and its recognition by Dicer can be regulated by specific 
ADARs and the exonuclease ERI-1. Taken from Meister and Tuschl [78].     
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mosquitoes showed significantly increased GFP expression and viral titres. AGO2 is a 
protein involved in the incorporation of dsRNA into the RISC complex during the 
RNAi pathway [81]. It is hypothesised that mosquitoes not expressing the AGO2 gene 
are unable to incorporate viral dsRNA into the RISC complex and are therefore 
unable to target viral dsRNA for degradation and reduce the rate of viral replication.  
In A. gambiae there are several other members in the Ago family – AGO1, AGO3, 
AGO4 and AGO5. Their role in RNAi was also investigated by Keene et al [80]. It was 
found that only AGO3 dsRNA treated mosquitoes demonstrated increased viral 
dissemination and viral titre. Campbell et al 2008 [82] investigated the role of RNAi 
against two different recombinant forms of SINV in Ae. aegypti mosquitoes. They 
demonstrated that silencing of three proteins involved in the RNAi pathway, AGO2, 
DCR2 and to a lesser extent TSN, resulted in higher titres of a moderately infective 
SINV strain, indicating that AGO2 and DCR2 have clear roles in inhibiting viral 
replication in Ae. aegypti mosquitoes, although silencing of these genes did not have 
an impact on mosquito mortality after viral infection. Importantly Campbell et al [82] 
demonstrate the presence of small viral RNA fragments in infected mosquitoes 
indicating that RNAi is active specifically against viral RNA. Interestingly siRNA’s could 
be seen using the moderately infective strain; however a more infective strain 
showed a reduced build up of siRNA’s. This suggests that RNAi activity is limiting 
infection of one strain but not the other, pointing to a difference in RNAi 
susceptibility or the presence of an RNAi inhibitor in the more infective strain. They 
also observed more siRNAs generated from the positive sense RNA strand than the 
negative sense, indicating that secondary structure in the + RNA strand may be the 
target of RNAi as opposed to +/- dsRNA replication intermediates, although this is 
speculative. From investigations into effects of infectious blood meals on RNAi 
component transcript levels, Campbell et al [82] suggest that TSN may act as a 
sensor for the RNAi pathway.  
 
RNAi mediated gene knock down of several key components of the RNAi pathway in 
Ae. aegypti also leads to increased DENV viral titres [83].  In particular Dicer-2, the 
enzyme that cleaves dsRNA, was shown to decrease the extrinsic incubation period 
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of the virus, and increase viral titres in the midgut, carcass and saliva of infected 
mosquitoes [83].  Mosquitoes infected with DENV showed staining with a dsRNA 
specific antibody in infected midguts, and virus specific 21-22nt length siRNAs were 
observed in infected carcasses indicating that viral infection leads to the production 
of dsRNA and the generation of siRNA’s during RNAi [83].   
 
Myles et al [84] carried out a study looking at the siRNA generated by Alphavirus 
infection and its role in the outcome of infection in several vector-virus 
combinations.  Initially focusing on SINV infection of Ae. aegypti, and using libraries 
of siRNAs generated from SINV infected and uninfected mosquitoes they 
demonstrated a peak at 21 nucleotides of viral specific siRNAs (viRNAs).  They also 
used a recombinant SINV containing the suppressor of RNAi B2 protein from Flock 
House Virus (FHV) (SIN-B2).  This recombinant virus had very little accumulation of 
viRNAs.  Mapping the viRNAs to the SINV genome demonstrated an asymmetric 
distribution across the genome, indicating ‘hotspots’ for viRNA generation, and also 
revealed that viRNAs were more often generated from the positive strand than the 
negative.  In a series of experiments using SIN-B2 and a recombinant virus containing 
a mutant of B2 that is unable to bind to RNA (SIN-B2mut), the authors demonstrate 
that the presence of the functional suppressor of RNAi leads to a build up of genomic 
and subgenomic RNA compared to the mutant, and a reduction in viRNA 
accumulation compared to the mutant [84].  SIN-B2 was also shown to increase 
mortality in infected mosquitoes compared to the mutant.  Similar results were 
observed by Cirimotich et al 2009 [85] where a recombinant SINV containing the FHV 
B2 protein caused higher mortality and increased viral titres in Ae. aegypti 
mosquitoes.  Additionally, decreases in viRNA accumulation and increases in 
genomic and subgemonic RNAs were also observed using the recombinant virus by 
Cirimotich et al [85].  Myles et al 2008 [84] also demonstrated that a recombinant 
ONNV containing the repressor of RNAi B2 protein from Nodamura Virus (NoV) 
causes increased mortality when intrathoracically inoculated in A. gambiae 
mosquitoes, which led to increased prevalence of infection after infectious 
bloodmeals.     These data demonstrate the ability of RNAi in the absence of a 
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repressor to regulate viral infection loads, which is critical in maintaining the balance 
between pathogenicity and persistent infection.  These data also demonstrate that 
introducing an inhibitor of the RNAi pathway and allowing viral infection to increase 
leads to mortality and morbidity that is not usually seen in Arbovirus infection of 
invertebrate hosts.     
 
RNAi in plants is systemic i.e. the RNAi signal spreads from a site of infection to distal 
parts of the plant, and so can reduce or prevent viral infection in other parts of the 
plant [86].  Plants typically use RNA dependent RNA polmerases (RDRPs) to amplify 
the dsRNA signal [86].  Insects however lack the RDRP’s necessary to do this, but 
there is some evidence of RNAi signals spreading in insects [87].  Limited evidence of 
localised spreading of the RNAi signal has been observed in an Ae. albopictus derived 
cell line [88].  In a series of experiments using the Renilla/Luciferase (RLuc) reporter 
system, siRNA’s against RLuc and several modified SFV viruses expressing RLuc siRNA 
and GFP, the authors initially found that SFV cannot interfere with existing RISC 
complexes and cannot inhibit RNAi mosquito cells.  They went on to show that by 
mixing cells transfected with a) the reporter gene and b) siRNA against the reporter 
gene, the siRNA ‘signal’ could be transferred to a neighbouring cell i.e. siRNA from 
one cell can silence the reporter gene in a neighbouring cell, provided that cells were 
plated at high density with many cell to cell contacts.  They further demonstrated 
the spread of siRNA using fluorescin-labelled siRNA, and found that infecting cells 
with truncated viruses (capable of infecting cells, but unable to make progeny virus) 
and mixing them with cells infected with a virus containing a reporter gene, resulted 
in significant reduction in expression of the reporter gene, an observation that was 
reversed when a RNAi inhibitor was also expressed by the reporter virus [88].  
Whether these effects are the result of genuine cell to cell communication, or are a 
by-product of the physical techniques used, such as scraping cells, which can cause 
significant damage to cell membranes, remains to be demonstrated convincingly.               
 
Another virus shown to be effected by RNAi is YFV.  Stable mammalian cell lines 
expressing siRNAs specific to the YFV have shown an inhibition of YFV infection 
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ranging from 11-97% depending on the region of the genome targeted by the siRNA 
[89].  Additionally the authors demonstrate that pre-treating mice with plasmids 
expressing these siRNAs prior to YFV infection reduces both morbidity of infection 
and mortality [89].  This is one of a small number of studies that support a role for 
RNAi in anti-viral defence in mammalian systems.  Currently, however, it is though 
not to play a significant role, with the interferon response being the primary anti-
viral response in mammals [84, 90].       
 
These studies are the first steps to elucidating and understanding the RNAi anti-viral 
pathway in mosquitoes. As Keene et al [80] point out; different mosquitoes may vary 
in their RNAi response to viruses. A. gambiae is known to have a strong RNAi 
response to dsRNA, indicating that they may have a particularly robust RNAi 
response. Keene et al [80] suggest that this could explain why A. gambiae is a poor 
vector of arboviruses. Although it has been shown by Campbell et al [82] that Ae. 
aegypti does use RNAi against SINV infection, the effects of silencing RNAi 
components in Aedes on viral infection seems weaker; gene silencing was shown to 
be transient, with gene expression and viral titre returning to normal 7 days after 
dsRNA treatment. This differs from the similar study by Keene et al, in which it was 
demonstrated that viral titres were significantly higher in dsRNA treated mosquitoes 
six days after treatment. Silencing RNAi in A. gambiae also appeared to increase 
prevalence of viral infection to a greater extent than in Ae. aegypti. It has been 
noted that ONNV will readily infect Ae. aegypti mosquitoes, but conversely SINV 
cannot infect A. gambiae mosquitoes [80]. Some of these observations may simply 
be a result of the different vector-virus combinations (for example the presence or 
absence of a receptor required for infection or a virally encoded suppressor of RNAi).  
They do, however, support the idea that the vector competence of mosquitoes may 
be in part dictated by RNAi responses to viral infection.  It has been shown from the 
several studies using repressor of RNAi proteins that the ability of the mosquito to 
generate viRNAs, and thus regulate the viral load of infection, is critical in 
maintaining a balance between low level infection and pathogenicity or mortality, 
and thus is critical in defining the vectorial capacity of the mosquito.         
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1.3.4 Toll pathway 
 
The Toll pathway was first identified as being involved in the control of dorsoventral 
polarity in early embryogenesis of D. melanogaster [91]. In Drosophila it appears to 
have evolved a dual role, with one in nine Toll receptors being used in immune 
signalling rather than in developmental signalling [92]. In Drosophila the Toll immune 
signalling pathway begins with the recognition of a pathogen by a PRR. Gram 
negative binding protein 1 (GNBP1) and peptidoglycan recognition protein SA (PGRP-
SA) are believed to be the PRR’s involved in the Toll response to Gram-positive 
bacteria, possibly forming a complex that activates a proteolytic cascade resulting in 
the cleavage of a cytokine – Spatzle [93]. The cleaved form of Spatzle then binds 
directly to the Toll receptor and triggers an intracellular signalling cascade [94].  
 
 
 
Figure 6.  The Toll pathway in A. gambiae.  Cleaved Spatzle binds to the 
transmembrane receptor Toll, resulting in the recruitment and activation of a 
cascade of signalling molecules, including MYD, TUBE, and PLL1.  CACT, the inhibitor 
of REL, is degraded, freeing the NF-kB-like transcription factor REL1 to translocate to 
the nucleus and promote transcription of REL responsive genes.  Genes with 
unidentified orthologs in A. gambiae are given the D. melanogaster gene name with 
the pre-fix d.           
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The direct binding of Spatzle alters the conformation of the Toll receptor resulting in 
intracellular recruitment of several proteins – MYD88, Tube and Pelle. Signalling 
downstream of these molecules results in the disassociation of the NF-κB like Dif 
from its I-κB like inhibitor, Cactus, which is degraded, possibly by Pelle [95]. Once 
Cactus has been degraded, Dif is free to translocate into the nucleus, where groups 
of genes, including immune genes such as Drosomycin, are up-regulated [96].  In A. 
gambiae the NF-κB protein in the Toll pathway is REL1.  Figure 6 outlines the Toll 
pathway in A. gambiae mosquitoes.   
 
In a study by Sanders et al 2005 [97] DNA microarray analysis of 2170 Aedes genes at 
three time points was carried out during infection with SINV.  It was observed that 
viral infection leads to the up- or down-regulation of several known and putative 
innate immune genes. These include the Ae. aegypti dif gene (Aedif, an NF-kB like 
protein involved in the signal transduction of the Toll pathway), which was up-
regulated early in infection; four chitin binding proteins similar to plant and 
horseshoe crab AMPs; several serine proteases and zinc-dependent proteases, as 
well as notable changes in some signalling molecules (such as membrane receptors, 
aGTPase, kinases, phosphatases, and transcriptional regulators).    
 
Sanders et al [97] speculate that the early up-regulation of Aedif, and a subsequent 
return to normal transcript levels at 4 and 8  days post infection (dpi), indicates that 
viral infection leads to activation of the Toll pathway, which is later inhibited. They 
speculate that the down-regulation of an ubiquitin ligase, Cullin-1, may lead to the 
inhibition of the Toll pathway via decreased degradation of the dif inhibitor, Cactus. 
Inhibition of unbiquitin ligase complexes and thus activation of the Aedif may be a 
mechanism by which SINV avoids Toll-mediated anti-viral responses; similar 
mechanisms have been observed in HIV-1 and Tobacco mosaic virus (TMV) infections 
[97]. 
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As previously mentioned in respect to the JAK/STAT pathway, a microarray based 
study by Xi et al [72] of DENV infected Ae. aegypti mosquitoes showed a strong bias 
towards genes involved in the Toll and JAK/SAT pathway: Spatzle, Toll, Rel1A and 
Cactus were differentially regulated at 10 dpi.  A comparison was performed 
between DENV induced gene expression and genes differentially regulated by two 
immune signalling pathways in Ae. aegypti.  Cactus, a negative regulator of the Toll 
pathway, and Casper, a negative regulator of the IMD pathway, were knocked down 
(KD) using RNAi, and gene regulation was analysed using microarrays. A small 
overlap between DENV induced and Casper KD induced genes was observed (9%), 
however 41% of DENV induced genes overlapped with Cactus KD induced genes. Xi 
et al [72] went on to investigate the effect of activation or silencing of the Toll 
pathway on DENV infection in Ae. aegypti mosquitoes. Silencing of Cactus, the 
negative regulator of the Toll pathway, prior to DENV infection resulted in a 4-fold 
decrease of virus in mosquito midguts 7 dpi. Silencing of Myd88, a positive regulator 
of the Toll pathway, prior to infection resulted in a 2.7 fold increase in virus. 
Silencing of Caspar, a negative regulator of the IMD pathway, had no effect on viral 
infection. These results suggest that viral infection leads to the activation of the Toll 
pathway, but not the IMD pathway, and that the Toll pathway regulates downstream 
effectors that, through unknown mechanisms, suppress viral infection. Dome, the 
receptor involved in JAK/STAT signalling, was similarly regulated by DENV infection 
and Cactus KD. The authors suggest that the JAK/STAT pathway could be activated 
by the same signalling cascades that activate the Toll pathway, or that it could be 
activated indirectly by the Toll pathway itself, as evidence suggests in D. 
Melanogaster [72]. Xi et al also observed that removing the natural bacterial flora in 
mosquito midguts by antibiotic treatment increased viral infection. It is proposed 
that the basal activation of immune genes by bacteria leads to the up-regulation of 
anti-viral immune genes, possibly by Toll pathway activation as indicated by the up-
regulation of several Toll regulated immune genes in septic compared to aseptic 
mosquitoes. 
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Figure 7. Three conserved pathways involved in anti-viral immunity in mosquitoes.  
The RNAi pathway recognises virally derived dsRNA formed during replication within 
host cells.  dsRNA is processed by the enzyme Dicer-2 siRNA is loaded into the RISC 
complex, which targets complimentary RNA for destruction.  The Toll pathway 
regulates the transcription of currently unknown anti-viral effectors.  The JAK/STAT 
pathway regulated the transcription of unknown anti-viral effectors, and is 
inhiobited by JEV infection in Ae. aegypti.  Dotted arrows represent unknown 
interactions.  D. melanogaster genes have been named where A. gambiae orthologs 
have not been identified (dSpz, dToll, dUpd).      
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1.4 Summary 
 
Over the last few years evidence has emerged that provides the first insights into 
invertebrate anti-viral immunology. Three major pathways have been implicated in 
anti-viral responses, the RNAi pathway, the JAK/STAT pathway and the Toll pathway 
(figure 7). These three pathways appear to have a conserved role in anti-viral 
immunity from flies to mosquitoes. Although we are beginning to understand which 
molecular pathways may be involved in the regulation of viral infection, there are 
many questions that remain to be answered, both in terms of the biology of the 
replication cycle of different viruses in mosquito vectors and the molecular 
mechanisms of anti-viral immunity. Anti-viral downstream effectors of the Toll and 
JAK/STAT pathways are currently not known and differences in RNAi susceptibility 
from mosquito to mosquito, and virus to virus is not well understood. With increases 
in the geographical distribution of vector mosquitoes and in international travel and 
transport, the probability increases that viral diseases will continue to affect new 
parts of the world. The elucidation of anti-viral mechanisms may provide new targets 
for combating these viral diseases. 
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2 Aims and objectives 
 
 
The broad aim of this project was to explore the mechanisms that A. gambiae 
employs to cope with viral infections.  The main objective was to identify genes 
involved in anti-viral immunity in A. gambiae mosquitoes through literature research 
into orthologous systems and transcriptional profiling of infected mosquitoes.  A 
secondary objective of this project was to develop a cell based assay for rapid 
identification of genes involved in viral infection in A. gambiae, with a view to 
carrying out a genome wide RNAi screen.        
 
The working hypothesis was that mosquitoes do posses anti-viral mechanisms 
capable of limiting or modulating viral infection.  Based on observations from the 
model system D. melanogaster and limited evidence in A. gambiae outlined in the 
introduction, several different pathways are thought to play a role in response to 
viral infection, namely the JAK/STAT and RNAi pathways.  The approach was to build 
upon the existing knowledge of anti-viral immunity mechanisms in invertebrates and 
couple this with a forward genetics methodology to study the mosquito responses to 
viral infection.  This study sought to increase our understanding of the interactions 
between the unique Anopheles-ONNV vector-virus combination and provide insights 
into the A. gambiae immune response to viral infection as a critical factor in the 
determination of its capacity to transmit viral disease.      
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3 Materials and methods 
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3.1 Maintenance of mosquitoes  
 
Adult mosquitoes were maintained as described in detail by Sinden and co-workers 
[98].  Three strains of A. gambiae were used in experiments; G3 (colonised from The 
Gambia in the 1950’s), Yaounde (colonised from the Yaounde area, Cameroon, in 
1988), N’gousso (recently colonised from wild mosquitoes collected in Cameroon).  
A. arabiensis and A.quadrinalatus SKUQUA strain (colonised from the Skukuza area, 
Kruger National Park, South Africa in December 2005) were also used.  In brief, 
mosquitoes were reared and maintained at 28oC, 65-70% relative humidity with a 12 
hour light/dark cycle. Adult mosquitoes were fed on sterile filtered and autoclaved 
10% fructose solution and used for experimental purposes when 1 or 2 days old.     
 
3.2 Maintenance of mosquito derived cell lines 
 
Seven A. gambiae derived cell lines were used during experiments.  All cell lines 
were derived from minced neonate larvae within one hour of hatching [99].  Strains 
used to generate cell lines were Suakoko 2La (cell lines SuaE1, Sua5.1, Sua4.0), L35 
(L35 cell line) and 4a r/r (cell lines 4a3A and 4a3B).  Cell lines are primary cultures 
that have not been cloned; they contain a heterogeneous population of cells derived 
from whole minced neonates.  Cells were maintained at 27oC in ‘complete insect 
media’; Schneiders medium (Gibco, UK) supplemented with 10% Fetal Calf Serum 
(FCS) (Sigma) heat inactivated at 56oC for 1 hour and 0.01mg/ml 
penicillin/streptomycin (Invitrogen, UK).  Cells were split by scraping cells or 
vigorously shaking the dish to loosen cells, and diluting 1:20 in fresh complete media 
every 4-7 days.       
 
3.3 Maintenance of mammalian derived cell lines 
 
African green monkey kidney cells (VERO) and Baby Hamster Kidney cells (BHK) were 
maintained at 37oC in ‘complete mammalian media’: minimum essential media 
(MEM) (Invitrogen) supplemented with 10% FCS (Sigma) heat inactivated at 650C for 
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30 minutes, 0.01mg/ml Penicillin/Streptomycin (Invitrogen), 0.292mg/ml L-
glutamine (Invitrogen), 0.01mM non-essential amino acids (aa’s) and 0.25ug/ml 
fungizone (Invitrogen).  Cells were split by trypsanisation with 0.5mg/ml 
Trypsin/0.2mg/ml Ethylenadiaminetetraacetic acid (EDTA) (Invitrogen), washing in 
phosphate buffered saline (PBS) and diluting 1:15 with complete mammalian media.     
 
3.4 Production, propagation and titration of 5′ONNVic-eGFP 
 
3.4.1 Production of 5′ONNVic-eGFP 
 
5′ONNVic-eGFP plasmid was kindly provided by Dr Brian Foy, Colorado State 
University.  The plasmid was transformed into DH5α E.coli (Invitrogen, UK) according 
to the manufacturers instructions.  A single colony was picked and used to inoculate 
a 5ml culture of lysogeny broth (LB), and grown at 37oC, shaking at 225 revolutions 
per minute (rpm) for 8-16 hours.  250µl of the 5ml culture were used to inoculate a 
250ml culture of LB, grown at 37oC, shaking at 225rpm for 8-16 hours.  Plasmid DNA 
was extracted using the Qiagen Maxiprep Kit (Qiagen, UK) according to the 
manufacturers instructions.   
 
Five micrograms of the plasmid was linearised using Not1 restriction enzyme (New 
England Biolabs) in a total volume of 100µl for 2 hours at 37oC.  200mg/ml of 
Proteinase K were added to the reaction and incubated at 37oC over night.  The 
linearised plasmid was phenol-chloroform extracted using ribonuclease (RNAse) free 
plasticware and reagents; linearised plasmid was brought to the total volume of 
450µl with water, an equal volume of cold saturated phenol/chloroform/iso-amyl 
alcohol (PCI).  The sample was vortexed briefly, placed on ice for 5 minutes and 
centrifuged at 4oC, 18000 g, for 3 minutes.  The top aqueous layer was removed and 
retained.  An equal volume of chloroform was added, the sample was vortexted 
briefly, placed on ice for 5 minutes and centrifuged at 4oC, 18000 g, for 3 minutes.  
The top aqueous layer was removed and retained.  The DNA was precipitated; 60µl 
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of 3M Sodium Acetate (pH5.2) was added followed by 1ml of ice-cold ethanol.  DNA 
was precipitated at -80oC for a minimum of 1 hour.  DNA was pelleted by 
centrifugation at 4oC, 18000 g for 15 minutes.  Supernatant was removed and the 
pellet was air dried for around 10 minutes.  The pellet was re-suspended in 25µl of 
water.  The linearised plasmid was transcribed into RNA using the T7 megascript Kit 
(Ambion, UK); 1µg of plasmid was transcribed in a 50µl reaction containing 2.5µl of 
each deoxyribonucleotide triphosphate (dNTP), 5µl of 10X buffer, 2µl T7 RNA 
polymerase and 1mM A Cap analogue (m7G(5’)ppp(5’)A) (Ambion), at 39oC for 1 
hour.          
      
Transcribed RNA was cleaned up using the RNeasy mini kit (Qiagen) according to the 
manufacturers instructions.  RNA concentration and purity was ascertained using a 
Nanodrop.  2μg of RNA were transfected into a confluent culture of VERO cells in a 
T75 flask using the Transmessenger transfection reagent (Qiagen) according to the 
manufacturers instructions.  At 24 hours post transfection cells were screened for 
GFP expression.  If the transfection was successful, cells were monitored for GFP 
expression and cell death caused by viral infection.  Cells were harvested at around 
72-96 hours post transfection: cells were scraped, stored in 200μl aliquots at -80oC 
and designated as Passage 1 Vero 5′ONNVic-eGFP (P1V 5′ONNVic-eGFP).      
 
3.4.2 Propagation of 5′ONNVic-eGFP 
 
For experimental use, a large volume of Passage 2 virus (P1/P2V 5′ONNVic-eGFP) 
was generated; one 200 μl aliquot of P1V 5′ONNVic-eGFP was used to inoculate a 
culture of confluent VERO cells in 20ml media in a T175 flask (Nunc).  Cells were 
checked every 12 hours for GFP expression and at 72 hours post infection (hpi) cells 
were scraped, filtered through a 0.45µm filter and stored at -80oC in 250µl aliquots.  
Alternatively P1V/P2L35 5′ONNVic-eGFP was generated as above, inoculating A. 
gambiae L35 cells with P1V 5′ONNVic-eGFP. 
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3.4.3 Standard plaque assay to determine viral titre 
 
Plaque assay was used to determine the titre of P1V, P1/P2V and P1V/P2L35 
5′ONNVic-eGFP stocks.  VERO cells were plated in 24 well plates (Nunc) and allowed 
to reach 100% confluency.  Samples to be titred were allowed to thaw on ice.  2% 
agar was autoclaved prior to use, melted on the day of use, and placed in a 400C 
waterbath to cool but not set.  Samples to be titrated were serially diluted 101-108 in 
Dulbecco’s Minimum Essential Media (DMEM) (Invitrogen).  Media was removed 
from cells and 2 replicates of 150µl of each dilution were added to a single well of 
the 24 well plate.  Plates were incubated for 1 hour at 37oC to allow for viral 
attachment to cells, plates were rocked every 10 minutes to ensure even distribution 
of samples.  During this hour, equal volumes of molten 2% agar, and a 2X nutrient 
solution (per litre of nutrient solution, 862ml 1X Earles Basic Salts solution, 66ml 
yeast extract/Lactalbumen solution (sterile filtered), 40mls FCS, 30mls 7.5% sodium 
bicarbonate, 2mls 10mg/ml Gentamycin) were mixed and kept in a 40oC waterbath 
to prevent setting.  After 1 hour incubation, 1ml of agar/nutrient solution was 
pipetted into each well of the 24 well plates, and allowed to cool for 1-2 hours at 
room temperature (RT) before returning to 37oC.  After 4 days incubation at 37oC, 
200µl of 5mg/ml Thiozolyl Blue Tetrazolium Bromide (MTT) (Sigma) in PBS was 
added to each well, and allowed to develop for at least 4 hours.  The number of 
plaques (seen as white plaques of dead cells against the purple colour of live cells) in 
each well was counted, and the plaque forming units (PFU)/ml calculated using the 
well in which the highest number of individual plaques could be counted.  Each 
sample was titred in duplicate and values were averaged.       
 
3.5 Infection of mosquitoes and mosquito cells with 5′ONNVic-eGFP 
 
3.5.1 Infection of A. gambiae cell lines with 5′ONNVic-eGFP 
 
Confluent cultures of A. gambiae cells lines (Sua4.0, Sua5.1*, SuaE1, 4a2, 4a3A, 4a3B 
and L35) were grown in 96 well/24 well/12 well/6 well plates or T25 flasks.  The 
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number of cells (counted using a haemocytometer) used to seed each well were 5 x 
104; 5 x 105; 1 x 106; 2 x 106 or 6 x 106 respectively.  An aliquot of previously titrated 
virus was thawed and diluted with complete insect media to an appropriate 
Multiplicity of Infection (MOI; referring to the number of infectious viral particles 
relative to the number of cells thus an MOI of 1 denotes 1 viral particle for every cell 
in a culture).  Diluted virus was added directly to the cell cultures.  Cultures were 
rocked gently for 30 minutes before being placed at 27oC.  Infected GFP expressing 
cells were viewed using a fluorescent microscope.     
 
3.5.2 Intrathoracic inoculation of A. gambiae mosquitoes with ONNVic-
eGFP 
 
Newly emerged female mosquitoes (A. gambiae G3/Yaounde/N’gousso strains, A. 
quadriannulatus and A. arabiensis) were inoculated with the required dilution of 
P1/P2V or P1V/P2L35 5′ONNVic-eGFP in MEM (Invitrogen), using a pulled capillary 
glass needle and a Nanoject (Drummond Scientific).  Inoculated mosquitoes were 
kept in cohorts of 50 and maintained as described by [98].  Incoculated mosquitoes 
were double-contained to prevent escape.    
         
3.5.3 Per Os infection of A. gambiae mosquitoes with 5′ONNVic-eGFP 
 
Cohorts of ~50 mosquitoes were starved of 10% sugar for 4-12 hours prior to blood 
feeding.  Infectious blood meals were prepared by mixing the required volume of 
P1/P2V 5′ONNVic-eGFP with a 1:1 mixture of compacted human red blood cells 
(RBCs) and human AB serum (GemCell©).  Compacted human RBCs were prepared 
by adding freshly drawn blood to 1/10th volume heparin sodium salt ( 1.66 mg/ml in 
PBS, sterile filtered) and centrifuging at 600g for 5 minutes in a 50ml Falcon tube.  
Compacted RBCs were pipetted when required from the bottom of the 50ml Falcon 
tube.  RBCs were kept for up to two weeks at 4oC.  Infectious blood meals were 
delivered using membrane feeders; plastic membrane feeders containing a 
compartment for flow of warmed water (via connection to a water bath set at 38oC) 
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and parafilm stretched across to form a second compartment at the bottom of the 
membrane feeder, into which the infectious blood meal is introduced using a 24 
Gauge blunt needle.  Mosquitoes were placed under the warmed blood meal and 
were allowed to feed to occlusion (30mins-1hour).  Infectious titre per mosquito was 
calculated based on the assumption that each mosquito will ingest approximately 
2µl of blood.  Unfed mosquitoes were removed 24-48h post blood feeding, when the 
blood meal can be clearly seen through the cuticle of the mosquito.     
 
3.6 Antibiotic treatment of A. gambiae mosquitoes 
 
Newly emerged G3 and N’gousso strain mosquitoes were fed on 10% fructose 
solution containing Gentamycin, Penicillin/Streptomycin (Invitrogen) for 5 days.  To 
confirm that anti-biotic treatment was successful, mosquitoes were homogenised in 
LB and plated onto LB agar plates and incubated at 27oC overnight.     
 
3.7 dsRNA preparation for gene knock down  
 
Primers were designed (Table 2) for 200-600bp sections of genes of interest, with a 
T7 promotor sequence (GAATTAATACGACTCACTATAGGGAGA) added to their 5’ 
ends.  Polymerase chain reaction (PCR) was carried out using cDNA derived from A. 
gambiae mosquitoes and PCR products were sequenced to confirm correct 
amplification for each probe.  PCR amplicons were used to synthesise dsRNA using 
the T7 MEGAscript kit (Ambion) according to the manufacturers instructions.  
Concentration of dsRNA was adjusted to 3µg/µl and stored at -80°C until use. 
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Table 2.  Primers for RNAi probes.  Primers were designed using the E-RNAi 
webservice from the German Cancer Research Centre 
(http://www.dkfz.de/signaling/e-rnai3/) 
 
Gene Primer ID 
Gene 
Name F primer R primer 
n/a 
LacZ RNAi 
F/R LacZ 
GAATTAATACGACTCACTAT
AGGGAGAATCCGACGGGTT
GTTACT 
GAATTAATACGACTCACTATAGG
G CACCACGCTCATCGATAATTT 
 
Hop(2) 
RNAi F/R HOP 
GAATTAATACGACTCACTAT
AGGGAGAGCCAAGGAGCTG
GTTATCAA 
GAATTAATACGACTCACTATAGG
GAGAAGAGCAGATCGTGCTTGGT
T 
 
AgAGO2 
RNAi F/R Ago2 
GAATTAATACGACTCACTAT
AGGGAGAGCATGAGCACGC
TCAACAAC 
GAATTAATACGACTCACTATAGG
GAGAGTTCGAGTCGTCGTACAGC
A 
n/a 
nsp3 RNAi 
F/R nsP3 
GAATTAATACGACTCACTAT
AGGGAGAACCGGTGTGTACT
CAGGAGG 
GAATTAATACGACTCACTATAGG
GAGACATAGGCACGGGACTGTTT
T 
AGAP002836 
Dicer1 
RNAi F/r Dicer1 
GAATTAATACGACTCACTAT
AGGGAGATGCTAAGCTTTGG
CTGGAAT 
GAATTAATACGACTCACTATAGG
GAGATTTCGTTCGACCATGTACCA 
AGAP006941 
STAT1 
RNAi F/R STAT1 
GAATTAATACGACTCACTAT
AGGGAGAGAAAATCAACCA
CCGCAAGT 
GAATTAATACGACTCACTATAGG
GAGACAGCTCTTCCTGTTCCAAG
G 
AGAP003508 
STAT2 
RNAi F/R STAT2 
GAATTAATACGACTCACTAT
AGGGAGACATGAACAACATC
GGCAATC 
GAATTAATACGACTCACTATAGG
GAGATGCATATTCTCTGCCGTGA
G 
AGAP005031 
PIAS RNAi 
F/R PIAS 
GAATTAATACGACTCACTAT
AGGGAGAAATCCAATTCCCA
CCAACAA 
GAATTAATACGACTCACTATAGG
GAGAGGACAGTTCCATGTTGGCT
T 
 
REL1 RNAi 
F/R REL1 
GAATTAATACGACTCACTATT
AGGGAGAATCAACAGCACG
ACGATGAG 
GAATTAATACGACTCACTATTAGG
GAGATCGAAAAAGCGCACCTTAA
TT 
 
CACT 
RNAi F/R CACTUS 
GAATTAATACGACTCACTATT
AGGGAGAGTCCGCTCTACAC
ATCAGCA 
GAATTAATACGACTCACTATTAGG
GAGACCGTTCGGGTTAATGATGA
C 
 
REL2 RNAi 
F/R REL2 
GAATTAATACGACTCACTATT
AGGGAGAAATCCGACGCAA
AGATACG 
GAATTAATACGACTCACTATTAGG
GAGAGACCGCAATGTGAAGGAT
G 
AGAP012352 
ML1 RNAi 
F/R ML1 
GAATTAATACGACTCACTAT
AGGGAGAGAAATGTCCCGG
TGAAGAGA 
GAATTAATACGACTCACTATAGG
GAGACCCACCAGCGTTGTTTTAGT 
AGAP002848 
ML9 RNAi 
F/R ML9 
GAATTAATACGACTCACTAT
AGGGAGAACGGTCCATAGC
AAGGATTG 
GAATTAATACGACTCACTATAGG
GAGAGTCAGCGGACAGGAAGTG
TT 
AGAP012529 
GALE8 
RNAi F/R GALE8 
GAATTAATACGACTCACTAT
AGGGAGAGGTCTAGGCATTT
ACCGCAA 
GAATTAATACGACTCACTATAGG
GAGAGAGCCGTCCTTATTCTGTG
G 
AGAP007343 
LYSC2 
RNAi F/R LYSC2 
GAATTAATACGACTCACTAT
AGGGAGAAAGAAATTGTTG
CCGGATTG 
GAATTAATACGACTCACTATAGG
GAGAGATGACGACAGGCTACAGC
A 
AGAP007385 
LYSC4 
RNAi F/R LYSC4 
GAATTAATACGACTCACTAT
AGGGAGAGAAGACGGTGAA
TCGGGTAA 
GAATTAATACGACTCACTATAGG
GAGAGTCGTTCAGAAAGTCCTCG
C 
  
 57 
AGAP005717 
LYSC6 
RNAi F/R LYSC6 
GAATTAATACGACTCACTAT
AGGGAGATGACATCTACTGG
TGCTCGC 
GAATTAATACGACTCACTATAGG
GAGAAACTCACTCCACAAGCCCA
C 
AGAP000694 
CEC3 RNAi 
F/R CEC3 
GAATTAATACGACTCACTAT
AGGGAGAGAGATCTCTTCCC
GTGTGGA 
GAATTAATACGACTCACTATAGG
GAGAGCGGTGACCTCTTTCAGTC
T 
AGAP008654 
TEP12 
RNAi F/R TEP12 
GAATTAATACGACTCACTAT
AGGGAGAACAAGCTCTAACC
TTCGCCA 
GAATTAATACGACTCACTATAGG
GAGAAGCACTTTGTTGCCTTGCTT 
AGAP006941 
 
helicase 2 
RNAi F/R Helicase 2 
GAATTAATACGACTCACTAT
AGGGAGATCTCATCCCACGA
TCATTCA 
GAATTAATACGACTCACTATAGG
GAGAACCACTATGTCGACCTTCG
G 
AGAP003508 
 
helicase 3 
RNAi F/R Helicase 3 
GAATTAATACGACTCACTAT
AGGGAGAAAGGGGGAGAAA
GAGATGGA 
GAATTAATACGACTCACTATAGG
GAGAGGCGCACAGCAGAATATGT
A 
AGAP005620 
DPT RNAi 
F/R Diptericin 
GAATTAATACGACTCACTAT
AGGGAGATGCCCTGACAGTT
GCATTTA 
 
GAATTAATACGACTCACTATAGG
GAGAGTAACTAGCCGAACCGTCC
A 
 
AGAP003776 
3776 RNAi 
F/R 3776 
GAATTAATACGACTCACTAT
AGGGAGACGCCATCTGAAG
CAACTGTA 
GAATTAATACGACTCACTATAGG
GAGAGACACCCTAGTTCTTTGCC
G 
     
 
 
3.8 Generation of LacZ derived ds/ssRNA  
 
A 500bp fragment of the E.coli LacZ gene was cloned into the PLL10 vector by a 
previous member of the laboratory (S. Pinto, unpublished data), where the LacZ 
sequence is flanked by T7 promotor sequences and multiple restriction enzyme 
cutting sites between the T7 promotor sequence and the LacZ sequence.  dsRNA was 
generated using the plasmid as a template for reverse transcription with the T7 
MEGAscipt kit according to the manufacturers instructions.  ssRNA was generated by 
using plasmid linearised with Xbal1, cutting the plasmid between the LacZ and the 3’ 
T7 promotor sequence, as a template for reverse transcription using the T7 
MEGAscript according to the manufacturers instructions.  Linearised plasmid was 
inspected by gel electrophoresis prior to use in reverse transcription reactions to 
ensure linearization.            
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3.9 Transfection of cell lines with dsRNA 
 
3.9.1 Bathing method 
 
Cells were seeded into 6/12/24 or 96 well dishes and allowed to settle for 2-24 
hours.  Cells were treated with the desired amount of dsRNA complementary to a 
gene of interest, mixed with complete insect media.  Conditioned media was 
removed from cells and replace with dsRNA containing media.  48h later dsRNA 
containing media was removed, cells were washed with PBS and complete media 
was replaced.        
3.9.2 Effectene transfection 
 
Cells were seeded into 6/12/24/96 well dishes and allowed to settle for 2-24 hours. 
Cells were transfected with dsRNA or DNA according to the manufacturers 
instructions using the equivalent ratios for a 24 well plate: 0.2μg dsRNA/DNA, 1.6μl 
Enhancer and 5μl of Effectene reagent.      
3.9.3 Transmessenger transfection 
 
Cells were seeded into a T25 flask and were transfected with capped ONNV RNA 
according to the manufacturers instructions using the following ratios: 2μg RNA, 4μl 
Enhancer and 8μl Transmessenger reagent.    
 
3.10 dsRNA treatment and infection of mosquitoes with 5’ONNViv-
eGFP 
 
 
Mosquitoes were treated with dsRNA and infected with 5′ONNVic-eGFP using three 
different protocols (see table 3).  In all three protocols mosquitoes were inoculated 
with 307ng of dsRNA.  In brief, mosquitoes were either A) inoculated with dsRNA on 
day 1, inoculated with 5′ONNVic-eGFP at day 4 and 10 mosquitoes were collected at  
1, 3 and 6 dpi; B) inoculated with dsRNA on day 1, inoculated with 5’ONVic-eGFP on 
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day 4 and 30-50 mosquitoes were collected at 7 dpi; or C) mosquitoes were 
inoculated with dsRNA and 5′ONNVic-eGFP on day 1 (5′ONNVic-eGFP and dsRNA 
were mixed 1:1 and each mosquito was injected twice) and 30-50 mosquitoes were 
collected 7 dpi.  Equal numbers of mosquitoes were collected for each gene KD.    
 
 
 
Table 3.  Methods for gene KD and ONNV infection in A. gambiae mosquitoes.   
 
Method dsRNA  
(Per mosquito) 
P1/P2V 
5′ONNVic-eGFP 
(PFU/mosquito) 
Day of 
inoculation 
Day of 
collection 
A 307ng ~1640 dsRNA D1, 
ONNV D4 
10 mosquitoes 
collected 1, 3 
and 6 dpi 
B 307ng ~1640 dsRNA D1, 
ONNV D4 
~30 
mosquitoes 
collected 7 dpi 
C 307ng ~3000 dsRNA and 
ONNV D1 
~30 - 50 
mosquitoes 
collected 7 dpi 
 
 
3.11 Total RNA extraction from mosquitoes 
 
Total RNA was extracted from whole mosquitoes or cells using TRIzol reagent 
(Invitrogen, UK).  A. gambiae whole mosquitoes were homogenised in 500µl TRIzol, 
200µl chloroform were added to extract RNA from protein impurities, and RNA was 
precipitated using 300µl isopropanol.  Precipitated RNA was centrifuged at 13000 g 
for 15 minutes and resuspended in RNAse free water.  Total RNA quality was 
assessed by gel electrophoresis and spectrophotometry using a Nanodrop® (Labtech 
International).  A. gambiae cells were lysed in 500µlof TRIzol and RNA was extracted 
as described for whole mosquitoes.       
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3.12 Viral RNA extraction 
 
3.12.1 vRNA extraction from cell culture 
 
Conditioned media containing virus was spun at 5000g for 15 minutes to pellet 
remaining cells. 140µl samples were used for viral RNA extraction using the Qiagen 
Viral RNA extraction kit following the manufacturers instructions.  Samples greater 
than 140µl in volume were concentrated using YM100 microcon centrifugation 
tubes: Samples were centrifuged at 15000 g at 12oC for 10-30 minutes (depending 
on the volume to be concentrated), the reserved supernatant was collected 
according to the manufacturers instruction and adjusted to 140µl with Drosophila 
Schneiders medium.     
 
3.12.2 vRNA extraction from whole mosquitoes 
 
Whole mosquitoes were homogenised in 200μl of Drosophila Schneiders medium 
(Gibco) using a motorised pestle.  Homogenates were centrifuged at 3000 g for 30 
minutes at 4oC to pellet debris.  Supernatant was transferred to a new 1.5ml 
eppendorf tube and centrifuged at 5000 rpm for a further 30 minutes at 4oC.  The 
supernatant was filtered through a 0.2um filter, and 140μl of the filtrate was used 
for viral RNA extraction using the Qiagen viral RNA extraction kit according to the 
manufacturers instructions.       
 
3.13 cDNA Production 
 
cDNA was produced using the Superscript II kit (Invitrogen).  For RNA extracted from 
whole mosquitoes or cell line extracts, 2μg RNA was reverse transcribed according to 
the manufacturers instructions.  For viral RNA extractions from whole mosquitoes, 
midguts or conditioned media from cell lines, 10μl of extracted viral RNA was 
reversed transcribed according to the manufacturers instructions.     
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3.14 Quantitative real time PCR 
 
qrtPCR was performed using the SYBR-Green detection and amplification reagent 
(Applied Biosystems) according to the manufacturers instructions. Primers for 
mosquito transcripts were designed using the Primer3 web interface 
(http://frodo.wi.mit.edu/primer3/).  Primers used for qrtPCR are shown in Table 4 .  
To ascertain transcript abundance of mosquito genes, a relative quantification 
method was used.  For every sample, primers against the transcript of interest, and 
the housekeeping gene, S7, were used.  S7 is constitutively expressed during all 
stages of the mosquito life cycle.  A mixture of all samples to be run on a single plate 
was used as a reference with S7 primers – all other samples are normalised using the 
transcript abundance of S7 relative to that of the reference mixture using a standard 
curve.  After normalisation, the relative transcript abundance of the gene of interest 
is calculated using a standard curve, giving a relative value compared to that of the 
control sample, thus giving a percentage increase or decrease of transcript 
abundance compared to the control.   
 
To ascertain the abundance of viral RNA, or viral genome copy number, an absolute 
quantification method was used.  Viral RNA was extracted from a sample with a 
known PFU, calculated using standard plaque assay, and cDNA was produced as 
described.  A standard curve the sample was generated using neat, 1:5, 1:10. 1:50, 
1:100 and 1:500 dilutions of cDNA.  This standard curve was used to calculate the 
viral genome copy number of an unknown sample by mapping the CT value to that 
of the standard curve, giving the viral genome copy number.         
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Table 4. Qrt-PCR primers.  Primers were designed using Primer3 
(http://frodo.wi.mit.edu/primer3/) specifying product size 50-150, primer size 18-25, 
TM 58-62, primer GC content 30-80.  Primers were designed to not overlap with 
RNAi probes (to avoid amplification of residual dsRNA used for gene silencing) and 
where possible to span exons.           
  
Gene Primer ID 
Gene 
name 
F R 
n/a 
ONNVnsP3-
qrt F/R 
nsP3 
TGA TGA AGC AGT GCC AGT 
TC 
CGA ATT TGC GTA CAT TGG 
TG 
n/a E2 qrt F/R E2 CCATACACCTGTGGATGCAG TACCGTCAGCGTCTCTCCTT 
AGAP0123
52 
ML1 qrt F/R ML1 GTCGCTATTGTGGCATTGTG 
AAAGTTTACTACTTCTGCCCA
AGC 
AGAP0125
29 
GALE8 qrt F GALE8 CTGCATACAGTCCGCCAAC GTCCGCGAATCGTAATCTTG 
AGAP0073
85 
LYSC4 qrt 
F/R 
LYSC4 
GATATCGAGTGTGCGAAGC
A 
CAGATCGGGCAGTGTCTTTT 
AGAP0057
17 
LYSC6 qrt 
F/R 
LYSC6 ACGGTGGCAGTGGCTATTAC TCAATGTCATCGTCCAGCTC 
AGAP0056
93 
5693 qrt F/R n/a TCGGTGAGCAACAGTTTGAC 
CAGGTCGAGATGGGTGAAC
T 
AGAP0107
31 
CLIPA8 qrt 
F/R 
CLIPA8 
GATCGATTCGACGACCAACT 
 
GCAGGTCGACTCGCTTTAAC 
AGAP0006
93 
CEC1 qrt F/R CEC1 
TCATCTTTGTCGTGCTGGCA
GCTT 
TCTTCAGCCGTCCCGCT 
AGAP0006
94 
CEC3 qrt F/R CEC3 GCTACAGCCAGTCGATGGTG AACACATTGCGTCCGAGCTT 
AGAP0112
94 
DEF1 qrt F/R DEF1 GCCTTTGTGCCGCTC ACT 
GCCTTACTGTTGCAGTAACC
ACC 
 
 
3.15 Preparation of labelled probes and Microarray Hybridisations  
3.15.1 Preparation of labelled probes 
 
Total RNA extracted from A. gambiae mosquitoes or cells was amplified and labelled 
using the Low RNA imput amplification kit (Agilent, UK) according to the 
manufacturers instructions.  In brief:  2µg of total RNA was used in a random primed 
reverse transcription reaction to generate cDNA.  After amplification by conversion 
to cDNA, cDNA was transcribed to copy messenger RNA (cmRNA) incorporating 
either Cy-3UTP (for the reference sample) or Cy-5UTP (for the test sample) 
fluorescent nucleotide analogs.  cmRNA quality and labelling efficiency was assessed 
by spectrophotometry using a Nanodrop® (Labtech International).  If cmRNA yield 
was sufficient and Cy-3UTP or Cy-5UTP labelling was successful, 825ng of RNA was 
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hybridised to the Agilent 4X44K array in 2X GEx-hybridisation buffer HI-RPM at 600C 
for 17 hours.  Hybridised slides were washed with GE wash buffer 1 at RT for one 
minute and GE wash buffer 2 at 37oC for one minute, to remove excess labelled 
cmRNA prior to scanning.       
 
3.15.2 Microarray scanning and data analysis 
 
Microarrays were scanned using a GenePix semiconfocal microarray scanner (AXON 
Instruments, Foster City, CA) Gene Pix Pro 4.0 or 6.1 were used to record feature 
signal intensity, to eliminate local backgrounds, for grid alignment and manual 
inspection of feature quality.  Average feature diameter was calculated and features 
lying outside three standard deviations of the mean were excluded from analysis.  
The ratio of feature intensity verses local and global backgrounds were calculated 
and features not exceeding background intensities were excluded from analysis.  
Features were normalised using Genespring 6.1 (Axon instruments) by locally 
weighted linear regression methods (Lowess).  Feature intensities over the three or 
four biological replicates were averaged.  T-test p-values were calculated, and 
normalised data was filtered to exclude data with p-values greater than 0.05.  Data 
was further filtered to include only genes showing 2-fold and greater regulation.  
Candidate genes were selected based on several criteria, including gene ontology, 
and known roles of orthologous genes.    
3.16 Immunofluorescence Assays 
 
Cells were plated into sterile coverslip in 6 well plates (coverslips were dipped in 75% 
ethanol and flamed before being placed into 6 well plates).  Plates were seeded with 
2 x 106 cells/well and allowed to reach confluency over 1-2 days.  Cells were infected 
with 1 MOI P1/P1V 5′ONNVic-eGFP by adding virus directly to conditioned media.  At 
the appropriate time point after infection, the coverslip was removed from the well 
plate and washed once gently with PBS.  Cells on the coverslip were fixed with 4% 
PFA in PBS for 15 minutes at RT.  Cells were washed twice with PBS.  Cells were 
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permeabilised with 0.5% Triton X 100 in PBS for 20 minutes, followed by two quick 
washes with PBS.  Cells were blocked with 3% Bovine Serum Albumin (BSA), 0.1% 
Tween 20 in PBS for 2 hours.  Cells were washed twice with PBS for 10 minutes.  Cells 
were incubated with a rabbit anti-STAT1, generated by a previous worker in this 
laboratory[100], at a 1:200 dilution in 3% BSA in PBS at 4oC overnight.  Cells were 
washed twice for 10 minutes with 3% BSA in PBS, and then incubated with secondary 
antibody - ALEXA FLUOR 568 mouse anti-rabbit (Molecular probes) at 1:1000 dilution 
in 3% BSA in PBS for 3-4 hours at RT.  Cells were washed twice with PBS and 
mounted on glass slides with Vectorshield© with DAPI (Vectorlabs).  GFP, DAPI and 
anti-STAT staining were imaged using a Leica DMT fluorescence microscope and a 
Zeiss AxioCam HRc camera with Zeiss Axiovision40 software.                
 
3.17 Coinfection of A. gambiae with ONNV and P. berghei 
 
3.17.1 Parasite maintenance  
 
P. berghei ANKA clone 259c12 (that constitutively expresses GFP throughout it’s 
lifecycle) was maintained in Theiler’s original mice (Harlan, UK) as described in 
Sinden et al 2002 [98].   All animal work was carried out by Dr Tibebu Habetewold 
and Kasia Sala.  Mice were infected by intraperitoneal (IP) injection of 100-200µl of 
P. berghei infected blood.  Parasitaemia was calculated from methanol fixed and 
Giemsa stained thin tail blood smears; blood smears were air dried, dipped in 
methanol and covered in Giemsa solution (1:5 dilution in Giemsa buffer – 0.7% (w/v) 
anhydrous KH2PO4, 1% (w/v) anhydrous Na2HPO4) for 15 minutes at RT.  For 
mosquito infections, three days after passage with infected blood mice were 
terminally anaesthetised with an intramuscular (IM) injection of 0.05ml/10g body 
weight of Rompun (2% stock solution, Bayer), Ketastet (100mg/ml ketamine, Fort 
Dodge Animal Health Ltd) and PBS in a 1:2:3 ratio).     
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3.17.2 Infection of mosquitoes with 5′ONNVic-eGFP and P. berghei 
 
Newly emerged adult G3 mosquitoes were intrathoracically inoculated with ~1640 
PFU P1/P2V 5′ONNVic-eGFP.  Inoculated mosquitoes were maintained at 27oC for 
48h.  Mosquitoes were starved of sugar for 4-5 hours prior to blood feeding.  
Mosquitoes were fed on a terminally anaesthetised P. berghei infected mouse by 
placing the mouse over the netted tops of the mosquito pots, alllowing mosquitoes 
to probe through the net for 30 minutes-1 hour in the dark.  Mosquitoes were 
maintained at 19oC for 72h post blood feeding to allow successful parasite 
development, and were subsequent maintained at 27oC to allow for optimal viral 
replication.  Unfed mosquitoes were removed between 24 and 48h post blood 
feeding, when the blood bolus is clearly visible through the abdomen of the 
mosquito.  Seven days post blood feeding, mosquito midguts were dissected and 
fixed in 4% PFA (midguts were fixed in 4% PFA in PBS for 45-60 minutes, and 
subsequently washed in PBS three times for 15 minutes).  Fixed midguts were 
mounted in Vectorshield© (Vectorlabs) on glass slides with sealed coverslips.  
Dissected midguts were kept in the dark wherever possible to prevent bleaching of 
GFP.   
 
3.17.3 Live oocyst and melanised ookinete counts 
 
Fixed and mounted midguts were observed under 20X magnification using a 
fluorescent microscope.  Live oocysts expressing GFP were counted using 
fluorescence, and melanised ookinetes were counted using light microscopy.             
 
3.17.4 Statistics 
 
For P.berghei oocyst, melanised ookinete counts and ONNVic-eGFP plaque assays 
tests results were compared to controls using the Mann Whitney U test; statistical 
significance was accepted when P<0.0001 (***), P<0.001 (**), P<0.01(*).  For 
microarray analysis test results were compared to controls using the students 
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unpaired T-test.  Statistical significance was accepted when P<0.05.  For per os 
infections, tests midguts were compared to controls using the Chi squared test.  
Statistical significance was accepted when P<0.0001 (***), P<0.001 (**), and P<0.01 
(*).  For infection of A.gambiae derived cell lines, viral RNA genome copy number in 
conditioned media was compared to controls using the students unpaired T-test.  
Significance was accepted when P<0.0001 (***), P<0.001 (**), P<0.01(*).     
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4 5′ONNVic-eGFP: production, propagation and 
characterisation in A. gambiae mosquitoes and cell lines 
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4.1 Introduction 
 
A. gambiae-ONNV is an unusual vector-virus combination, with ONNV being the only 
known arbovirus to be transmitted by Anopheline mosquitoes.  This chapter will 
describe the generation of infectious clones of ONNV that express GFP and the 
dynamics of ONNV infection in adult A. gambiae mosquitoes and in A. gambiae 
derived cell lines.  Characterising ONNV infection in A. gambiae was important for 
the design of subsequent microarray studies and gene silencing experiments. 
 
4.2 Generation of infectious clones 5′ONNVic-eGFP 
 
In order to study the mosquito immune responses to viral infection, in collaboration 
with Colorado State University, Arthropod Infectious Diseases Laboratory (AIDL), an 
ATS of ONNV was obtained from Dr Brian Foy.  The ATS was generated by Brault et al 
(2004)[42], using the genome sequence of the SG650 strain of ONNV isolated from 
human serum in Uganda during the 1996 outbreak in Africa [29].  Five overlapping 
fragments of the SG650 genome were generated by high fidelity RT-PCR and were 
subcloned into pBluescript II SK(+)[42].  The fragments were combined by ligating 
segments digested with rare cutting restriction enzymes.  Enhanced GFP (eGFP) was 
subsequently added along with a duplicate of the ONNV subgenomic promoter 
(figure 8)[42], thus when the subgenomic promoter is switched on during infection, 
GFP is expressed.  The first nucleotide of the virus genome was modified to allow for 
the addition of a cap analogue [19].  Having obtained this ONNV ATS, infectious 
clones were generated (section 3.4).  In brief an RNA copy of the viral genome was 
transcribed using the T7 promotor in pBluescript II SK(+), from plasmid linearised 
using the unique restriction site Not1 as a template.  An A-nucleotide cap analog was 
added to the transcription reaction, to generate 5′ capped transcripts of the viral 
genome.  The capped transcripts were transfected into VERO cells using the 
Transmessenger kit (Invitrogen).  Transfected cells were monitored for cytolytic 
infection and GFP expression every 12 hours.  GFP expression was observed at 24 
hours after transfection: single cells expressing GFP could be seen (figure 9), in some 
cases the infected cells were already rounding up and dying.  Infection spread rapidly 
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throughout VERO cells, with spreading foci of infection visible at 48 hours post 
infection (hpi).  At 72h extensive cell death was seen, presumably caused by 
apoptosis as is typical in mammalian cells after infection with alphaviruses.  72 hours 
after successful transfection, the first passage virus (P1V 5′ONNVic-eGFP) was 
harvested (by scraping the cell monolayer), aliquoted and stored at -80oC until 
further use.      
 
 
 
 
Figure 8.  Plasmid map of 5′ONNVic-eGFP; the full length genome of the SG650 
strain of ONNV was cloned into pBluescript II SK(+), the viral subgenomic promoter 
was duplicated and eGFP was placed under control original viral subgenomic 
promoter by Brault et al[42].  The plasmid was kindly given by Dr Brian Foy, Colorado 
State University, Arthropod Infectious Diseases Laboratory (AIDL).   
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4.2.1 Propagation and calculation of titre of infectious clones 
 
To obtain large quantities of high titre 5′ONNVic-eGFP for use in experiments, the 
virus was passaged a second time.  Serial passage of 5′ONNVic-eGFP results in the 
gradual loss of GFP expression, and decreased ability of the virus to infect cells[42].  
Thus 5′ONNVic-eGFP was only ever passaged for a second time before use in 
experiments.   
 
 
 
Figure 9.  Transfection of VERO cells with 5′ONNVic-eGFP:  Confluent cultures of 
VERO cells were transfected with capped transcripts of 5′ONNVic-eGFP.  Successfully 
transfected cells expressed GFP (white) at 24h.  At 48h, 5′ONNVic-eGFP had spread 
to neighbouring cells.  At 72h 5′ONNVic-eGFP infection had spread across the whole 
monolayer and infected cells had rounded up and died.        
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To obtain second passage virus, 250μl of P1V 5′ONNVic-eGFP was added to a 
confluent culture of VERO (mammalian) cells or L35 (mosquito) cells in a T175 flask.  
The virus was allowed to infect cells for 72 hours, when cells were scraped, filtered 
through a 0.22μm filter, and stored at -80oC in aliquots until required.  Second 
passage virus was thereafter referred to as P1/P2V when passaged through VERO 
cells for the second time, or P1V/P2L35 when passaged through L35 cells for the 
second time.  The titres of P1/P2V and P1V/P2L35 were ascertained using standard 
plaque assay in VERO cells (as described in material and methods).  Table 5 gives the 
Plaque forming units (PFU) calculated for all batches of viruses produced and used in 
this thesis.   The highest titre obtained was from virus passaged the second time in 
mosquito cells ( P1V/P2L35).   
 
 
Table 5.  PFU/ml for P1 and P1/P2 5′ONNVic-eGFP stocks calculated using standard 
plaque assay in VERO cells.       
 
Batch  PFU/ml 
P1V batch A (14/6/8) 2.6 X 10^7 
P1 V batch B (30/6/8) 5.2 X 10^7 
P1/P2V batch A (18/6/8) 7.4 X 10^6 
P1/P2V batch B (18/6/8) 8 X 10^ 6 
P1/P2V batch C (1/7/8) 7.4 X 10^7 
P1/P2V batch D (26/6/9) 5.45 X 10^7 
P1/P2V batch E (14/7/9) 1.73 X 10^8 
P1V/P2L35 (28/7/8) 5 X 10^8 
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4.3 5′ONNVic-eGFP infects A. gambiae derived cell lines 
 
Seven cell lines derived from A. gambiae larvae were tested for susceptibility to 
5′ONNVic-eGFP infection.  Initially cells were infected at a multiplicity of infection 
(the number of infectious viral particles or PFU for every cell; MOI) of 0.25 i.e. ~ 0.25 
viral particles for every cell in the culture.  Two cell lines showed substantial 
susceptibility to viral infection: L35 derived from neonates of the L35 strain of A. 
gambiae and 4a3A derived from the neonates of the 4a r/r strain of A. gambiae 
(figure 10).  The L35 cell line was selected for use in the majority of cell based assays 
during this project.   
 
Initially infection of L35 cells was optimised.  Cells were infected at 0.1, 1 and 5 MOI 
with and without washing cells in PBS prior to infection.  Washing cells had no 
discernable effect on viral infection (data not shown).  Cells infected with 5 MOI 
showed little infection, and the cells showed signs of cell death (data not shown).  
Consequently 1 MOI was used to characterise infection in L35 cells.   
 
The dynamics of infection was investigated over a 96h time course.  L35 cells were 
infected at 1MOI by adding virus directly into conditioned media of confluent 
cultures in 6 well plates, and rocking the cells for 30 minutes.  Cells were incubated 
at 27oC.  Conditioned media from cells was collected at 1, 3, 6, 9, 12, 24, 48, 72 and 
96hpi.  Cells were also collected in TRIzol at the same time points.  Viral RNA was 
extracted from conditioned media using the QiaAmp viral kit.  Total RNA was 
extracted from cells collected in TRIzol.  Qrt-PCR was used to ascertain viral genome 
copy number from conditioned media and total RNA samples.  cDNA was generated 
from 10µl of viral RNA (vRNA) from conditioned media and 1µg of total RNA (tRNA) 
from cells.  Qrt-PCR was carried out using a standard curve consisting of a serial 
dilution of a sample of a known PFU (ascertained using plaque assay) and the viral 
genome copy number was calculated.  Figure 11A shows the dynamics of viral 
infection over 96h in conditioned media (i.e. released virus) and within cells (i.e. 
replicating virus within the cytoplasm of infected cells).  During the first 12 hours 
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after infection no GFP was expressed and no virus was released from infected cells.  
Between 12-24 hours the first cells expressed GFP and virus was released into 
conditioned media (Figure 11B).  The peak of infection occurred at 72 hpi, and began 
to drop at 96 hpi.   
 
 
 
 
Figure 10.  5′ONNVic-eGFP infection in 7 A. gambiae derived cell lines: Cells were 
grown to confluency in T25 flasks, and were infected with 0.25 MOI P1/P2V 
5′ONNVic-eGFP by adding virus directly to the conditioned media and rocking the 
cells for 30 minutes.  Cells were incubated at 27oC.  Pictures were taken at 72 hpi.  
Coloured bars represent the average % of cells expressing GFP counted from three 
fields of view at 72 hpi.            
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Figure 11.  Dynamics of 5′ONNVic-eGFP infection in L35 A. gambiae cells; Cells were 
grown to confluency in 6 well plates, and were infected with P1/P2V 5′ONNVic-eGFP 
at 1MOI. A) LOG10 Viral genome copy number/ml in conditioned media (released 
virus) and total RNA extracted from cells (cytoplasmic virus) over 96 hours was 
calculated using qrt-PCR.  Error bars standard error of three biological replicates.  B) 
Brightfield (BF) and GFP expression (white) images of infected cells at 24, 48 and 72 
hpi.     
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4.4 5′ONNVic-eGFP infects A. gambiae after intrathoracic 
innoculation 
 
~1640 PFU of 5′ONNVic-eGFP was injected into the thorax of adult A. gambiae 
mosquitoes.  Initially two strains of A. gambiae (G3 and Yaounde) were tested using 
P1/P2V and P1V/P2L35 5′ONNVic-eGFP.  Ten innoculated mosquitoes were collected 
at 1, 3 and 6 days post infection (dpi).  Mosquitoes were homogenised in Schneiders 
Drosophila medium, vRNA was extracted using the QiaAmp Viral kit, and qrt-PCR was 
used to calculate the vial genome copy number per mosquito.  Infection in G3 strain 
of A. gambiae with P1/P2V 5′ONNVic-eGFP was far higher than that observed using 
P1V/P2L35 5’ONNV and infection with either in the Yaounde strain of A. gambiae 
(figure 12).  G3 mosquitoes were subsequently used in the majority of experiments 
using adult mosquitoes.            
 
The dynamics of 5′ONNVic-eGFP infection in G3 mosquitoes was investigated 
further; a time course following GFP expression and viral genome copy 
number/mosquitoes was carried out over nine days (figure 13A/B).  Mosquitoes 
were injected with ~1640 PFU of P1/P2V 5′ONNVic-eGFP.  GFP expression was 
checked and 10 inoculated mosquitoes were collected each day for 9 days.  VRNA 
extraction and qrt-PCR was carried out (section 3.12.2. and 3.14).  Viral RNA genome 
copy number peaked at 6 dpi, levelling out at 7 dpi, and decreasing by 9 dpi.  GFP 
expression conversely increased and the highest number of GFP expressing 
mosquitoes was observed at 9 dpi (figure 13B).  GFP expression could be seen often 
in the head tissues (seen clearly through the ommaditia of the eyes) and occasionally 
in the thorax through the cuticle (figure 13D).  After injection, mosquitoes were 
dissected at 7 dpi; head squashes, thorax and abdomen preparation and fixed guts 
were observed for GFP expression.  Autofluorescence in the head and thorax 
preparations meant that GFP could not be distinguished from uninfected tissue (data 
not shown), however prepared guts showed GFP expression in what appear to be 
muscle bands or nerves running close to the muscle bands around the anterior- and 
mid-gut (figure 13C).               
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Figure 12. ONNV infects adult A. gambiae mosquitoes; G3 and Yaounde A. gambiae 
mosquitoes were intrathoracically inoculated with ~1640 PFU P1/P2V (Vero) or 
P1V/P2L35 (L35) 5′ONNVic-eGFP.  10 mosquitoes were collected at 1,3 and 6 dpi.  A) 
viral genome copy number/mosquito ascertained using qrt-PCR and B) GFP 
expression observed by fluorescent microscopy in inoculated mosquitoes.   
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Figure 13.  A. gambiae G3 mosquitoes intrathoracically inoculated with 5′ONNVic-
eGFP.  Cohorts of 50 mosquitoes were inoculated with ~1650 PFU of P1/P2V 
5′ONNVic-eGFP.  A) 10 inoculated mosquitoes were collected daily and qrt-PCR was 
used to ascertain viral genome copy number/mosquito.  B) Percent of inoculated 
mosquitoes showing GFP expression at 1, 4 and 9 dpi.  C) GFP expression in nerves 
and/or muscle bands in the anterior- (A) and mid-gut (M) of inoculated mosquitoes 
and D) GFP expression in the head tissues through the ommatidia (O) of inoculated 
mosquitoes at 9 dpi.  Error bars represent SD of 3 biological replicates.       
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4.5 5′ONNVic-eGFP infects A. gambiae mosquitoes after per os 
infection 
 
To see if 5′ONNVic-eGFP can infect A. gambiae mosquitoes by the natural per os 
route of infection, cohorts of two strains of A. gambiae (G3 and N’gousso) were 
given infectious bloodmeals via membrane feeders.  Compacted human red blood 
cells (RBCs) were mixed in a 1:1 ratio with human serum.  Virus was mixed with the 
resuspended RBCs; initially the same dose per mosquito that was used during 
intrathoracic inolculation was added (~1640 PFU), based on the assumption that 
each mosquito will consume ~ 2µl of blood.  Infectious blood was loaded into 
membrane feeders and mosquitoes were allowed to feed for an hour in the dark.  
Mosquitoes were maintained at 27oC.  Bloodfed mosquitoes were separated from 
unfed mosquitoes 24-48h after feeding.  Bloodfed mosquitoes were dissected at 3 
and 6 dpi; midguts were removed from the carcass, taking care to keep the anterior 
gut and cardia attached, and fixed in 4% paraformaldehyde (PFA) for 30-60 minutes.  
Fixed guts were washed three times with PBS before mounting on slides in 
Vectorshield with DAPI.  Anterior-, mid-guts and the cardia were observed using a 
fluorescent microscope to check for GFP expression.  Prevalence of infection ranged 
from ~40-60% in N’gousso mosquitoes and 40-80% in G3 mosquitoes during 
different replicates of the same experiment (data not shown).  The effect of 
antibiotic treatment on prevalence of viral infection was investigated; mosquitoes 
were fed on 10% fructose containing gentamycin, penicillin and streptomycin for 5 
days prior to feeding on an infectious bloodmeal.  Treatment of antibiotics did not 
effect the prevalence of viral infection in G3 (Figure 14A) or N’gousso (data not 
shown) mosquitoes.  The dependence of prevalence on dose was also investigated; 
mosquitoes were fed with a single dose (~1640 PFU) or a double dose of virus (~3280 
PFU) and prevalence was assessed at 3 and 6 dpi.  Infection was seen to be dose 
dependent, with prevalence increasing around 2.6 fold at day 3, and 1.5 fold at day 6 
when a double dose was given (Figure 14B).   
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Figure 14.  Effect of antibiotics and dose on infection in A. gambiae mosquitoes; A) 
Prevalence of GFP in cardia/anterior gut/midguts dissected at 6 dpi; G3 mosquitoes 
were fed on 10% fructose with (+) or without (-) antibiotics for 3 days prior to blood 
feeding.  Mosquitoes were starved of sugar overnight, and then allowed to feed on 
an infectious bloodmeal.  At 6 dpi midguts with a complete anterior gut and cardia 
were screened for GFP expression.  B) Prevalence of infection is dose dependent; 
mosquitoes were allowed to feed on an infectious bloodmeal containing a single 
dose (~1640 PFU) or a double dose (~3280 PFU) of virus.  At 3 and 6 dpi midguts with 
a complete anterior gut and cardia were screened for GFP expression. 
 
 
 
 
 
 
 
Figure 15.  Diagram of the mosquito alimentary canal.  Blood meals are taken up 
through the proboscis, to the midgut (M) via the esophagus, cardia (C) and anterior-
gut (A).  Sugar and water are taken up into the crop.  Adapted from Gusamo et al 
2007[101].       
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Figure 16.  Infection patterns of 5′ONNVic-eGFP in per os infected A. gambiae 
mosquitoes at 5 X magification; Infection patterns in per os infected mosquitoes; G3 
mosquitoes were given infectious bloodmeals of ~5000 PFU/mosquito.  Pictures 
were taken of dissected midguts with an intact cardia and antierior gut at 6 dpi.  GFP 
expression, and thus viral infection, can be seen frequently in the cardia (C), anterior 
gut (A) and occasionally in the midgut (M).      
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Figure 17.  Infection patterns of 5′ONNVic-eGFP in per os infected A. gambiae 
mosquitoes at 20 X magification; Infection patterns in per os infected mosquitoes; 
G3 mosquitoes were given infectious bloodmeals of ~5000 PFU/mosquito.  Pictures 
were taken of dissected midguts with an intact cardia and antierior gut at 6 dpi.  GFP 
expression, and thus viral infection, can be seen frequently in the cardia (C)), 
anterior gut (A) and occasionally in the midgut (M).    
 
 
 
To further investigate susceptibility to infection, N’gousso mosquitoes were fed with 
a high dose (~5000 PFU/mosquito) of P1/P2V 5′ONNVic-eGFP.  Prevalence of 
infection was 48% (259 out of 519 mosquitoes) at D3 post feeding, dropping to 38% 
(267 out of 697 mosquitoes) by D6 post feeding.  Figure 15 outlines the alimentary 
canal of a typical mosquito indicating the positions of the cardia, the anterior gut and 
  
 82 
the midgut.  Tissue tropism of infection was restricted mainly to the cardia and 
anterior gut, with typically small clumps or several single cells expressing GFP (figure 
16 and 17).  Some individuals displayed widespread infection of the cardia and 
anterior midgut (10% of blood fed mosquitoes at D3 dropping to 9% by D6) and 
fewer individuals still demonstrated infection of the midgut, typically small patches, 
sometimes extending across around half the midgut (7% of blood fed mosquitoes at 
D3 dropping to 4% by D6).      
 
4.6 Cross species comparison of ONNVic-eGFP infection in Anopheles 
gambiae, Anopheles arabiensis and Anopheles quadriannulatus.   
 
Three different species of Anopheles mosquitoes were infected with P1/P2V 
5′ONNVic-eGFP; A. gambiae, A. arabiensis and A. quadriannulatus.  Cohorts of 50 
mosquitoes were intrathoracically inucolated with ~1640 PFU.  Survival rates of 
infected mosquitoes were recorded (see Figure 18 A/B/C/D) and at day 7, viral titre 
for the remaining mosquitoes was calculated using qrt-PCR.  A. quadriannulatus 
consistently showed substantial death compared to control inoculated mosquitoes, 
with only around 35% of mosquitoes surviving to 7 dpi.  A. arabiensis also showed 
some death associated with viral infection, however this was not consistent between 
replicates.  G3 and N’gousso, two strains of A. gambiae, showed no difference in 
survival rate when infected with 5′ONNVic-eGFP compared to control mosquitoes.  
Interestingly A. quadriannulatus, as well having reduced survival rates to infection 
compared to A. gambiae and A. arabiensis, also showed the highest titre of viral 
infection (Figure 18D).         
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Figure 18.  Infection of three different mosquito species;  Survival curves for A) A. 
gambiae N’gousso strain, B) A. gambiae G3 strain, C) A. quadriannulatus and D) A. 
arabiensis intrathoracically inoculated with ~ 1640 PFU/mosquito 5′ONNVic-eGFP.  E)   
Viral RNA genome copy number/mosquito at 6 dpi calculated by qrt-PCR.  Error bars 
represent SD from two biological replicates.      
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4.6.1 Summary 
 
This chapter has covered: 
 Production of infectious clones of 5′ONNVic-eGFP; GFP expressing clones of 
ONNV were generated in a mammalian cell line.   
 Propagation and titring of infection clones; Infectious clones were 
propagated for use in experiments and standard plaque assay was used to 
titre viral stocks.   
 Infection of A. gambiae derived cell lines; Seven A. gambiae derived cell lines 
were tested for susceptibility to 5′ONNVic-eGFP infection.  Infection 
dynamics in one of those cells lines, L35, was optimised and characterised.   
 Infection of adult A. gambiae mosquitoes: Intrathoracic inoculation and per 
os infection; Adult A. gambiae mosquitoes were tested for susceptibility to 
5′ONNVic-eGFP through two infection routes; intrathoracic inoculation 
directly into the hemolymph of the mosquito, or through infectious blood 
meals.   
 Cross species comparison of 5′ONNVic-eGFP infection; Differences in 
susceptibility to 5′ONNVic-eGFP between three Anopheles spp. was 
investigated 
 
4.7 Discussion 
 
4.7.1 Generation of infectious clones and infection of mammalian and insect cells 
 
ATSs are invaluable tools for the study of host-pathogen interactions between 
viruses and their mosquito hosts, allowing large scale production of viruses 
genetically modified to incorporate markers, genes of interest or RNAi cassettes.  In 
these studies, an ONNV ATS expressing GFP developed by Brault et al [42] was tested 
for infection in vivo and in vitro.  The advantages and limitations of the GFP marker 
are discussed below.          
  
 85 
Two of the seven A. gambiae cell lines tested for infection showed significant 
susceptibility - the L35 and the 4a3A cell lines.  The A.gambiae cell lines were derived 
from newly hatched larvae of several A.gambiae strains.  These are primary cell 
cultures that have a heterogeneous population of cells with varying propterties form 
cell line to cell line.  Microarray analysis of cell line responses to pathogen challenge 
show immuno-responsiveness (Dr G Christophides, personal communication) and as 
such the cell lines are considered to be a good model for studing immune genes.  
However differences in gene expression do exist between these cell cultures and 
may change over time due to the heterogenicity of the cells.  It is possible that the 
4a3A and L35 cell lines are less immuno-competent and thus are more susceptible to 
infection that the other cell lines tested.  It is known that some cell lines lack the 
ability to express certain immune genes, for example the 4a3A cell line does not 
express pro-phenoloxidases (PPOs; exzymes involved in the melanisation cascade) 
whereas the 4a3B cell line expresses 6 PPOs, despite being derived from the same 
initial pool of newly hatched larvae [99].  The ability of a cell line to express immune 
genes may explain the differences in infecrtivity observed, although the presence or 
absence of a receptor required for infection could also explain this.          
 
In both cells lines, not all cells within an infected culture become GFP positive, even 
after several days of infection.  It is unclear why these cells remain apparently 
uninfected – perhaps due to the heterogenicity of the cells, some lack a receptor 
utilised by the virus for infection, or perhaps some cells are more immuno-
competent than others and thus prevent or clear infection.  Another possibility is 
that the virus may no longer be expressing GFP during infection.  The fast and 
efficient replication cycle of viruses results in very short generation times compared 
to many other organisms, allowing genetic mutations to appear, and if 
advantageous, spread through a population quickly.  Additionally RNA virus 
populations are believe to exist as a plethora of quasispecies, where due to high 
rates of error during genome replication (likely due to the high error rates of RDRPs 
and the lack of proof reading enzymes) different mutations occur during each 
genome replication resulting in a mixed population of viruses [102].  It is believed 
that the presence of a large and varied population allows for quick adaptation of 
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arboviruses to the disperate vertebrate and invertebrate hosts during their 
transmission cycle [102-103].  The addition of genetic material to the genome of the 
virus impairs the ability to replicate, and this additional material will be under strong 
pressure to be removed.  Eventually this additional material will be lost in the virus 
population after a certain number of generations (as demonstrated by a decrease in 
mammalian cells infected with 5′ONNVic-eGFP expressing GFP from 55% in a first 
passage to less than 5% by a fifth passage [42]).  In order to limit the possibility of 
genetic changes to the virus, such as deletion of the GFP cassette, or mutations in 
viral genes, the virus was only passaged twice before use in experiments.  However, 
once cells are infected, several generations of viral replication may occur before all 
cells are infected, during which the GFP cassette may be lost.  Thus cells may be 
infected with an infectious clone of ONNV that no longer expresses GFP.  Carrying 
out immunofluorescence assays (IFAs) using an antibody against one of the highly 
conserved envelope proteins would allow distinction between uninfected cells and 
those infected with an infectious clone that no longer expresses GFP.          
   
Infection of VERO cells with 5′ONNVic-eGFP leads to extensive cell death, 
presumably by apoptosis, which is typical of Alphavirus infection in mammalian 
cells[33], as well as a variety of other families of viruses, including the herpesviruses, 
adenoviruses, poxviruses, baculoviruses and many others [104].  In stark contrast to 
infection of mammalian cells, infection of A. gambiae derived cell lines resulted in no 
morphological pathology, although in the literature there have been reports of 
cytopathic infection caused by arboviruses in mosquitoes [105-109] and in 
invertebrate cell lines infected with certain arboviruses [39].  It is not clear whether 
the overall lack of apoptosis in arbovirus infected cells is due to inhibition of 
apoptosis by the virus, avoidance of detection by host cells, or whether host 
invertebrate cells do not use apoptosis as a defence mechanism against infection.  
Indeed, using SIN ATSs expressing inhibitors and activators of apoptosis, it has been 
demonstrated that triggering apoptosis in infected cells does not reduce the initial 
acute phase of virus production in the A.aegypti derived C6/36 cell line, although 
subsequent virus production was reduced as the cells died [38].  Current evidence 
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suggests that apoptosis may be triggered by high levels of Arbovirus infection, but is 
generally not active during persistent infection[110].   
 
Higher titres of virus are generated during the initial acute stage of infection of 
invertebrate cells compared to mammalian cells (5X108 in L35 cells compared to an 
average of ~6X107 in mammalian cells).  This is most likely due to the rapid cell death 
that occurs in mammalian cells following infection, and thus fewer cells producing 
progeny virus during the acute phase of infection.       
 
Infection of A. gambiae cells follows the typical pattern of Alphaviruses in 
invertebrate cells [110], with an initial acute phase of infection between 12 and 72h, 
where production of infectious clones peaks.  After this peak infection levels begin to 
fall, consistent with the observation that alphaviruses form a lifelong but low level 
infection in invertebrate cells [11, 110].  A single replication cycle of 5′ONNVic-eGFP 
takes between 12 and 24h, where the first virus is released from cells.  The 
expression of GFP clearly shows that the infection spreads from a cell to 
neighbouring cell, forming patches of infection, probably arising from a single 
infected cell.  This indicates that the virus can spread more easily between 
neighbouring cells, possibly through the contacts formed between the cells such as 
gap juctions, although this remains to be proven.     
 
Correlation between GFP expression and production of infectious clones is 
consistent until 96 hours, when GFP expression persists but infectious clone 
production has slowed.  Thus GFP is a good marker in cells for early infection, but it 
gives you a ‘yes or no’ answer for infection, and does not necessarily reflect the level 
of virus being produced in infected cells i.e. is a qualitative but not a quantitative 
marker of infection.  If components from the subgenomic promoter i.e. the 
structural proteins and in this case GFP, are the limiting factors in production of 
virus, then we might expect cumulative GFP expression to be roughly proportional to 
the amount of new virus being produced.  If the structural proteins are produced in 
excess, and it is the number of replicated genomes that is the limiting factor, then 
the GFP may not correspond to the amount of new virus being produced.  
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Additionally GFP will remain within the cytoplasm of an infected cell after viral 
replication has slowed or ceased, until the protein is degraded.  Considering that the 
genome is the likely target of RNAi through dsRNA replication intermediates or 
secondary structure, we might expect the limiting factor to be the number of 
replicated genomes available to produce new clones.  Qrt-PCR analysis of viral RNA 
genome copy number gives a more accurate and quantitative measure of viral 
infection in A. gambiae cells.  Although the GFP marker cannot be used as a measure 
of viral production within cells, GFP can still be used to identify genes involved in 
viral infection, such as genes required for invasion.             
 
4.7.2 Infection of adult A. gambiae mosquitoes – intrathoracic innoculation 
 
Initially two different strains of A. gambiae were infected with virus passaged 
through mammalian (VERO) or insect (L35) cells.  The highly laboratory adapted 
strain of A. gambiae, G3, showed the high levels of infection compared to a relatively 
recently colonised strain, Yaounde.  Infectivity of mosquitoes was severely impaired 
by passaging virus through A. gambiae cells prior to infection, consistent with 
previous observations (Dr B Foy, personal communication).  The reason for such a 
large difference in infectivity is not known.  One major difference in post 
translational processing of virus envelope proteins between invertebrate and 
vertebrate cells is glycosylation.  In SINV, both envelope protein E1 and E2 have two 
glycosylation sites  [111].  During SINV infection of insect cells, all glycosylation sites 
have high-mannose sugars due to the absence of n-acetylglucosaminyl-, galactosyl-, 
and sialyltransferases [111].  In vertebrate cells a combination of complex 
oligosacaccharides and high-manose sugars are used, depending on the accessibility 
of the site to processing enzymes in the golgi apparatus [111].  Mammalian-cell 
derived and mosquito-cell derived RRV has been shown to differentially induce type I 
interferons in mammalian cells.  Mosquito-cell derived viruses are poor inducers of 
IFN alpha/beta, whereas mammalian cell derived viruses are potent inducers of IFN 
alpha/beta [112].  This differential induction is attributable to the differences in N-
linked glycosylation resulting from passage through mosquito cells [112-113].  
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Whether the complex oligosaccharides present in mammalian-cell derived virus are 
required for binding to a receptor and thus infection, or whether the high-mannose 
sugars from mosquito-cell derived virus trigger anti-viral immune responses in the 
mosquito and so prevent or clear infection is not clear, but may explain the 
differences in infectivity observed.    
 
The dynamics of 5′ONNVic-eGFP infection of adult G3 mosquitoes follows a similar 
trend as that seen in the L35 cell line, with an initial acute phase of infection peaking 
at days 6-8, followed by a decline in production of virus by day 9.  The cause of the 
switch from initial acute phase of infection where large amounts of virus are 
released from infected cells, to the persistent phase of infection, where small 
amounts of virus are released from infected cells, or a small number of cells release 
virus, is not known.  This switch could be mediated either by the virus, in order to 
limit damage to the vector and establish a lifelong infection ensuring transmission to 
as many other hosts as possible, or could be mediated by the host i.e. immune 
reactions that limit viral infection may be switched on.  In cultured A.albopictus cells 
infected with SINV or SFV, a polypeptide factor is secreted that downregulates 
production of virus [11, 114].  This factor is mosquito and virus specific i.e. it only 
effects mosquito cells, and the factor secreted in response to SINV is ineffective for 
SFV infection and vice versa [11].  Uninfected cells treated with the secreted factor 
arrest cell division, but subsequently recover and are resistant to virus infection 
[114].  They also constitutively secrete the factor, and another protein that is 
associated with lysosomes [115].  It is possible that in mosquitoes, where virus is 
typically downregulated at 7 dpi, a similar mechanism is in place [11].  In the case of 
SFV, an alternative model suggests that the virus is responsible for the switch, 
through the mechanism it employs to prevent ‘superinfection’ of cells [116].  Early 
after infection nsP4 and P123, formed from cis-cleavage of P1234, function to 
synthesise minus strand RNA, later further trans-cleavage forms nsP1, P23 and nsP4, 
capable of both plus and minus strand synthesis.  A final cleavage to form the 4 nsP’s 
abolishes the ability to generate minus strand RNA, and due to the presence of high 
concentrations of trans-acting protease at this stage, new P123 is not generated [11, 
116].  At this stage the virus can continue to produce progeny from already 
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established replicase complexes, but no new replicase complexes can be formed.  
Thus, viral production is dramatically reduced, preventing ‘superinfection’ of cells 
[116].  It is suggested that eventually the non-structural proteins and trans-acting 
protease will be degraded, removing the inhibition of minus strand synthesis, and 
hense the cell is once again susceptible to infection, explaining how low levels of 
infection continue persistently in infected vertebrates [116].  Whether either of 
these mechanisms is present in ONNV infection of A. gambiae is unknown.       
 
The spread of 5′ONNVic-eGFP infection in intrathoracically inoculated A. gambiae 
mosquitoes is slow compared to other vector-virus combinations.  In fact, when 
ONNV is injected into Culicine mosquitoes it rapidly replicates and spread 
throughout the mosquito host [80].  It has been suggested that the robust RNAi 
response observed in A. gambiae mosquitoes [117] may contribute to the poor 
vectorial capacity of these mosquitoes in comparison with other typical vector-virus 
combinations [80].   
 
Tissue tropism of infection after intrathoracic inoculation was similar to that 
observed previously using this vector-virus combination [80], with the head tissues 
most commonly showing GFP expression, however this may be due to the reflective 
quality of the ommatidia in the eye of the mosquito, reflecting light out as well as 
into the eye and thus allowing clear observation of GFP.  When observing whole 
mosquitoes, GFP expression through the cuticle was more difficult to see, coupled 
with the autofluorescent quality of the cuticle itself.  As such, it can be difficult to 
discern whether a mosquito is infected or not based on the presence of GFP 
expression.  The more reliable and accurate quantitative real-time PCR method or 
standard plaque assay were used subsequently to quantify infection in mosquitoes, 
giving more accurate results, but also a quantitative result rather than the qualitative 
results obtained from observing GFP expression alone.  Although tissue tropism in 
intrathoracically inoculated mosquitoes was not observed in detail (as previous 
studies have done so [42]), interestingly either nerve or muscle cells surrounding the 
gut were often seen to be infected, as observed in other vector-virus combinations; 
Rift Valley Fever (RVF) infects skeletal and visceral muscles, SIN infects visceral 
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muscles in Ae. albopictus [118] and Ae. Aegypti [119] and WNV infects the 
contiguous muscles of the posterior and anterior midgut in Culex mosquitoes [106, 
118].  It is possible that infection of nervous or muscle tissue of the gut may provide 
a route of dissemination from the gut after a blood meal.     
4.7.3 Infection of adult A. gambiae mosquitoes – Per Os infection 
 
Patterns of viral infection following an artificial blood meal show limited and 
restricted tropism in comparison to many other virus-vector combinations.  Viral 
infection was almost exclusively seen in the cardia and anterior gut tissues, with 
occasional midgut infection in a small number of individuals (7% at D3 dropping to 
only 4% at D6 post blood feeding).  This restricted tissue tropism is similar to those 
observed in ONNV infections of A. gambiae in the past [42]. In comparison, midgut 
infection rates in A.aegypti infected with DENV are 87-90% (in three different 
A.aegypti strains)[120] and infection is spread throughout the midgut by 10 dpi 
despite a lower infectious loads in the blood meal than used for 5′ONNVic-eGFP.  SIN 
infection of A.aegypti leads to large patches of infected midgut epithial cells and 
midgut musculature [119-120].  EEEV infection of Culiseta melanura (the virus’ 
enzootic vector) results in rapid infection of the midgut [121].  Several other viruses 
closely related to ONNV cause broad midgut infection in their natural vectors, 
including VEEV, SIN in Culex pipiens, and WEEV [42].  Although not carried out in this 
study, dissemination rates for ONNV infection in A. gambiae have also been shown 
to be low compared to other vector-virus combinations [42].  This indicates that A. 
gambiae should be a poor vector of ONNV, and may not be the natural vector of the 
disease outside of epidemics.  This is supported by the findings of ONNV positive 
mosquitoes only during epidemics of the disease [23].  A.funestus mosquitoes that 
have been found positive for ONNV infection and are postulated to be the main 
vector of the virus [25, 122].   
4.7.4 Comparison of 5′ONNVic-eGFP infection in three freshwater 
Anopheles species 
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A comparison of 5′ONNVic-eGFP infection in A. gambiae was carried out with two 
other fresh water Anopheles species; A. arabiensis and A.quadiannulatus.  A. 
arabiensis shares a similar geographical distribution to A. gambiae, spread across the 
whole of central Africa from Senegal through to Sudan and Ethiopia, and further 
south throughout Kenya, Tanzania, Mosambique, and the Democratic Republic of 
the Congo [123].  A. arabiensis is additionally found through Angola and Zambia, 
where A. gambiae is less prevalent.  In contast, A. quadriannulatus is restricted to 
two zones; one in the highlands of Ethiopia (called A. quadriannulatus B), and the 
other in South Africa, Botswana and Zimbabwe (called A. quadriannulatus A) where 
the weather is more temperate than other parts of Africa [123].  It is believed that A. 
arabiensis is the most ancient of the three spp, from which an ancestral A. 
quadriannulatus evolved.  A. quadriannulatus A, A. quadriannulatus B and A. 
gambiae speciated from this ancentral form.  A. gambiae and A. arabiensis are both 
important vectors of human malaria in sub-Saharan Africa, however A. 
quadriannulatus are not known to be vectors of malaria in natural populations, 
indeed no malaria parasites have ever been found in field caught female mosquitoes 
[63].  In laboratory experiments with A. quadriannulatus and the rodent model of 
malaria, Plasmodium berghei, invading parasites crossing the midgut are frequently 
melanised, with a small proportion forming oocysts.  This partial refractoriness to 
infection is heritable and dominant.  Silencing key components of the mosquito 
immune system (LRIM1, APL1C and TEP1) allows parasites to develop normally in A. 
quadriannulatus, effectively turning the mosquito into a competent vector [63].  It is 
speculated that through repeated exposure to malaria parasites in A. gambiae and 
A. arabiensis spp may have led to an evolutionary co-adaptation between mosquito 
immune responses and the parasite, however A. quadriannulatus, through limited 
geographical range and a more zoophillic lifestyle retained an ancestral refractory 
phenotype, based on innate immune responses [63].  A. gambiae and A. arabiensis 
are relatively refractory to 5′ONNVic-eGFP infection compared to A. 
quadriannulatus, with viral titres at 6 days post infection of 20 times higher in A. 
quadriannulatus compared to A. arabiensis, and 6 times higher in A. quadriannulatus 
compared to A. gambiae.  The distribution of ONNV epidemics reported to date 
occurred in areas where both A. gambiae and A. arabiensis are prevalent, however 
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A. quadriannulatus are scarce.  It is possible that the repeated exposure of A. 
gambiae and A. arabiensis has resulted in the evolution of immune mechanisms to 
cope with viral infection, limiting the ability of the virus to replicate, whereas in A. 
quadriannulatus these immune mechanisms have not evolved, allowing the virus to 
replicate to high levels in mosquito tissues.  Current evidence in insects indicates 
that when high levels of virus are present, exceeding a threshold, apoptosis is 
induced [110].  This could explain the death induced by viral infection; by 6 dpi, 
around 60% of infected A. quadriannulatus mosquitoes had died.  The cause of death 
was not determined; however studies looking at differences in gene copy number of 
the whole genome between A. gambiae and A. quadriannulatus show large 
differences in apoptotic related genes (Tibebu Habtewold, unpublished data).  It 
would be interesting to investigate further whether apoptosis induced by viral 
infection may be responsible for the shortened life span observed in A. 
quadriannulatus mosquitoes.   
 
It is also noteworthy that the cell line susceptible to 5′ONNVic-eGFP infection, L35, is 
derived from a genetically selected Plasmodium refractory line of A. gambiae 
mosquitoes that, similarly to A. quadriannulatus, melanise all invading Plasmodium 
berghei parasites as they cross the midgut.  There may be a link between genetic 
refractoriness to one pathogen, and genetic susceptibility to another, perhaps 
rooted in the innate immune system.   
4.7.5 Final comments 
 
In most arbovirus-mosquito vector combinations viral infection leads to widespread 
infection of multiple tissues, including the midgut, fat body and, importantly for 
transmission, the salivary glands of the infected mosquito.  Although infection of A. 
gambiae with 5′ONNVic-eGFP does lead to infection, tissue tropism is restricted in 
adults infected both intrathoracially and through infectious blood meals.  Infection 
of a variety of A. gambiae cell lines similarly shows limited infection in the majority 
of cell lines tested. This indicates that A. gambiae is a poor vector of ONNV, and 
probably only functions as a vector of the virus during epidemics of the disease.   
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The use of GFP as a marker of infection in this model system has limitations, 
particularly in reference to infection of adult mosquitoes.  GFP is a good marker of 
early infection in the susceptible L35 cell line, however GFP expression does not 
correspond to generation of new virions after the acute phase of infection.  The GFP 
marker could be used to screen genes for functions in initial infection of cells, 
however for quantitative data measuring the titre of the virus directly would give 
more accurate results.  In adult mosquitoes an additional problem lies in the innate 
auto-fluorescence and thickness of the mosquito cuticle.  GFP expression is difficult 
to see and is not an accurate marker for infection. Again, direct titring of the virus 
provides more accurate quantitative data.   
 
This unusual vector virus combination offers an interesting opportunity to study the 
interactions between a mosquito and virus that often leads to clearance of viral 
infection, possibly mediated by the robust immune system of A. gambiae 
mosquitoes.  Investigating these interactions may give insight into the genetic 
determinants of vectorial capacity in mosquitoes.      
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5 A. gambiae transcriptional responses to viral infection, and 
identification of genes regulating viral infection in adult 
mosquitoes 
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5.1 Introduction 
 
In order to identify components of an organism’s immune system, there are several 
approaches that can be adopted.  Firstly a literature based approach can be taken, 
where already characterised genes from model systems; typically D. melanogaster 
for insects, can be hypothesised to have similar functions in closely related systems.  
Using this approach narrows the window of focus to a few distinct immune signalling 
pathways with, in this case, known roles in anti-viral immunity in various insects.  
Although focusing studies to more likely relevant genes or gene families, this 
approach will miss any species specific adaptation to the pathogens that they will 
encounter.  The haematophagous lifestyle of A. gambiae confers exposure to a wide 
variety pathogens that D. melanogaster does not encounter, as such we might 
expect the immune responses to these disparate groups of pathogens to be quite 
different.  Using a genome wide forward genetics approach to study pathogen-
vector interactions can reveal genes with important functions that are not present or 
utilised in other model systems.  A good example of this is the leucine rich repeat 
immune (LRIM) family of proteins identified in A. gambiae.  This family of genes was 
discovered through microarray analysis of A. gambiae responses to Plasmodium and 
bacterial infection [124-125].  LRIM1 is a potent inhibitor of Plasmodium berghei 
development in A. gambiae mosquitoes [62, 126].  It belongs to a family of similar 
proteins that are mosquito specific and are not found in D. melanogaster.  
Subsequently it has been seen that other members of this family are also potent 
antagonists of P. berghei development [127-128].  Without using genome wide 
approaches to study vector-pathogen interactions, such gene families may not be 
discovered.   
 
Microarray technology allows researchers to study the transcriptional profiles of 
entire genomes, generating huge datasets containing vast amounts of biological 
information.  Although very powerful, microarray experiments must be carefully 
planned and tightly controlled to avoid generating false positive data.  During this 
project a full genome microarray using Agilent technology was used.  In order to 
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begin identifying A. gambiae genes involved in anti-viral immunity, the global 
transcriptional responses of mosquitoes to ONNV infection were investigated.    
5.2 Transcriptional response to 5′ONNVic-eGFP infection: experimental design 
 
A microarray study carried out by previous members of the laboratory, in 
collaboration with the University of Notre Dame, transcriptionally profiled A. 
gambiae mosquitoes infected with ONNV using a spotted amplicon microarray 
encompassing only a small number of genes [129].  With the rapid improvement of 
microarray technology, and the significantly improved gene predictions from the A. 
gambiae genome on which a genome wide microarray chip was developed, 
repeating the transcriptional analysis was necessary to gain a global view of A. 
gambiae responses to viral infection.  In this study a microarray platform was 
developed by colleagues in the laboratory using Agilent technology.  This microarray 
platform covered the full genome of A. gambiae based on the PEST strain, assembly 
version AgamP3, gene build Agam P3.3 
(http://www.vectorbase.org/Help/AgamP3.3_annotation_metrics).  The probes 
were designed using Agilent’s eArray online service.  In brief, the transcript 
sequences of all predicted A. gambiae genes were uploaded into Aglient eArray, and 
60 base pair (bp) probes with similar TMs were designed.  Each probe was duplicated 
and placed randomly on the array to avoid spatial effects such as drying 
out/scratches on the array.  The predicted immunity gene transcripts were split into 
10 sequences and a single probe was designed for each of the 10 sequences, giving 
10 unique probes for each immunity gene in addition to the probes designed for 
every predicted gene.  A large number of controls for both Cy-3 and Cy-5 labelled 
probe hybridisations were included.  All probes were randomly spotted on the array.  
All probe design was carried out by Dr Amanda Jackson and Seth Redmond.          
 
Based on the dynamics of 5′ONNVic-eGFP infection in A. gambiae mosquitoes three 
time points were selected for transcriptional analysis (figure 19):  Day 1 post 
infection (dpi) represents the early stages of infection, when the first cells become 
infected; 4 dpi represents the exponential phase of infection, where viral infection is 
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spreading from cell to cell, and tissue to tissue; 9 dpi represent the persistent lower 
level of infection established by alphaviruses in their mosquito host.   
 
 
Figure 19. Experimental design for transcriptional analysis of 5′ONNVic-eGFP 
infection.  Total RNA from infected (~1640 PFU/mosquito P1/P2V 5′ONNVic-eGFP in 
69 nl) and mock infected (injected with 69nl of conditioned media from mock 
transfected Vero cells) mosquitoes was extracted at 3 time points after infection – 1, 
4 and 9 dpi.  RNA from infected mosquitoes was labelled with Cy-3 and mock 
infected with Cy-5 nucleotide analogs.  Equal amounts of RNA from each were 
hybridised on an aglient 4 X 44K array platform.     
 
 
5.3 Transcriptional response to 5′ONNVic-eGFP infection: experimental 
procedure 
 
Mosquitoes were intrathoracically inoculated with the virus to ensure dissemination 
of the virus to all mosquito tissues; mosquitoes were injected with either P1/P2V 
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5′ONNVic-eGFP (~1640 PFU/mosquito) or with conditioned medium generated by 
transfecting LacZ RNA into VERO cells, and ‘passaging’ in an identical manner to 
passaging virus (P1/P2V LacZ).  Three biological replicates were carried out, with 
each replicate using G3 strain A. gambiae that have hatched from the same batch of 
eggs and reared in identical conditions.  Each cohort of mosquitoes was injected at 
the same age, and kept in identical conditions for the duration of the experiment.  
Mosquitoes were not screened for GFP expression prior to total RNA extraction to 
prevent selection of susceptible individuals.  This microarray study aimed to 
investigate the immune responses of A. gambiae to infection, including those 
capable of clearing viral infection.  At each selected time point, 10 mosquitoes were 
collected and homogenised in 500µl TRIzol reagent.  Total RNA was extracted, and 
assessed for quality using gel electrophoresis and spectophotromotry (section 3.11).  
Using the Agilent low RNA imput kit (Agilent), RNA from infected and control 
mosquitoes was amplified and labelled with Cy-3 and Cy-5 nucleotide analogues 
respectively.  Equal quantities of labelled RNA were mixed and hybridised to the 
Agilent 4X44K microarray (section 3.15.1). Hybridised slides were washed to remove 
unbound labelled RNA (section 3.15.2) and were scanned using an GenePix 
semiconfocal microarray scanner (AXON Instruments, Foster city, CA).                         
5.4 Analysis of transcriptional responses 
 
Candidate gene lists were generated as follows (summarised in figure 20); Gene Pix 
Pro 6.1 was used to record feature signal intensity, to eliminate local backgrounds, 
for grid alignment and manual inspection of feature quality.  Average feature 
diameter was calculated and features lying outside two standard deviations of the 
mean were excluded from analysis.  The ratios of feature intensity versus local and 
global backgrounds were calculated and features not exceeding background 
intensities were excluded from analysis.  Features were normalised using Genespring 
6.1 (AXON Instruments, Foster city, CA) by locally weighted linear regression 
(Lowess) methods.  Feature intensities over the three biological replicates were 
averaged.  T-test p-values were calculated, and normalised data was filtered to 
exclude data with p-values greater than 0.05.  Data was further filtered to include  
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Figure 20. Microarray feature filtering and candidate gene selection process.  
GenePixPro 6.0 was used to record feature intensities, and remove manually 
checked features.  Local background elimination, feature diameters and filtering of 
ratio intensities to remove features not exceeding background intensities was 
performed in Micorsoft Exel.  Genespring was used to normalise feature intensities, 
calculate T-tests, remove data with P values >0.05 and to calculate fold-change 
ratios.  Biomart was used to identify GO terms and orthologous genes in other 
insects.      
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only genes showing 2-fold and greater regulation.  For immune genes, where 
multiple probes for each gene are present, fold change ratios that pass all the 
described filters were averaged and given a single value.   
 
5.5 Genome wide responses to 5′ONNVic-eGFP infection in A. gambiae 
mosquitoes 
 
Transcriptional profiling of infected versus mock infected mosquitoes revealed a 
large number of genes that are differentially regulated (figure 21).  At 1 dpi, 64 genes 
are differentially regulated; these genes represent the early onset genes, rapidly 
responding to virus injected into the hemocoel, to virus attaching to, and invading 
cells.  At 4 dpi 214 genes are differentially regulated.  This is during the acute phase 
of infection where viruses are released from infected cells and spread throughout 
the carcass of the mosquito.  By 9 dpi a dramatic drop in the number of differentially 
regulated genes is observed from 214 to 23.  These genes are regulated during the 
persistent phase of infection.  A full list of regulated genes can be found in Table1 
Appendix 1.          
   
Clustering the differentially regulated genes by time point allows us to see how the 
temporal pattern of gene expression changes during infection.  Genes can be divided 
into 6 catagories: early onset genes (those differentially regulated only at D1); early 
to mid onset genes (those regulated at D1 and D4); mid onset genes (regulated at D4 
only); mid to late onset genes (those regulated at D4 and D9); late onset genes (D9 
only); broadly responsive genes (those regulated at D1, D4 and D9).     
 
5.5.1 Early onset genes 
 
There are 23 early onset genes that respond to 5′ONNVic-eGFP infection (Table 1 
Appendix 1).  A cluster of 3 guanine nucleotide binding proteins (G-proteins, with 
functions in signal transduction) are down-regulated.  There are 4 up-regulated 
genes with putative immune functions; 3 are pathogen recognition/immune  
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Figure 21.  Global transcriptional responses to 5′ONNVic-eGFP infection.  The 
transcriptional responses of A. gambiae mosquitoes to 5′ONNVic-eGFP infection 
were profiled using 4X44K Agilent RNA microarrays.  Gene lists include only features 
that pass strict criteria outlined in Figure 20.  Genes included the analysis are 2-fold 
or greater regulated at a minimum of 1 of the 3 time points, with T-test P values of 
<0.05.  Genes were categorised based on gene ontology and orthologs in other 
insects.    
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signalling activation proteins (ML9, LRIM1 and TEP5), and 1 is a peroxidise (GPXH3) 
with a putative function in pathogen clearance.  A further possible immune related 
gene is down-regulated; the orthologs of AGAP005901 from D. melanogaster to 
humans have putative functions in innate immune signalling, specifically in the 
regulation of apoptosis[130-133].  Of the 16 up-regulated genes, 9 are genes with no 
putative function or predicted gene ontology (GO), including a gene cluster 
(AGAP003773/5/7/8).   Other up-regulated genes have diverse functions in 
metabolism, fatty acid synthesis & translation, and structure (cytoskeletal proteins).  
 
5.5.2 Early to mid onset genes 
 
Thirty eight genes are differentially regulated at both D1 and D4 post infection, the 
majority of which are up-regulated.  Of the 32 up-regulated genes, a significant 
proportion is immune related: 13 putative immune genes with diverse functions 
from pathogen recognition, immune signal modulation and pathogen clearance are 
described in detail later.  Nine genes with no known function or predicted gene 
architecture are up-regulated.  Two fatty acid synthesis related proteins are up-
regulated (a fatty acid synthase, and a fatty acid elongation protein).  Further up-
regulated genes include: a laminin B-like gene (the ortholog of an extracellular 
matrix protein, which regulates growth factor-like signalling pathways in C.elegans 
and humans); two insect odorant binding proteins; genes associated with nitrogen 
compound metabolism and carboxylesterase type B activity.   
   
Two genes associated with cell division are down-regulated: a putative cell cycle 
checkpoint kinase and a gene with cell cycle associated roles in D. melanogaster.  
Additionally a matrix metalloproteinase (MMP) is down-regulated, ortholog of 
MMP1 in D. melanogaster, which has diverse functions in cell proliferation, 
apoptosis and immune defence.   Further down-regulated genes include a 
translation initiation factor-like gene, an actin/microtubule binding protein, and a 
protein with no predicted functional domains.   
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5.5.3 Mid onset genes 
 
The mid onset genes are by far the largest cluster regulated by 5′ONNVic-eGFP 
infection.  170 genes are differentially regulated, and unlike the other clusters where 
the majority of genes are up-regulated, 52% are down-regulated.  Some striking 
groups of genes with similar functions respond to ONNV infection during the acute 
phase of infection.  Twenty seven putative immunity genes are differentially 
regulated (described in detail in section 5.5.6).  Four genes associated with RNA 
degradation are down-regulated: Dicer-1; the ortholog of D. melanogaster P-
element induced wimpy testis (PIWI); a gene involved in RNA metabolism; TSN, a 
member of the RNAi pathway.  Additionally 6 RNA helicases are down-regulated.  
Eight genes associated with cell division are down-regulated, and 13 genes with roles 
in cellular signalling are down-regulated: 4 transcription factors (including the 
general transcription factor TFIIH); 2 genes implicated in WNT signalling in D. 
melanogaster (a negative regulator of the WNT pathway, and a gene thought to 
phosphorylate dishevelled in the WNT pathway); 2 protein phosphatases (1 tyrosine 
and 1 serine/threonine specific); a PI-4 kinase (with typically diverse roles in 
signalling); a GTPase activator; a GTP binding protein; a TGF-beta superfamily protein 
and an ortholog of a D. melanogaster regulator of transcription in the 
decapentaplegic (DPP) pathway (both of which have diverse putative functions in cell 
growth and differentiation).           
   
Nine genes associated with translation and transcription are down-regulated 
including: three regulators of splicing; a tRNA synthesis enzyme; an enzyme that 
catalyses the addition of tRNA to growing amino acid chains; a translation initiation 
factor; an ortholog of the RNA polymerase 1 specific transcription initiation factor 
RRN3; an inhibitor of transcription.  A histone acetyltransferase (a promoter of 
transcription) is up-regulated.        
   
Forty genes have no known putative function and/or no predicted protein domain 
architecture.  Thirty nine genes have diverse functions in many aspects of cell 
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biology.  There are 13 genes associated with metabolism, and as seen in the early to 
mid onset cluster of genes, 3 more genes associated with fatty acid synthesis.   
             
5.5.4 Mid to late onset genes 
 
Only 4 genes are differentially regulated at both 4 and 9 dpi, demonstrating a large 
switch in gene regulation between D4, where a large number of genes are regulated, 
and D9, where a small number of genes are regulated.  The change in gene 
expression differentiation follows the dynamics of viral infection, where by 9 dpi viral 
infection is persistent but at a low level.  A single putative immunity gene (an LRR 
gene), a thio-reductase, a protein with unknown function and a fumerate lyase are 
all up-regulated at this stage.   
 
5.5.5 Late onset genes 
 
Fifteen genes are differentially expressed only at the late phase of infection – a 
dramatic decrease from the 170 expressed at D4.  The majority of genes are up-
regulated including 4 genes with no putative function and/or predicted gene 
architecture, 3 immunity genes (described in detail in section 5.5.6), and 
interestingly 2 genes associated with RNA degradation.  The first contains a PIWI and 
a PAZ domain (similarly to PIWI and several genes associated with RNAi) and the 
second is a closely related to TSN (a member of the RNAi pathway).   
   
The expression of 3 genes peaked during early and late infection; 2 with no predicted 
gene architecture, and a putative immunity gene (FREP44).  Only 1 gene was found 
to be up-regulated throughout the time course (Lysozyme C4).    
 
Qrt-PCR was used to independently confirm the differential regulation of 4 genes 
found to be virally responsive (figure 22).   
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Figure 22. Qrt-PCR confirmation of virally responsive genes.  The expression of 4 
virally responsive genes ascertained by microarray analysis (red) was confirmed 
using qrt-PCR (blue).  cDNA was generated from RNA extracted from 5’ONNVic-eGFP 
infected and mock infected (LacZ control) mosquitoes.  Transcript levels are 
expressed as a % of those observed in the LacZ control.  Error bars represent 
standard deviation of 3 biological replicates.               
 
5.5.6 Immune genes regulated by 5′ONNVic-eGFP infection 
 
In addition to the probes designed against all predicted genes in the A. gambiae 
genome, the array platform used during this project encompassed an additional 10 
probes for each predicted immunity gene.  During analysis, data was rejected 
according to the filtering criteria outlined in figure 20.  The majority of this data is 
rejected due to high levels of variation between biological replicates.  As a result, 
data from all 10 probes corresponding to each immunity frequency did not pass the 
filtering criteria, giving data for only a few of these 10 probes.  For each immunity 
gene where at least 1 probe passed the filtering criteria, in order to add confidence 
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that the probe was showing true differential regulation, the whole probe set was 
plotted including data that did not pass the T-test filter (i.e. data that had passed all 
filtering criteria except filtering on P value) (Appendix 1, figure S1).  These plots gave 
two valuable insights into the data that have passed all the filtering criteria: firstly 
the trend of expression over the whole time course was seen; secondly, using the 
multiple probes generated for immunity genes, the trend of multiple probes 
corresponding to the same gene was visualised.  The plots, although containing data 
that is statistically inaccurate, gave an increase or decrease in confidence of the data 
that passed the filtering criteria.     
 
Four examples are given in figure 23.  ML1 expression shows a trend of up-regulation 
at 1 dpi, followed by a peak of expression at 4 dpi reducing by 9 dpi.  Four of the 10 
probes designed for this gene did not generate data, most likely due to a 
combination of poor sequence from which the probes were designed and/or low 
intensity data.  Five of the 6 probes show the same trend of expression, 
demonstrating that there is an overall increase in ML1 expression during early to mid 
infection.  GALE8 expression shows a peak at 4 dpi.  For this gene, nine probes have 
generated data.  Agreement between the probes is better than that for ML1 
expression, and the data demonstrate that GALE8 expression is up-regulated during 
mid infection.  LYSC4 expression is up-regulated throughout the time course.  For 
this gene only 5 of the 10 probes generate data, however the trend of expression is 
similar for these 5 probes, showing increased expression throughout the time 
course, peaking at 4 dpi.  For LYSC6, only 2 of the 10 probes generate data.  Both 
probes follow the same trend, with expression peaking at 4 dpi, however the change 
in expression level is lower for one probe than the other, reducing the confidence 
that this gene is up-regulated by ONNV infection.  These four examples show how 
the inclusion of statistically in-accurate data can still be used to indicate where false 
positive data has been included in analysis.  Appendix 1 figure S1 shows plots for all 
the immunity associated genes that were identified as being differentially regulated 
using the filtering criteria used for this study.  Using these plots, several genes were 
removed as probable false positives; FREP10 (1 probe shows up-regulation at 4dpi 
and 3 probes show no differential regulation); SRPN5 (1 probe shows up-regulation 
  
 108 
at 4 dpi and 5 show no differential regulation); CLIPB9 (2 probes show up-regulation 
at 4 dpi and 4 probes show no differential regulation).  Two further genes, HPX6 and 
CTL5, show discrepancies between the probes sets, however it is not clear whether 
these genes are differentially regulation or not.    
 
 
 
 
 
Figure 23. Relative gene expression plots of immunity genes. A) ML1 expression B) 
GALE8 expression C) LYSC4 expression and D) LYSC6 expression in ONNV infected 
mosquitoes expressed as fold change ratios compared to a mock infected control.  
Data has passed all the filtering criteria outlined in figure 20, excluding filtering on P 
value.           
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Plotting the data in this way also indicated whether the genes had been clustered 
into the appropriate temporal clusters.  The majority of genes are clustered 
correctly, with a few exceptions.  An example is LRIM1, which is shown to be up-
regulated during early infection using the current filtering criteria.  Data for LRIM1 
expression at 9 dpi is rejected during the filtering due to inconsistency between 
replicates.  If all the data is plotted including the highly variable results for 9dpi (see 
figure 24), the indication is that LRIM1 up-regulation is not only an early response to 
infection, but may also increase in expression during late infection.  This observation 
would require confirmation using qrt-PCR.    
 
 
 
 
Figure 24.  Gene expression plot for LRIM1.  LRIM1 expression in ONNV infected 
mosquitoes plotted as a fold change ratio compared to a mock infected control. Data 
has passed all the filtering criteria outlined in figure 20, excluding filtering on P value.  
As such the data is not statistically accurate.       
 
 
Infection of A. gambiae with 5′ONNVic-eGFP led to the differential regulation of 45 
genes with putative functions in immunity.  Clustering these genes based on their 
putative function within the 6 temporal clusters of gene expression (Table 6) shows a 
broad range of genes with function in all aspects of immune signalling including 
pathogen recognition, complement, immune signalling pathway components, 
immune signal modulation and effector genes.   
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Figure 25.  Immunity genes differentially regulated by 5′ONNVic-eGFP at 4 dpi.  
Genes differentially regulated by ONNV at 4 dpi are shown in black bold text, with 
black outlined cartoons.  Other genes in signal transduction pathways are shown in 
grey text.  Four major signalling pathways are represented; the RNAi pathway, the 
JAK/STAT pathway, the IMD pathway and the apoptotic pathway.  Differentially 
regulated genes are grouped based on cellular location (intracellular/secreted) and 
putative function (recognition, humoral response proteins, opsoniation and 
effectors).  Red arrows indicate the direction of differential regulation.      
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Table 6  Putative immunity genes regulated by 5′ONNVic-eGFP organised by 
function.  Putative immune genes are grouped based on temporal expression, and 
functional category (Recognition, Complement, Signal modulation, Effector, 
Apotosis, IMD pathway, JAK/STAT pathway, RNAi pathway).      
 
        Fold change ratio  
Gene 
Functional 
group Name Day 1 
Day 
4 Day 9 putative function 
       
Early onset       
AGAP010814 Complement TEP5 2.604   
Thioester containing protein, 
complement 
AGAP006348 Complement LRIM1 2.284   
LRIM protein, complement 
[126] 
AGAP004248 Effector GPXH3 2.267   peroxidase, GPX sub familiy 
AGAP002848 Recognition ML9 2.006   MD2-like lipid recognition 
AGAP007039 Recognition LRIM4 2.676   
LRIM protein, unknown 
function 
       
Early to Mid onset       
AGAP010812 Complement TEP4 2.876 2.48 1.611 
Thioester containing protein, 
complement [134] 
AGAP008654 Complement TEP12 2.153 2.36  
Thioester containing protein, 
complement 
AGAP010819 Complement TEP10 3 2.10  
Thioester containing protein, 
complement 
AGAP010830 Complement TEP9 2 2.06  
Thioester containing protein, 
complement 
AGAP005620 Effector DPT 2.024 2.92  Anti-microbial prptide 
AGAP011790 Melanisation CLIPA2 2.089 2.08  
Clip domain serine protease, 
inhibitor of melanisation 
AGAP012352 Recognition ML1 2.31 2.70  MD2-like lipid recognition 
AGAP009556 Recognition FREP50 2.153 2.71  
Fibrinogen like, function 
unknown  
AGAP007457 Recognition LRIM7 2.1 2.31  
LRIM protein, function 
unknown 
AGAP004455 Recognition GNBPB1 2.099 2.45  
GRAM NEGATIVE BINDING 
PROTEIN SUBGROUP B 
AGAP004845 Opsonisation SRCB8 2.007 3.13  
Scavenger receptor, cell 
adhesion,  
AGAP010968 
Signal 
modulation CLIPA9 2.466 2.64  
Clip domain serine protease, 
function unknown 
AGAP003247 
Signal 
modulation CLIPB19 2.136 2.17  
Clip domain serine protease, 
function unknown 
       
Early and late onset       
AGAP005848 Recognition FREP44 2.051  2.59 
Fibrinogen-like, function 
unknown 
       
Mid onset       
AGAP004920 Apoptosis CASPS6  2.05  
Caspase, promoter of 
apotosis 
AGAP007294 Apoptosis IAP1  0.48  Inhibitor of apoptosis 
AGAP008368 Complement TEP14  2.35  
Thioester containing protein, 
complement 
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AGAP005717 Effector LYSC6  2.10  Lysozyme, lysis of pathogens 
AGAP007343 Effector LYSC2  2.08  Lysozymes, lysis of pathogens 
AGAP000694 Effector CEC3  2.04  Anti-microbial peptide 
AGAP004036 Effector HPX7  0.49  Peroxidase 
AGAP004038 Effector HPX8  0.48  Peroxidase 
AGAP009166 
IMD 
pathway IKK1  0.49  IMD pathway component 
AGAP008354 
JAK/STAT 
pathway HOP  0.41  
Janus kinase of JAK/STAT 
pathway 
AGAP005334 Melanisation CTLMA2  2.10  
C-type lectin, inhibitor of 
melanisation 
AGAP004846 Opsonisation SRCB9  2.21  
Scavenger receptor, cell 
adhesion,  
AGAP007455 Recognition LRIM10  2.96  
LRIM protein, function 
unknown 
AGAP004806 Recognition GALE6  2.20  galectin, sugar binding 
AGAP004807 Recognition GALE7  2.16  galectin, sugar binding 
AGAP010774 Recognition FREP27  2.13  
Fibrinogen-like, function 
unknown 
AGAP012529 Recognition GALE8  2.08  galectin, sugar binding 
N/A 
Signal 
modulation CLIPC9  2.59  
Clip domain serine protease, 
function unknown 
N/A 
Signal 
modulation CLIPE4  2.33  
Clip domain serine protease, 
function unknown 
AGAP000443 
Signal 
modulation CTL5  2.04  
C-type lectin, function 
unknown 
AGAP005672 RNAi TSN 0.61 0.34  RNA degradation 
       
Mid to late onset       
       
AGAP005693 Recognition LRIM17  3.90 2.763 
LRIM protein, function 
unknown 
AGAP003246 
Signal 
modulation CLIPB2  2.05 2.176 
Clip domain serine protease, 
function unknown 
       
Late onset       
       
AGAP012037 
Signal 
modulation CLIPB20   2.262 Clip domain serine protease 
AGAP003502 Effector HPX6   2.551 Peroxidase 
       
Broadly responsive       
       
AGAP007385 Effector LYSC4 2.026 2.37 2.037 Lysozyme, lysis of pathogens 
 
Genes from 3 well characterised immune signalling pathways were differentially 
regulated; the RNAi pathway, the IMD pathway, and the JAK/STAT pathway, as well 
as genes with putative roles in apoptosis.   Figure 25 shows putative immune genes 
differentially regulated at 4 dpi.   There are 5 up-regulated early onset immunity 
genes showing a strong bias toward recognition of pathogens and complement 
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associated genes; 2 genes have putative roles in pathogen recognition (an LRR 
protein (LRIM4) and an MD2-like receptor (ML9)); 2 genes are complement proteins 
(LRIM1 and a thioester containing protein – TEP5).  The remaining gene (GPXH3, a 
glutathione peroxidise-like enzyme) has putative functions in immune effector 
mechanisms.  The early to mid onset genes are also biased towards to genes with 
putative roles in recognition and complement, with 4 (of 13) genes being recognition 
receptors or molecules; ML1, GNBPB1 (a Gram negative bacteria binding protein), 
FREP50 and LRIM7; and 4 being complement thioester-containing proteins: 
TEP4/9/10/12.  In addition to pathogen recognition and complement-associated 
genes, 2 CLIPs with likely functions in the regulation of immune responses, a possible 
oposonisation associated gene (scavenger receptor (SCRB8)) and an anti-microbial 
peptide Diptericin (DPT) are also up-regulated.         
 
The largest number of immune-related virally responsive genes are regulated at 4 
dpi.  Although genes associated with recognition are still differentially regulated, 
there is a shift towards genes involved with the regulation of immune signalling and 
effector mechanisms of the immune system at this stage.  Several pathogen 
recognition genes are up-regulated, including 3 carbohydrate binding galectins 
(GALE6/7/8) and 2 fibrinogen-like proteins (FREPS) that have a putative function in 
pathogen recognition although the mechanism of recognition remains unknown.  
Four genes with roles in immune signal modulation are up-regulated: CLIPE4/C9 (Clip 
domain serine proteases that putatively regulate immune signalling cascades); 
CTLMA2 and CTL5 (C-type lectins that modulate immune signalling).  Three effector 
molecules are up-regulated: 2 lysozymes (LYSC2/6) that hydrolyse the cell wall of 
bacteria and Cecropin 3 (CEC3), an AMP that has been shown to be regulated by the 
IMD pathway in mosquitoes[135].     
 
Two apoptotic genes are differentially regulated at D4 - Inhibitor of apoptosis 1 
(IAP1) is down-regulated, and Caspase 6 (CASPS6) is up-regulated.  Three other 
genes are down-regulated: 2 peroxidises HPX7/8; Hopskotch (the Janus kinase from 
the JAK/STAT pathway).   
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A dramatic reduction in the number of mid to late and late onset genes occurs, with 
only 1 mid to late onset immunity gene, and 3 late onset immunity genes.  An LRR 
(putative recognition protein) gene is up-regulated at D4 and D9.  HXP6 and 
CLIPB2/20 are up-regulated at D9 only.  One single gene is differentially regulated 
throughout the time course; Lysozyme C4 (LYSC4).   
 
5.6 Development of a qrt-PCR-based screen for genes with anti-viral properties 
in A. gambiae 
 
In order to identify genes that may have a role in anti-viral immunity in A. gambiae 
mosquitoes, an RNAi and qrt-PCR based assay was developed to asses the impact 
gene KD has on viral infection and replication.  Standard RNAi methods were used to 
silence GOIs[117], in brief dsRNA complimentary to a GOI was injected into 1-2 day 
old adult A. gambiae mosquitoes.  The mosquito RNAi pathway uses the exogenous 
dsRNA as a template to destroy mRNA corresponding to the same gene, and thus 
silence gene expression.  Three different methods were tested to optimise the 
protocol; initially cohorts of mosquitoes were injected with dsRNA on day 1, and 
subsequently injected with 5′ONNVic-eGFP on day 4.  Pools of 10 mosquitoes, at 
three time points, were collected and homogenised in 140μl media using a 
motorised pestle, debris was centrifuged, and viral RNA was extracted from the 
resulting supernatant.  Viral RNA was used as a template for cDNA production and 
qrt-PCR was performed, using primers designed against the viral E2 protein, to 
ascertain the viral genome copy number per mosquito.  Two genes were tested using 
this protocol; the known viral antagonist in A. gambiae AGO2 and HOP (the janus 
kinase of the JAK/STAT pathway, known to be anti-viral in Ae. aegypti mosquitoes), 
with interesting, yet inconsistent results.  Figure 26A shows the corresponding viral 
titres from these experiments with very high levels of variation from replicate to 
replicate.  To account for variation in viral titre between the experiments, the data 
were normalised to the internal LacZ (non-specific) dsRNA control.  This allows the 
trend to be visualised disregarding overall higher or lower levels of infection in one 
replicate compared to another.  Figure 26B shows the normalised numbers where 
levels of variation are still very high, and as such the data may not be reliable, 
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however it appears that both HOP and AGO2 KD results in increase viral titre in A. 
gambiae mosquitoes 
 
 
 
Figure 26. Viral genome copy number/mosquito for gene silenced A. gambiae; A) 
mosquitoes were injected with dsRNA complementary to a gene of interest on day 1, 
and further injected with 5′ONNVic-eGFP on day 4.  Pools of 10 mosquitoes were 
collected at 1, 3 and 6 dpi, homogenised, viral RNA was extracted, cDNA was 
generated and qrt-PCR using primers against the viral E2 protein was carried out to 
calculate viral genome copy number/mosquito.  B) Numbers were normalised 
relative to the internal LacZ (non-specific) dsRNA control and are displayed as a % of 
the LacZ titre for each time point.  Error bars represent SD of 3 biological replicates.   
To try and limit the variability from replicate to replicate, the number of mosquitoes  
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pooled was increased from 10 to 30, assuming that a larger population size would 
decrease the variation observed.  Increasing the sample size from 10 to 30 
mosquitoes had little effect on the variability observed from replicate to replicate 
(data not shown).  A third method was tested, where mosquitoes were injected with 
dsRNA and ~3000 PFU P1/P2V 5′ONNVic-eGFP concurrently, and 30-50 mosquitoes 
were collected at day 7 post infection.  Consistency between replicates was 
improved using this method, however variation remained quite high.   
 
Considering the variation that appeared to be inherent to the A. gambiae-ONNV 
system, the third qrt-PCR method described above was used to initially screen a 
selection of genes, after which any interesting phenotypes were investigated using 
standard plaque assays, allowing the infection load of individual mosquitoes to be 
calculated.  Nineteen genes were selected for screening from a) the transcriptional 
analysis of infected mosquitoes b) genes known to have anti-viral roles in other 
insects and c) the four well known immune signalling pathways in A. gambiae 
mosquitoes.  Additionally a viral non-structural protein (nsP3) was included in the 
screen.  Table 7 summarises the 19 genes selected for screening.  Figure 27 shows 
the viral genome copy number/mosquito normalised to the LacZ control for each 
gene KD.  Importantly 2 controls included in the screen (the known viral antagonist 
AGO2, and the viral nsP3 gene) behave as expected, with AGO2 KD resulting in 
increased viral titre, and nsP3 KD resulting in markedly decreased viral titre.      
 
5.7 Four genes found to be viral antagonists in A. gambiae adult mosquitoes 
 
Five genes were selected from the screen of 19 for further investigation (see figure 
27, shaded in light blue).  In order to observe the dynamics of 5′ONNVic-eGFP within 
a population of highly variable individuals, standard plaque assays were carried out, 
where the viral titre of individual mosquitoes can be calculated, allowing for 
statistical analysis of larger population numbers.  Around 30 mosquitoes were 
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Table 7.  Genes selected for qrt-PCR screen in A. gambiae mosquitoes.  Candidate 
genes were selected from transcriptional analysis of ONNV infection in A. gambiae, 
and also included genes with known anti-viral roles in other insects and genes from 
the four well characterised immune signalling pathways in A. gambiae.   
 
Gene Name Regulated  
By ONNV 
Putative function Category Orthologs with known 
phenotype 
LacZ  Non-specific control Control  
nsP3  Viral gene Control  
Ago2  RISC complex 
formation 
Control/RNAi pathway Viral antagonist in A. 
gambiae [80] 
Dicer 1  Enzyme  RNAi pathway  
Hopskotch 0.41 Janus kinase JAK/STAT pathway Viral antagonist in Ae. 
aegypti [75] 
STAT1  Transcription factor JAK/STAT pathway  
STAT2  Transcription factor JAK/STAT pathway  
PIAS  Negative regulator of 
JAK signalling 
JAK/STAT pathway Viral agonist in Ae. 
aegypti [75] 
REL1  Transcription factor Toll pathway Viral antagonist in Ae. 
aegypti [72] 
CACTUS  Inhibitor of REL1 Toll pathway  
REL2  Transcription factor IMD pathway  
ML1 2.7 Lipid recognition 
receptor 
Pathogen recognition  
ML9 2.0 Lipid recognition 
receptor 
Pathogen recognition  
GALE8 2.08 Sugar recognition 
receptor 
Pathogen recognition  
LYSC2 2.1 Lysis of pathogens Immune effector  
LYSC4 2.3 Lysis of pathogens Immune effector  
LYSC6 2.1 Lysis of pathogens Immune effector  
CEC3 2.04 Pathogen clearance Immune effector  
TEP12 2.36 Pathogen clearance Immune effector  
Helicase 2 0.4 Unwinds dsRNA Helicase  
Helicase 3 0.3 Unwinds dsRNA Helicase  
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Figure 27.  RNAi and qrt-PCR based screening of 19 genes for anti-viral function in 
A. gambiae mosquitoes.  Mosquitoes were injected with dsRNA and 
~3000PFU/mosquito 5’ONNVie-eGFP concurrently, 30 mosquitoes were collected at 
7 dpi, and qrt-PCR was used to ascertain viral genome copy number/mosquito.  
Values were normalised relative to the LacZ (non-specific) control and are given as a 
percentage relative to the LacZ titre.  nsP3, a viral gene was included in the screen.  
Genes are divided into functional categories based on which immune signalling 
pathway they belong to, or their putative function.  Genes with an asterix* and light 
blue shading were selected for further characterisation.         
 
injected with dsRNA complimentary to LacZ, ML1, CEC3, GALE8, LYSC4 or LYSC6 and 
5′ONNVic-eGFP concurrently and were collected at 7 dpi.  Individual mosquitoes 
were homogenised in MEM, debris was centrifuged, and the resulting supernatant 
was sterile filtered.  A serial dilution of each filtered supernatant was placed onto 
confluent VERO cells and immobilised with a layer of nutrient agar, forcing virus to 
infect only the neighbouring cells to the first cell infected, and forming plaques of 
dead cells.  After 5 days cells were live stained, and the dead plaques were counted.  
Two biological replicates were carried out.  Plaque forming units/mosquito were 
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calculated and subjected to Mann Whitney Testing for significant difference to the 
LacZ control.  Four of the 5 genes tested showed significant increases in viral titre 
upon gene knock down (see figure 28).  CEC3 showed an increase in viral titre in one 
replicate, however this was not consistent in the second replicate and so it was 
excluded from analysis.  ML1 knock down resulted in a 5.7 fold increase in viral titre 
(*** P<0.0001), the highest of the four genes.  LYSC4 KD resulted in a 4.9 fold 
increase (*** P<0.0001), LYSC6 KD resulted in a 2.8 fold increase (** P<0.001) and 
GALE8 KD resulted in a 3.9 fold increase (* P=0.0163) in viral titre at 7 dpi. Qrt-PCR 
was used to confirm gene KD in mosquitoes; ML transcripts were reduced to ~9%, 
GALE8 transcripts were reduced to ~20% and LYSC4 transcripts were reduced to 
~12% compared to LacZ controls at 7 days post dsRNA treatment.  LYSC6 KD 
efficiency was not ascertained due to in-efficient primers.    
 
5.7.1        Effect of silencing viral antagonists and agonists on per os infected 
A. gambiae  
 
The effect of silencing two viral antagonists (ML1 and AGO2) on per os infections 
with 5′ONNVic-eGFP was investigated.  Newly emerged female G3 mosquitoes were 
injected with dsRNA complementary to the bacterial LacZ gene, AGO2, ML1 and 
nsP3.  48h later mosquitoes were fed a blood-meal containing compacted RBCs, 
human serum and 5′ONNVic-eGFP.  Assuming each mosquito ingested ~2µl of blood, 
each mosquito was infected with ~1640 PFU.  At 3 dpi mosquito midguts were 
dissected and fixed in 4% PFA.  GFP expression was observed using a fluorescent 
microscope; midguts were scored negative for GFP (uninfected), few GFP positive 
cells (low infection), patches of GFP positive cells throughout the cardia (medium 
infection), many GFP cells/most of the cardia and spreading into the anterior gut 
(high infection).  Figure 29A shows the prevalence of GFP expression, and thus 
infection at 3 dpi.  Chi squared tests show that silencing the viral nsP3 gene 
significantly reduces the prevalence of infection (P value<0.001).  Silencing AGO2 or 
ML1 does not significantly change the prevalence of infection; however the 
distribution of infection is affected.  Figure 29 shows the distribution of infection in 
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B) ML1 KD, C) AGO2 KD and D) nsP3 KD mosquitoes at 3 dpi. Silencing ML1 shifts the 
distribution towards medium-high infection, with significantly fewer midguts 
showing low infection levels (Chi Squared test P<0.001).  Silencing nsP3 shifts the 
distribution towards uninfected/low infection with significantly larger numbers of 
uninfected midguts and significantly fewer highly infected midguts (Chi Squared test 
P<0.001).  AGO2 KD shows a similar infection distribution to the LacZ control. 
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Figure 28.  Four antagonists of 5′ONNVic-eGFP in A. gambiae mosquitoes.  
Mosquitoes were injected with dsRNA and ~3000 PFU/mosquito P1/P2V 5′ONNVic-
eGFP concurrently.  Individual mosquitoes were collected and subject the plaque 
assay at 7 dpi.  Data was Log10 transformed.  Two independent biological replicates 
were carried out.  Error bars represent standard deviation.  P values indicate 
significance from Man Whitney Testing of each gene KD compared to the LacZ 
control.   
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Figure 29. Effect of gene silencing on per os infection of A. gambiae A) % prevalence of per 
os infected A. gambiae after gene KD.  G3 mosquitoes were injected with dsRNA against 
LacZ, ML1, AGO2 and nsP3 and given an infectious blood-meal of ~ 1640 PFU/mosquito 48h 
later.  Dissected midguts were screened for GFP expression.  Error bars represent standard 
deviation of 2 biological replicates.  * indicates statistically significant difference in 
prevalence compared to the LacZ control using the Chi Squared test (where P<0.001).  
Infection distribution of B) ML1 C) AGO2 and D) nsP3 gene silenced per os infected G3 
mosquitoes.  Midguts were scored for no infection (uninfected), low infection (low), medium 
infection (medium) and high infection (high).  * indicates statistically significant difference in 
distribution of infection between LacZ control and gene KDs using the Chi squared test 
(where P<0.001).              
 
5.8 Co-infection of 5′ONNVic-eGFP and P. berghei in A. gambiae mosquitoes 
 
5′ONNVic-eGFP is transmitted (at least during epidemics of the disease) by the 
important malaria vector A. gambiae.  Epidemics of ONNV during the early 1960s 
and in 1996 occurred in areas of Africa where malaria is prevalent.  Due to the 
lifelong infection formed by the alphaviruses in their mosquito hosts, it is likely that 
A. gambiae were exposed to both pathogens simultaneously during these epidemics.  
A study published shorted after the outbreak in the early 1960s observed a decrease 
in malaria cases being reported in areas where ONNV infections were recorded.  In 
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order to investigate whether viral infection has any effect on parasite development 
in A. gambiae, co-infections of the two pathogens were carried out.  Newly emerged 
female G3 mosquitoes were injected with ~1640 PFU 5′ONNVic-eGFP or were mock 
infected.  48h later mosquitoes were fed from a mouse infected with the rodent 
malaria, P. berghei.  Unfed mosquitoes were removed, and seven days post blood-
meal midguts were dissected and fixed in 4% PFA.  Parasite oocysts on the midgut 
(live oocysts), and melanised ookinetes were counted.  Additionally midguts were 
scored for 5′ONNVic-eGFP infection of the midgut musculature or nerves.  Figure 30A 
shows the oocyst and melanised ookinete distribution in virally infected (+ virus) and 
mock infected (- virus) A. gambiae mosquitoes.   
 
 
 
Figure 30. Co-infection of A. gambiae with P. berghei and 5′ONNVic-eGFP.  G3 mosquitoes 
were inoculated with ~1640 PFU 5′ONNVic-eGFP (+) or mock inoculated (-).  48 hours later 
mosquitoes were fed on a mouse infected with P. berghei.  A) 7 days post blood feeding 
midguts were dissected, live oocysts/melanised ookinetes were counted, and guts were 
scored positive or negative for 5′ONNVic-eGFP expression in midgut musculature or nerves.  
Parasite numbers were only included for the + virus category when 5′ONNVic-eGFP 
expression was observed.   B)  Prevalence of parasite infection at 7 dpi in uninfected (mock) 
and infected (ONNV) midguts.   
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An approximately 40% reduction in the number of live oocysts was observed in 
virally infected mosquitoes showing 5′ONNVic-eGFP infection, although this decrease 
is not statistically significant using the Man Whitney test.  A statistically significant 
decrease in the numbers of melanised ookinetes was observed (** P=0.001). 
Additionally the prevalence of melanised ookinetes decreased from 35% in mock 
infected to 18.5% in virally infected mosquitoes (figure 30B).   
 
5.9 STAT1 is not translocated to the nucleus upon viral infection of L35 cells 
 
The observation that depletion of HOP increased titres of ONNV poses the question 
if JAK/STAT signalling is triggered by viral infection in L35 cells.  Downstream of HOP 
in the JAK/STAT pathway is the transcription factor STAT.  In A. gambiae two STATs 
have been characterised, STAT-1 and STAT-2.  A previous worker in this laboratory 
generated a polyclonal antibody against STAT-1 and described translocation of STAT-
1 into the nucleus of fat body cells in A. gambiae after exposure to bacterial 
pathogens[100].  Immunofluorescence assays (IFAs) were carried out using L35 cells 
to see if STAT-1 is also translocated into the nucleus upon viral infection.  L35 cells 
were grown on coverslips and infected with 5′ONNVic-eGFP (or mock infected) when 
100% confluent.  At 24, 48 and 72hpi cells were fixed in 4% PFA before incubating 
with anti-STAT-1 antibody.  Stained cells were mounted in vector shield with DAPI 
and observed under a fluorescent microscope.  Secondary antibody only controls 
were also carried out.  STAT-1 staining was observed mostly in the cytoplasm of cells, 
but occasionally throughout the cytoplasm and the nucleus.  Secondary only controls 
showed very little background (see Figure 31A).  No difference in STAT-1 staining was 
observed between uninfected cells and cells expressing GFP (and thus infected), no 
translocation of STAT-1 into the nucleus was seen in virally infected cells or other 
cells in virally infected cultures (figure 31B) compared to mock infected cultures. 
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Figure 31.  Patterns of STAT-1 staining in L35 cells infected with 5′ONNVic-eGFP at 
48h post infection.  Confluent L35 cells were mock infected or infected with 1MOI 
5′ONNVic-eGFP.  Cells were fixed and stained with anti-STAT-1 antibody and DAPI.  
A) 63X magnification of virally infected (5′ONNVic-eGFP) and mock infected (Mock) 
cells labelled with a-STAT1 and DAPI.  A secondary antibody only control (secondary 
only) was carried out.   B)  100X magnification of virally infected cultures stained 
with a-STAT1 and DAPI.  Yellow arrows indicate infected cells.      
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5.10 Summary 
 
This chapter has covered: 
 Transcriptional responses to 5′ONNVic-eGFP infection 
 Development of a qrt-PCR based screen for viral antagonists in A. gambiae 
mosquitoes 
 Identification of four viral antagonists in A. gambiae mosquitoes 
 Effect of silencing viral anatagonists and agonists on per os viral infections 
 Co-infection of A. gambiae with 5′ONNVic-eGFP and the rodent malaria 
model P. berghei 
 The activation of the JAK/STAT pathway in virally infected cells 
 
6 Discussion 
6.1 Transcriptional responses to ONNV infection 
 
Due to their small genome size, RNA viruses are dependent on a variety of host cell 
factors to complete their life cycle.  In addition to this, they must co-ordinate and 
regulate the host machinery to produce new viral proteins and replicate their RNA 
[136].  Investigating the transcriptional responses to viral infection can help to 
identify the factors that are used by viruses to complete their unique life cycle, and 
in turn, shed light on the mechanisms employed by mosquitoes to combat viral 
infection.   
 
Analysis of the transcriptional responses of A. gambiae to 5′ONNVic-eGFP infection 
revealed a large number of genes that are differentially regulated by viral infection.  
During a time-course of infection, transcriptional responses at D1, D4 and D9 post 
infection were studied.  D1 represents early infection, when inoculated virus has 
infected cells and begun to replicate.  D4 represent the acute phase of infection, 
where virus is spreading from cell to cell and from tissue to tissue in the mosquito.  
D9 represent the persistent phase of infection, where levels of virus drop 
substantially and a low, but lifelong level infection is formed.  The majority of 
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differential gene regulated occurs at D4, with 214 genes showing 2-fold or greater 
changes in expression.  This might be expected as D4 represents the acute phase of 
infection, which is systemic.  The huge decrease in differential gene expression seen 
by D9 follows the dramatic decrease in viral titre observed at D9.  Differentially 
expressed genes can be grouped based on their predicted function, and temporal 
pattern of expression.  Several patterns emerge when the genes are grouped in this 
way, with groups of genes representing fatty acid biosynthesis, cell division, 
translation and transcription, RNA degradation and interestingly immunity.  These 
genes will be discussed in detail below:       
 
 
6.1.1 Fatty acid synthesis up-regulation and viral infection 
 
Several genes associated with fatty acid biosynthesis are upregulated: in the early 
onset genes a fatty acid sythase is upregulated; in the early to mid-onset genes 
another fatty acid synthase and a gene with putative fatty acid elongation function 
are upregulated; in the mid onset genes a further fatty acid sythase is up-regulated, 
along with two further genes with putative functions in fatty acid elongation.  The 
differential regulation of these six genes indicates that fatty acid biosynthesis is up-
regulated during early infection, and maintained during the acute phase of infection.  
Fatty acid sythases are up-regulated by a variety of viruses (Epstein Bar [137] and 
HCV [138-139] included).  A study carried out by Cherry et al [136] looked at genes 
identified as being essential for viral replication in a genome wide RNAi screen of 
DCV infection in D. melanogaster cells.  Several genes involved in fatty acid 
biosynthesis were identified in the RNAi screen, including CG3523, a fatty acid 
sythase that is the first rate limiting enzyme in the fatty acid biosynthesis 
pathway[140].  Depletion of this gene using RNAi resulted in a 10-fold decrease in 
virus in cell culture.  Additionally animal mutants for the fatty acid biosynthesis 
pathway showed decreased levels of DCV infection.  Cherry et al [136] observed that 
DCV infection induces a vesicular compartment where viral RNA replication is 
localised.  They also observed that within 10 hours of DCV infection, membrane 
surface area within infected cells doubled, and that depletion of CG3523 blocked the 
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formation of virus induced vesicular compartments.  The fatty acid sythase regulated 
at D1 and D4 post 5′ONNVic-eGFP infection (AGAP009176) is the ortholog of 
CG3523.  Cherry et al [136] commented that the genes identified during their RNAi 
screen were biased towards highly conserved genes, indicating that the virus 
targeted highly conserved cellular functions.  They speculate that this may be helpful 
for infection of disparate hosts, as is common in the life cycle of many insect viruses 
e.g. mosquito and man for the arboviruses.  The up-regulation of the orthologous 
fatty acid sythase in a mosquito-virus system supports this idea.             
 
6.1.2 Cell division/growth slowing 
 
Several genes associated with the regulation of the cell cycle are down-regulated 
during early-mid infection (2) and mid infection (8).  A cell cycle checkpoint kinase, 
and a gene putatively involved in the regulation of cell proliferation are down 
regulated during early to mid infection.  Another cell cycle checkpoint protein, 
several genes with putative roles in regulating cellular proliferation, an ortholog of a 
DNA replication licencing factor MDM7 (part of a complex required for initiation and 
elongation of replicative forks during S-phase) and a putative regulator of 
chromosome condensation, are all down-regulated at D4 post infection.  This 
suggests that normal cell division is disrupted by viral infection.  The majority of 
these genes have roles in the promotion of cell division and/or proliferation, 
suggesting that cell growth slows during viral infection.  It has been reported that a 
peptide produced by Ae. aegypti cells in response to SINV infection, when used to 
treat uninfected cells leads to a temporary arrest in cell growth, followed by 
recovery to normal rates of growth.  These treated cells are subsequently refractory 
to viral infection [114].  Whether a similar peptide is produced in infected A. 
gambiae cells that causes a similar reduction in cell growth, remains to be seen.  
 
An ortholog of CDC42 (cell division cycle protein 42) although initially classified as a 
cell division related protein, actually has functions in actin polymerisation in insects 
where roles in the formation of polarised actin filaments, elongation of cell shape 
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and cell signalling have been reported [141].  In A. gambiae CDC42 has been shown 
to be required for the formation of actin zones around invading P. berghei ookinetes, 
and, through an unknown mechanism mediates melanisation.  However it has no 
effect on parasite killing [142].  Interestingly CDC42 has been shown in endothelial 
cells to be required for the formation of filipodia that facilitate the internalisation of 
DENV-2 particles [143].  Inhibition of actin re-organisation in endothelial cells led to 
dramatic decreases in DENV-2 infection.  CDC42 was shown to be active in infected 
cells, and to be required for the formation of filipodia triggered by binding of DENV-2 
to the surface of cells, leading to the uptake of virus [143].  The ortholog of CDC42 is 
down-regulated in 5′ONNVic-eGFP infected A. gambiae, suggesting the inhibition of 
actin re-organisation.  It would be interesting to see if depletion of the CDC42 gene 
would affect ONNV infection, as seen in human endothelial cells infected with 
DENV2.                
 
6.1.3 Inhibition of RNA degradation including RNAi 
 
RNAi is a potent and well characterised anti-viral mechanism in mosquitoes. One of 
the components of the RNAi pathway, Tudor-SN (TSN), is down-regulated by 
5′ONNVic-eGFP infected A. gambiae at D4 post infection.  TSN is a known viral 
antagonist in Ae. aegypti mosquitoes; depletion of TSN in Ae. aegypti mosquitoes 
results in significant increases in prevalence of SINV infection, and a modest 
increases in viral titre [82].  TSN is a component of the RISC complex in D. 
melanogaster [144] although its specific function remains elusive.  The down-
regulation of TSN may be advantageous to the virus, by limiting the destruction of 
viral RNA targets.  Whether TSN is regulated by the virus itself, or perhaps by the 
host through a negative feedback loop, is unclear.   
 
Several other genes with putative functions in non-classical RNAi are also down-
regulated.  A member of the Argonaute protein family (termed AgAgo5 by Campbell 
et al [77]) that is closely related to the D.melanogaster Piwi and Aubergine proteins 
is down-regulated at D4 post infection.  In D. melanogaster, Piwi, Aubergine and 
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Ago3 form a subclass of the Argonaute protein family.  They contain the 
characteristic Piwi and Paz domains; Paz is a small RNA binding domain and Piwi is an 
RNAse-H type domain that relies on divalent cation binding to facilitate dsRNA-
guided cleavage of ssRNA [77].  In D. melanogaster, small RNAs bound to Piwi and 
Aubergine and Ago3 were found to be derived from hotspots of the genome, the 
majority of which were genomic repeats or transposons, and so there were called 
repeat-associated small RNAs (rasiRNAs) [145] or more recently, piwi-associated 
RNAs (piRNAs).  Generation of piRNA does not require a dicer enzyme, as they are 
believed to be generated from ssRNA [146].   They have been associated with a 
variety of functions in germ-line tissue; ensuring genomic stability by silencing 
endodgenous selfish genetic elements such as transposons, maintenance of 
telomeres and mRNA silencing in germ-line cells [77, 146].  In a comparative genomic 
study of components of the small RNA regulatory pathways in mosquitoes by 
Campbell et al [77], AgAgo5 was shown to form a clade with several Piwi proteins 
from Aedes and Culex but distinct from the Drosophila piwi proteins.  Campbell et al 
suggest that the piwi subfamily comprises several gene families, some of which have 
arisen from recent gene duplication.  The function of AgAgo5 has not been 
investigated to date.  There is limited evidence that Piwi mediated RNAi also 
contributes to anti-viral defence in insects along with the classical RNAi pathway; D. 
melanogaster Piwi mutant flies are more susceptible to WNV infection [61]. 
Additionally depletion of AgAgo3 results in increases susceptibility of adult A. 
gambiae to ONNV infection [80].  How this non-classical RNAi pathway may be 
targeting viral genomes remains unclear.                     
 
In addition to AgAgo5, Dicer-1 is also down-regulated at D4 post infection.  In D. 
melanogaster, Dicer-1 (DCR-1) generates miRNA from endogenous RNA and 
mediates gene expression regulation through RNAi [78].  DCR-1 is required for the 
production of miRNA, however it may also contribute towards the production of 
siRNA in the classical RNAi pathway [78].  Although DCR-1 and DCR-2 have distinct 
(although somewhat overlapping) functions in the fruitfly, it remains to be seen if 
this division in functionality is maintained in A. gambiae.  In Ae. aegypti Dicer-2 has 
been shown to be important in regulating DENV2 infection [83]; whether or not 
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Dicer-1 has a similar role has yet to be tested.  The down-regulation of several 
components of the RNAi pathway (albeit it from different arms of the RNAi pathway 
in Drosophila) suggests that RNAi is inhibited in A. gambiae infected with 5′ONNVic-
eGFP.  Suppression of RNAi would be advantageous to the virus, and could be a 
result of interference with host gene expression.  Viruses have developed a range of 
mechanisms to suppress RNAi – strategies range from direct interference with 
components of the RNAi pathway, such as the FHV B2 [85] protein and the 
tombusviral P19 protein [147]; recruitment of endogenous inhibitors of RNAi; out-
competition of the RISC complex by unproductive viral-derived small RNAs; 
alteration of host gene expression, illustrated by Geminiviral transactivator proteins 
that either promote the transcription of genes that interfere with RNAi, or 
suppressing expression of mediators of RNAi [148].  This wide variety of evasion 
mechanisms illustrates the strong pressure exerted on viruses by the RNAi pathway 
in plants and invertebrates.  The changes in gene expression of several RNAi 
components seen in this study may be mediated by ONNV to allow efficient 
replication within infected cells.  ONNV is not thought to encode a protein that 
suppresses RNAi directly [11], however viral products are known to translocate into 
the nucleus of cells infected with alphaviruses, for example 90% of SFV nsP2 protein 
localises to the nucleus of infected cells [149].  Viral products that translocate to the 
nucleus may interfere with the host cell transcriptome.                        
 
6.1.4 The DEAD-box helicases 
 
Whereas invertebrates utilise the siRNA pathway to recognise exogenous dsRNA, 
vertebrates employ other pathways that trigger interferon (IFN) signalling [150].  The 
mammalian RIG-1 like receptors (RLRs) recognise exogenous dsRNA and contain a 
DExD/H box domain, similar to the dicer enzymes in invertebrates.  It is suggested 
that the RLRs may have evolved from a dicer-like ancestor [150].  The DEAD-box 
helicases are a large family of conserved proteins found in almost every organism, 
with diverse functions in all aspects of RNA metabolism [150].       
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A DEAD-box helicase called Belle was identified in D. melanogaster as a component 
of the RNAi pathway by Ulvila et al [151].  In addition, a Belle paralog in C.elegans 
was identified as an RNAi component [152].  Interestingly the human ortholog of 
belle, DDX3X, was recently shown to be anti-viral; in response to viral pathogens, 
DDX3X promotes IFN production [153].  Additionally multiple viruses have been 
shown to interact with DDX3X, and modulate its function [153].  These studies 
indicate intriguing roles for the DEAD-box helicases in anti-viral immunity and 
warrant further investigation into this function of the protein family [150]. 
 
In this study a group of five DEAD-box helicases, and a further possible helicase, 
were down-regulated at D4 post infection.  This raises the possibility that they may 
have functions in sensing viral infection/contributing to RNAi responses, although 
any function in anti-viral immunity has yet to be investigated.  
 
6.1.5 Regulated Immunity genes 
 
Almost 1/3 of regulated genes at D1 and D9 post infection and 1/5 of genes 
regulated at D4, are immune related.  The vast majority of these genes are up-
regulated, with only five being down-regulated in response to ONNV infection, 
indicating that A. gambiae is capable of recognising viral infection, resulting in the 
activation of immune signalling.    The mosquito immune response comprises several 
arms of response to pathogens.  The cellular response involves phagocytosis and 
melanotic encapsulation of invading bacteria and parasites.  The humoral respose is 
made up of hemolymph proteins that recognise invading pathogens and trigger 
melanisation, lysis or opsonisation.  The immune signalling pathways respond to 
specific pathogens and regulate the expression of a variety of immune genes.  Of the 
numerous putative immunity genes regulated by ONNV, a large number are 
associated with the humoral response and are hemolymph proteins including many 
complement-associated genes (several TEPs and LRIM1) and a smaller number of 
melanisation-associated genes (CLIPA9 and CTLMA2) and opsonisation-associated 
genes (SRCB8/9).  Considering that virus was inoculated directly into the hemolymph 
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of mosquitoes during these experiments, it is not surprising that a large number of 
hemolymph genes respond to infection.  
 
The early responsive genes are mostly complement associated and recognition 
associated genes.  LRIM1 functions during Plasmodium infection to lyse parasites 
through the targeting of TEP1 to parasite surfaces.  During 5′ONNVic-eGFP infection, 
LRIM1, but not other members of the parasite targeting complex APL1C and TEP1, is 
up-regulated.  This suggests that LRIM1 may also function independently of the 
described complex, possibly regulating other immune mechanisms that may target 
viral infection.  During early and mid infection 3 further LRIMs and 5 TEPs are up-
regulated.  These may comprise a different branch of the complement pathway that 
targets viral infection.  Two MD2-like receptors are up-regulated in response to 
5′ONNVic-eGFP infection.  The MLs will be discussed in detail in section 6.2.2.       
 
During mid infection, in addition to complement and recognition-associated genes, 
genes with known functions in the inhibition of melanisation (CTLMA2 and CLIPA2) 
are up-regulated.  This suggests that viral infection triggers a shift in hemolymph 
proteins towards those with roles in lysis and opsonisation and shuts down the 
melanisation pathway.  Additionally the IMD, JAK/STAT and RNAi pathway appear to 
be inhibited through the down-regulation of components of these pathways (IKK1, 
HOP and TSN respectively).   
 
D. melanogaster IKK1, a member of a complex that activates NF-kB in the IMD 
pathway, was identified as being required for the activation of Relish [154].  As part 
of the IKK complex, it targets relish for cleavage and subsequent activation, leading 
to the up-regulation of several AMPs [155].  The down-regulation of IKK suggests 
that the IMD pathway is being inhibited.  An anti-microbial peptide, ortholog of D. 
melanogaster Diptericin (DPT) is up-regulated during early to mid infection (2 and 
3.6 fold regulated at D1 and D4 respectively).  DPT is though to be down-stream of 
the IMD pathway in D. Melanogaster [156], indicating that the IMD pathway is 
switched on by ONNV infection, although it has yet to be confirmed in A. gambiae 
that DPT is regulated by the IMD pathway.  The IMD pathway has recently been 
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implicated in anti-viral immunity in D. melanogaster; two studies demonstrated 
increases in SINV [157] and CrPV [158] infection in Drosophila mutants for 
components of the IMD pathway.  To date no evidence has suggested that the IMD 
pathway is involved in anti-viral defence in mosquitoes, by contrast, the IMD 
pathway was shown to have no effect on DENVs infection via silencing of Caspar (the 
negative regulator of the pathway) in Ae. aegypti mosquitoes [72].   
 
As outlined in the introduction to this study, the JAK/STAT pathway is a well 
characterised anti-viral signalling pathway in mammalian systems.  Recent evidence 
has also implicated the JAK/STAT pathway in anti-viral immunity in mosquitoes [75].  
HOP, the Janus kinase of the JAK/STAT pathway, is down-regulated during mid-
infection.  The role of JAK/STAT signalling in A. gambiae will be discussed in detail in 
relation to gene KD experiments in A. gambiae cells.     
 
The down-regulation of an inhibitor of apoptosis (IAP1), and the up-regulation of a 
caspase (CASPS6) indicate that apoptosis may be triggered by ONNV infection.  
Although apoptosis has not been shown to be an important regulator of SIN in Ae. 
aegypti derived cells [38], and is generally not shown to be an important 
invertebrate response to viral infection, apoptosis is certainly a well characterised 
response to viral infection in mammalian cells.  It would be interesting to investigate 
the effect of activation or inhibition of apoptosis in A. gambiae mosquitoes on viral 
infection.     
 
6.1.6 Genes with unknown function 
 
Despite the differential regulation of a number of putative immunity genes, a large 
number of uncharacterised genes, many with no predicted function and/or gene 
architecture are differentially regulated by 5′ONNVic-eGFP infection.  Some of these 
genes may represent uncharacterised anti-viral mechanisms that are specific to A. 
gambiae.  Genes with now well characterised mosquito-specific immune functions 
have been discovered previously through transcriptional profiling of pathogen 
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challenged A. gambiae.  An example of this being LRIM1, a potent malaria parasite 
antagonist that led to the discovery of a mosquito specific family of LRR proteins 
with functions in mosquito immunity [126].  Sixty six genes with unknown functions 
were differentially regulated by ONNV infection.  A number of the most highly 
regulated genes are found in a cluster on chromosome 2R; AGAP003773/5/6/7/8.  
All are predicted to encode mosquito specific conserved small proteins (<200KDa) 
with orthologs in Ae. aegypti and C. quinquefaciatus but no orthologs in D. 
melanogaster.  AGAP003773/5/7/8 are up-regulated during early infection 
(4.3/2.7/4/4.1 fold respectively), and AGAP003776 is up-regulated during mid-late 
infection (8.3 and 2.8 fold at D4 and D9 respectively).  As the most highly 
differentially regulated gene, the anti-viral activity of AGAP003776 was investigated 
in A. gambiae cells, however did not appear to have a substantial effect on viral 
replication.                      
 
6.1.7 Limitations of the microarray study 
 
The main limitation of the microarray analysis of viral infection in A. gambiae relates 
to the rejection of data through the strict filtering criteria applied during analysis to 
limit the number of false positive data.   Data can be rejected for several reasons.  
The first is low intensity and poor feature quality; features with intensity ratios that 
do not exceed background levels are excluded from analysis through a flagging 
system.  These features are flagged as ‘absent’ and are excluded from analysis in 
Genespring.  Further to this features with diameters that exceed two times the SD of 
the mean are excluded, along with manually flagged features (such as those with 
scratches and/or dirt on the surface of the array) and features with saturated 
intensity (i.e. the intensity of one or more dyes is higher than the upper threshold of 
measurement).  These data are excluded prior to normalisation (which counteracts 
dye specific effects) and thus cannot be ‘retrieved’ from the raw data and compared 
to normalised data.  The second major reason for the rejection of data is poor 
consistency across biological replicates; T-test P values of >0.05 are excluded from 
analysis.  The limitation that arises from this rejection of data, is the loss of power to 
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cluster data temporally with accuracy.  Where fold change ratios have passed all the 
filters for only one of three time points, it is not necessarily accurate to say that this 
gene is only differentially regulated at this one time point.  However, including data 
with poor consistency, or data that fails other filtering criteria increases the number 
of false positive data and decreases accuracy.  As such, there is a balance between 
how strict or relaxed the filtering criteria are, and often this will depend on the 
reason for conducting the microarray analysis in the first place.  In this study, the 
broad responses to viral infection were investigated as a starting point for identifying 
anti-viral immune mechanisms in A. gambiae mosquitoes.  Considering the large 
amount of variation that is seen in viral infection between individually infected A. 
gambiae mosquitoes, it was decided not to exclude data where fold change ratios 
for all three time points were not present.  Although perhaps increasing the number 
of false positive data, this prevents the exclusion of a number of potentially immune 
related genes.  Although the data cannot be accurately clustered, the overall trend 
of expression of each gene was plotted over the time course including data with high 
P values.  These plots gave two valuable insights into the data that have passed all 
the filtering criteria: firstly the trend of expression over the whole time course was 
seen; secondly, using the multiple probes generated for immunity genes, the trend 
of multiple probes corresponding to the same gene was visualised.  The plots, 
although containing data that is statistically in-accurate, gave an increase or 
decrease in confidence of the data that passed the filtering criteria.     
 
6.2 Viral antagonist discovery in vivo 
 
 
An assay utilising RNAi and quantitative real time PCR was developed in order to 
identify genes that play a role in anti-viral immunity in A. gambiae.   Target genes 
were silenced using standard RNAi techniques (as described by [117]) in adult 
mosquitoes that were subsequently infected with 5′ONNVic-eGFP.  Qrt-PCR was then 
used to assay the titre of a viral gene, nsP3, in pools of 10 or 30 mosquitoes. Using 
this technique, high levels of variation in infection levels were observed between 
biological replicates of experiments, despite normalising data to the internal LacZ 
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control to remove overall changes in infection level from experiment to experiment.  
The protocol was modified, and two controls were added; dsRNA against the viral 
gene, nsP3, and against the known viral antagonist Ago2 were used during 
experiments.  High levels of variation between pools of mosquitoes were still 
observed, however the controls behaved as expected with higher titres of virus in 
Ago2 KD mosquitoes, and very low viral titres in nsP3 KD mosquitoes (as seen by 
Keene et al [80]).  The high levels of variation reflect the inherent high levels of 
variation seen between individuals infected with ONNV.  Using the fast and efficient 
qrt-PCR method, 19 genes were screen for roles in anti-viral immunity, and five 
candidates were taken forward for further study.  Carrying out standard plaque 
assays determined the viral load from individual mosquitoes, allowing the spread of 
the data (originally lost when pooling groups of mosquitoes) to be observed, and 
taken into account for statistical analysis of the results.  This gives a more powerful 
dataset for analysis and gives more accurate and robust statistical results.  Four of 
the five genes tested showed consistent and significant changes in viral titre when 
depleted by RNAi, and are discussed below.     
 
6.2.1 The Galectins – GALE8 
 
 
The defining feature of the Galectin family of proteins in the ability to bind β-
galactosidase sugars [159].  Galectins are found in a wide variety of organisms from 
parasites to sponges to mammals [160].  The complex galectin repertoire found in 
many organisms, multiple isoforms and observed plasticity in sugar binding suggests 
substantial diversity in the glycan recognition properties of the Galectins [160].  Most 
Galectins are soluble, do not contain transmembrane (TM) or signal peptides and are 
secreted by the non-classical secretion pathway [159].  Three forms of Galectins are 
found in mammalian systems; the prototype galectins, containing a single 
carbohydrate recognition domain (CRD), often forming homodimers of non-
covalently linked subunits; the chimera galectins, and the tandem repeat galectins 
that contain two CRDs.  In D. melanogaster, galectins are of the tandem repeat type, 
however in A. gambiae, the galectins are of the prototype galectins [159].  
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In mammalian systems galectins have diverse functions in cell adhesion, 
proliferation, migration, apoptosis, inflammation, immunity and immunoregulation 
[159].  In D. melanogaster expression patterns of Dmgal during embryogenesis also 
suggest important roles in mesoderm and neural layer tissue formation during 
development. A. gambiae IGALE20 was found to be up-regulated in response to 
bacterial and malaria infection, and was postulated to be involved in pathogen 
recognition by binding saccharide ligands on microbial surfaces [161].   
 
There are 10 putative galectins in A. gambiae (CEGG ImmunoDB), three of which are 
up-regulated by ONNV infection – GALE 6/7/8.  All three galectins are mosquito 
specific (part of a mosquito species specific expansion including AgGALE4-8), and 
have no orthologs in D. melanogaster (see figure 32).  Both AgGALE6 and AgGALE8 
have orthologs in Culex quinquefasciatus, and show duplications in Ae. aegypti 
(AeGALE6A/6B and AeGALE8A/8B).  GALE7 is specific to A. gambiae and does not 
have othologs in either mosquito (Cegg immuno dB 
http://cegg.unige.ch/Insecta/immunodb).  This mosquito species specific expansion 
maybe due to the haematophagous lifestyle of the mosquitoes, and subsequent 
exposure to a disparate group of pathogens compared to D. melanogaster, including 
viral pathogens.  The up-regulation of several galectins in response to ONNV 
infection suggests that this group of mosquito specific galectins have anti-viral roles.          
 
In mammals, galectins have known functions during viral infection.  Nipah virus, a 
paramyxovirus that causes severe encephalitis, infects cells through attachment of 
its envelope glycoproteins to host endothelial cell ephrinB2/B3 receptors, 
additionally triggering cell-cell fusion forming syncytia [160]. Galectin 1 crosslinks the 
N-glycans displayed in the envelope proteins of Nipah virus, and Hendra virus 
(another paramyxovirus), blocking cell infection and cell-cell fusion [160].  
Additionally Galectin expression is regulated by herpesvirus 1, Newcastle disease 
[162], Epstein Barr Virus [163], Hepatitus C virus [164] and Human papiloma virus 
(HPV)[165].  Additionally Galectin 3 secretion and carbohydrate binding increase 
upon herpesvirus 1 infection [166], suggesting that Galectins function at several 
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levels of anti-viral defence, from initial recognition and blocking of envelope and 
fusion glycoproteins to the activation and amplification of the innate and adaptive 
immune reponses [160].   
 
 
 
 
 
 
Figure 32. Phylogenetic tree of Galectins in three mosquitoes and Drosophila.   
Phylogenetic tree of Galectins in D. melanogaster (Dm or CG), Ae. aegypti (Aa), C. 
quinquefaciatus (Cq) and A. gambiae (Ag) adapted from Waterhouse et al 2007 
[167].  The mosquito specific expansion of GALE4/5/6/7/8/9/11 is indicated by the 
pale yellow balloon.  GALEs up-regulated by ONNV infection are indicated by blue 
boxes.                 
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GALE8, shown here to be an antagonist of ONNV infection, may function in several 
ways to limit viral infection.  Firstly a direct function can be envisaged – GALE8 may 
bind to and cross link the sugars on ONNV envelope proteins and thus directly 
prevent infection of cells.  Alternatively galectin binding may target viral particles for 
opsonisation by hemocytes.  A second function of the galectins may be to recruit or 
activate hemocytes circulating in the hemolymph, leading to the activation of other 
anti-viral immune mechanisms, and so may have an indirect effect on viral infection.                                 
6.2.2 The MD2-like receptors – ML1 
 
Lipopolysaccharide (LPS), a component of bacterial cell walls, is one of the best 
characterised pathogen associated molecular patterns (PAMPs).  Many studies have 
shown that in mammals LPS binds to the toll-like receptor (TLR)-4 (reviewed by 
[168]).  In order to trigger TLR-4 signalling, other ancillary proteins are required, one 
of which is MD-2 [169].  In fact MD-2 is absolutely required for TLR-4 signalling 
induced by LPS as shown by the fact that TLR-4 and MD-2 form a heterodimer 
complex capable of sensing LPS [168].  A family of proteins with high sequence 
homology to MD-2 has been reported by Inohara and Nunez [170], called the MD2-
like receptors (MLs).  It consists of genes with four conserved cysteine residues, an 
MD2-like lipid binding domain, and an N-terminal signal peptide, indicating the 
protein family is secreted [170].  At that time 155 MLs were identified in animals and 
plants.  MLs, like MD-2, have been implicated in lipid recognition and metabolism. It 
is postulated that MLs may act as a cofactor for the recognition of LPS in flies, where 
LPS triggers an immune response, however a TLR that recognises LPS has not been 
identified [170].  In a recent comparison of the transcriptional responses of A. 
gambiae to P. falciparum and P. berghei infection, AgM1 was shown to be up-
regulated during P. falciparum ookinete invasion of the midgut [134].  Subsequent 
RNAi of the AgML1 gene resulted in significant increases in P. falciparum oocysts 
after infectious blood meals.  In A. gambiae there are 15 MLs (CEGG ImmunoDB), an 
expansion of the 10 predicted MLs in D. melanogaster, which may be a result of 
adaptation to a haematophagous lifestyle and thus, changes in pathogen exposure 
[134].   
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ONNV infection differentially regulated two MLs; ML1 and ML9. AgML1 has single 
copy orthologs in Ae. aegypti and C. quinquefasciatus. AgML9 has an ortholog in C. 
quinquefasciatus but has been duplicated in Ae. aegypti (AeML9A/AeML9B) (Cegg 
ImmunoDB).  ML1 KD significantly increases viral titre in A. gambiae mosquitoes (~5-
fold increase in virus).  There is evidence in mammalian systems that the envelope 
glycoprotein of the Ebola virus triggers expression of pro-inflammatory cytokines in a 
TLR-4/MD-2 receptor dependent manner [171].  Several other studies also link viral 
infection (Vesicular stomatitus virus (VSV), respiratory syncytial virus, mouse 
mammary tumor virus [171] and Kaposi sarcoma herpesvirus [172]) with TLR-4 
signalling, however the role of MD-2 in these interactions is not clear.  The 
mechanisms through which ML1 may modulate viral infection are unknown.  A 
possible mode of action (based on MD2 signalling) could be that ML1 acts as a 
recognition protein that recognises a viral PAMP and subsequently is able to bind to 
a signalling receptor on the surface of cells, resulting in dimerisation and activation 
of signalling that induces expression of anti-viral genes.  There are 10 predicted Toll-
like receptors in A. gambiae with unknown functions (ImmunoDB, 
http://cegg.unige.ch/Insecta/immunodb).  TOLL9 is of particular interest due 
observed patterns of midgut expression, and its location within the 2La inversion 
that is accociated with melanotic encapsulation of Plasmodium parasites [173].    It 
would be interesting to see if silencing any of the TOLLs would give the same 
phenotype as ML1 KD, indicating that they may be functioning in the same genetic 
pathway.  An alternative possibility is that ML1 bound to a PAMP can activate other 
immune genes in a direct signalling cascade, activating anti-viral mechanisms.                  
6.2.3 The Lysozymes – LYSC4/6 
 
Lysozymes have been implicated in anti-bacterial immunity for over 40 years [174].  
They are described as proteins that hydrolyse the 1-4 glycosidic linkage between the 
alternating N-acetylglucosamine and N-acetylmuramic acid residues of the 
peptidoglycan layer of bacterial cell walls [174].  Lysozymes are found in many 
organisms, including a wide range of insects including the Lepidoptera, Orthoptera 
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and the Diptera.  There are two types of lysozyme identified in insects – the c (or 
chicken) type and the i (or invertebrate) type.  There are eight predicted lysozyme Cs 
in A. gambiae; all are predicted to be secreted, 7 having a single lysozyme domain 
and are found in 2 clusters on chromosome 2L – LYSC1,2,3,5 &8, and LYSC4 & 7 
[174].  LYSC6 is unusual in that is has 5 lysozyme domains.  Similarly long lysozymes 
have also been identified in other insects, including D. melanogaster.  A pattern of 8 
cysteine residues is required for carbohydrate binding of the lysozymes, and 2 other 
amino acids have been shown to be essential for muramidase activity [174].  LYSC2 
has all the conserved amino acids, however LYSC4 is missing the one of the residues 
important for muramidase activity.  Several of the lysozyme domains in LYSC6 are 
also missing this amino acid, suggesting that LYSC4 and 6 have reduced or abolished 
enzymatic activity [174].  Whether this putative change in enzymatic activity alters 
their ability to kill bacteria is unclear; evidence has shown that reducing or abolishing 
enzymatic activity in several lysozymes does not alter their bactericidal activity [175-
177].  Both proteins still retain the putative ability to bind N-acetylglucosamine or 
other oligoschharides [174]. Three killing mechanisms have been put forward for the 
lysozymes.  Each begins with an interaction between the lysozyme and polyanionic 
molecules in the bacterial cell wall followed by a) stimulation of autolysin activity, b) 
membrane perturbation or c) peptidoglycan hydrolysis [174].   
 
Although evidence of immune function for LYSC1 and 2 has been seen in A. gambiae, 
the roles of the other putative lysozymes is unclear.  It is suggested that LYSC3 and 8 
may be involved in the digestion of bacteria as a food source, fitting with the 
expression profiles of the two genes being restricted to the larval stage of the 
mosquito, where the larvae live in a moist and bacteria rich environment [174].  
Expression of LYSC4 is ubiquitous throughout the developmental stages of the 
mosquito, but it restricted to expression in the fat body, ovaries and malphigian 
tubules [174].  LYSC6 expression is restricted to adult mosquitoes where expression 
was detected in the head and abdomen of adult mosquitoes, however transcripts 
could not be detected in individual tissues tested (fat body, ovaries, midgut, 
malphigian tubules and salivary glands)[174].   
 
  
 143 
LYSC2, 4 and 6 were all seen to be up-regulated by ONNV infection.  Screening the 
three genes for anti-viral activity showed that LYSC4 and 6 are antagonists of ONNV 
infection.  Human lysozyme demonstrates anti-viral immunity: Human urinary 
Lysozyme C as well as lysozyme from chicken egg whites, human milk lysozyme and 
human neutrophil lysozyme all have an anti-Human Immunodeficiency Virus (HIV) 
activity [178].  A lysozyme from a marine organism was shown to inhibit Pseudo 
Rabies Virus (PRV) growth in cell culture [179].  The mechanism of lysozyme anti-viral 
activity is not clear.             
 
6.3 JAK/STAT pathway and ONNV infection in A. gambiae derived cells 
 
 
The JAK/STAT pathway has been shown to be involved in anti-viral immunity in a 
variety of organisms, from humans to flies and mosquitoes.  The data in this study 
indicate that the JAK/STAT pathway regulates viral infection in L35 cells, however 
infection of cells does not trigger translocation of STAT-1, the transcription factor of 
the JAK/STAT pathway, into the nucleus.  Therefore JAK/STAT signalling switches on 
anti-viral genes, but the pathway is not activated by ONNV infection.  There are two 
STAT genes in A. gambiae, and it is possible that STAT-1 is not the transcription 
factor that responds to JAK/STAT activation in response to viral infection.  It would 
be interesting to investigate whether HOP is phosphorylated in ONNV infected cells, 
thus indicating that the pathway is switched on in response to viral infection.  These 
results suggest that there is some constitutive activation of the JAK/STAT pathway in 
L35 cells that results in a moderate decrease in virus, however the pathway is not 
switched on in response to viral infection.  It is not clear if silencing PIAS, the 
putative negative regulator of the JAK/STAT pathway, is sufficient to activate the 
pathway, since markers for JAK/STAT activation are not known in A. gambiae 
mosquitoes.                           
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6.4 Co-infection of A. gambiae with ONNV and P. berghei 
 
During the outbreak of ONNV in the 1960’s, viral transmission occurred across many 
regions where malaria is endemic.  A. gambiae is one of the most important vectors 
of human malaria in the world, and is the only known Anopheline vector of an 
arbovirus.  A paper published in 1962 observed that during the epidemic of ONNV, 
there was a decrease in the reported malaria cases in a study area in central Uganda 
[180].  The authors studied parasite numbers in captured mosquitoes, and 
monitored the number of local children infected with malaria over 12 months.  They 
found during May 1960, when the ONNV epidemic was just starting to spread 
throughout central Uganda, that the number of mosquitoes harbouring parasites 
was unusually low (in A. gambiae, 0.6% compared to an average of 3.2% for the 
whole 12 months of the study), considering the ideal conditions for high 
transmission and abundance of A. gambiae and A.funestus, the major vectors of 
malaria in the area.  They also noted a sharp drop in the number of school children 
positive for parasites in the blood during May-November (a drop from 53% in 
December 1959 to 11% in May and 21% in November 1960).  The authors speculate 
that the development of the parasite may have been inhibited by the virus, either in 
the mosquito or human host [180].  It is possible that mosquito infection by ONNV, 
which is lifelong, could trigger immune responses that indirectly attack invading 
malaria parasites, preventing infection and reducing transmission rates of malaria.  
In order to investigate this, co-infections of A. gambiae with 5′ONNVic-eGFP and the 
rodent malaria parasite P. berghei were carried out.  During normal parasite 
development, the invasive ookinete form of the parasite crosses the midgut of the 
mosquito, and forms a cessile cyst (oocyst) on the basal laminal.  The oocyst matures 
over 10 days, forming thousands of motile sporozoites which eventually disrupt the 
oocyst and are released into the hemolymph of the mosquito [181].  Sporozoites 
invade the salivary glands, and are injected into a new host when the mosquito takes 
its next blood meal.  Even in susceptible mosquitoes, only a small number of 
ookinetes will successfully form an oocyst.  Parasite losses can be attributed to the 
mosquito innate immune system [62, 126].  Some parasites are lysed and cleared, 
but a small proportion are coated in melanin as they emerge from the midgut in a 
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process called melanisation.  It is still not clear if the melanisation process directly 
kills the invading parasite, or simply coats already dead parasites.  In some refractory 
strains of A. gambiae such as the L35 strain, all invading parasites are melanised 
during midgut invasion.   
 
There are a number of hemolymph genes that regulate the responses of the immune 
system in response to pathogens.  Three major immune mechanisms employed by 
mosquitoes (melanisation, lysis or opsonisation of pathogens) are regulated by these 
proteins.  The co-infection experiments were designed such that parasite invasion of 
the midgut and exposure to the hemolymph occurred at approximately 4 dpi with 
5′ONNVic-eGFP.  Therefore it is probable that any differences in immune response to 
invading parasites are mediated by the genes that are differentially regulated by 
5′ONNVic-eGFP at 4dpi.  When mosquitoes infected with 5′ONNVic-eGFP are 
exposed to P. berghei, there is a significant decrease in the number of melanised 
ookinetes and a small decrease in the number of live oocysts in infected midguts.  
This indicates that in virally infected mosquitoes, there is an inhibition of 
melanisation and promotion of lytic immune mechanisms.  Indeed 2 genes up-
regulated by 5′ONNVic-eGFP infection are known inhibitors of melanisation in A. 
gambiae: silencing of both CTLMA2 and CLIPA2 results in massive melanisation of 
invading parasites [62, 67].  This finding is corroborated by the observation that 
melanisation is inhibited in mosquitoes when these two genes are up-regulated.  
There are 4 further CLIPs and 1 CTL that are up-regulated by 5′ONNVic-eGFP 
infection.  These proteins can be hypothesised to have roles in the inhibition of 
melanisation or the promotion of lysis, and it would be interesting to test these 
genes for interactions with both viral infection and Plasmodium infection.   
 
A large number of TEPs and LRIMs are differentially regulated at 4dpi.  Several TEPs 
and LRIM1 are complement proteins and some have known functions in the lysis of 
parasites.  LRIM1 silencing in A. gambiae mosquitoes results in large increases in live 
oocyst numbers, demonstrating that LRIM1 functions in the killing of parasites 
independently of melanisation [126].  TEP1 has a similar phenotype in A. gambiae 
and functions as part of a complex with LRIM1 that targets parasites for lysis [126].  
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Two further LRIMS (LRIM7 and LRIM10) and 5 TEPs (TEP4/9/10/12/14) are up-
regulated at 4dpi and may have similar functions in complement mediated lysis or 
opsonisation of pathgens.  Strikingly there are some key differences in the immune 
response triggered by viral infection compared to that triggered by Plasmodium 
infection.  For example, LRIM1 is up-regulated but APL1C, which forms a complex 
with LRIM1 and is often co-regulated with LRIM1, is not up-regulated.  This suggests 
that viral specific pathways may be activated, utilising different components of the 
immune system to target viral infection than those used to target parasite infection.  
This may explain why there is only a small reduction in the number of live oocysts in 
virally infected mosquitoes.  The viral responsive genes inhibit melanisation 
(reducing the number of melanised parasites) and divert signalling to another arm of 
the immune system that, although slightly decreases oocyst numbers, does not lyse 
all invading parasites.                            
 
Immune responses to the model rodent malaria parasite and the human malaria 
parasite P. falciparum have been shown to be different; as such it is important that 
these experiments be carried out using P. falciparum parasites.  In addition to 
differences in susceptibility to immune responses, P. falciparum infections tend to 
have lower infection loads than P. berghei infections carried out in the laboratory, 
with oocyst numbers per midgut in the field being more in the range of 1-10 
depending on field isolates and mosquito strains, rather than the average of ~30 
seen in these experiments.  This is very important when considering the impact of 
co-infection on transmission of malaria, as only a single oocyst can produce 
thousands of infective sporozoites.  It would also be interesting to investigate any 
changes in the number of sporozoites in co-infected mosquitoes, as they ultimately 
determine the outcome of infection in the mosquito.            
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6.5 Final comments 
 
The transcriptional response of A. gambiae mosquitoes to ONNV infection reveals 
that the mosquito does indeed recognise and respond to viral infection by 
differentially regulating a number of genes, including many involved in the innate 
immune system.  Some of the differentially regulated genes are in-keeping with the 
literature on invertebrate anti-viral immunity.  Indeed, there are genes from the 
RNAi pathway and from the JAK/STAT pathway are differentially regulated.  However 
genes from immune signalling pathways shown not to be involved in anti-viral 
immunity in Ae. aegypti are differentially regulated, primarily the IMD pathway.  This 
indicates that A. gambiae mosquitoes may utilise different immune mechanisms to 
target viral infection to other spp of mosquitoes, possibly contributing to their poor 
vectorial capacity.  Indeed screening the effect of gene KD for the major immune 
signalling pathways in invertebrates demonstrated that the Toll pathway, known to 
be important for anti-viral immunity in Ae. aegypti and D. melanogaster, is not 
involved in targeting virus in A. gambiae.  Additionally the JAK/STAT pathway has 
little effect on viral infection in A. gambiae mosquitoes.  Experiments using A. 
gambiae cells revealed that the JAK/STAT pathway is capable of moderately reducing 
viral infection, although viral infection does not trigger activation of the pathway 
through translocation of the STAT1 transcription factor.  The role of the JAK/STAT 
pathway in A. gambiae anti-viral immunity warrants further investigation.  Four anti-
viral immunity genes were identified through gene KD in A. gambiae mosquitoes.  All 
4 of these genes have novel roles in mosquito anti-viral immunity and require further 
investigation to begin to elucidate the mechanism of viral antagonism.  It appears 
that A. gambiae utilises some core anti-viral mechanisms, such as RNAi, in 
combination with possibly species specific anti-viral mechanisms to target ONNV 
infection. 
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7 Gene silencing and RNA PAMPs in A. gambiae derived cells 
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7.1.1 Introduction 
 
The forward genetics approach of transcriptionally profiling virally infected 
mosquitoes identified many genes with roles in the regulation of ONNV infection.  
However genes that may have an effect on viral infection are not always 
differentially regulated upon infection.  An example is AGO2, a component of the 
RNAi pathway (which has a central role in regulating viral infection), is not 
transcriptionally induced upon viral infection.  It is assumed that components of the 
RNAi pathway are already present at sufficient levels for efficient RNAi to take place.  
An alternative method for identifying genes such as AGO2 is a reverse genetics 
approach.  Although a small scale reverse genetic RNAi screen was carried out in 
adult mosquitoes, cell based assays are essential for developing a high throughput 
RNAi screen.  This would allow rapid identification of anti-viral genes, as well as 
genes associated with the replication of the virus.  These assays would require an 
easily measured output, for example GFP expression from the 5′ONNVic-eGFP 
infectious clone, and high throughput methods for conducting genome wide RNAi.  
In this chapter, the testing of two independent methods of gene silencing are 
described.  Observations made during these experiments led to the investigation of 
foreign RNA as a PAMP in A.gambaie.     
 
7.2     Developing cell based RNAi assays to detect viral agonists and antagonists 
 
With a view to developing a genome wide RNAi screen, a protocol was designed for 
identifying viral antagonists using the L35 cell line and 5′ONNVic-eGFP.  Two 
independent methods for knocking down mosquito genes in A. gambiae cell lines 
were tested; transfection of dsRNA into cells and bathing cells in dsRNA.  In initial 
experiments 5 genes were selected for gene knock down via transfection of dsRNA in 
L35 cells; AGO2 – the known viral antagonist was selected as a control, 3 genes up-
regulated by viral infection identified by transcriptional profiling (ML1, DPT and 
AGAP003776 – referred to as 3776), and HOP, a known viral antagonist in other 
mosquito species.  Cells were transfected with dsRNA and infected 48 hours later  
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A 
 
B 
 
 
Figure 33.  Viral RNA copy number/ml in conditioned media of gene KD L35 cells.  
Cells were transfected with dsRNA complementary to 5 genes of interest.  48 hours 
post tansfection cells were infected with 1MOI of P1/P2V 5′ONNVic-eGFP.  
Conditioned media was collected at 24, 48, 72 and 96 hpi.  Viral RNA genome copy 
number was ascertained using qrt-PCR.  A) Viral genome copy number/ml.  B) Viral 
RNA genome copy number represented as a percentage of the infection level 
observed in the LacZ control.  Error bars represent SD of 3 biological replicates    
 
 
0.00E+00
5.00E+07
1.00E+08
1.50E+08
2.00E+08
2.50E+08
3.00E+08
3.50E+08
4.00E+08
LacZ ML1 DPT 3776 HOP Ago2
V
ir
al
 R
N
A
 c
o
p
y 
n
u
m
b
er
/m
l
24h
48h
72h
96h
-50%
50%
150%
250%
350%
450%
550%
650%
750%
LacZ ML1 DPT 3776 HOP Ago2
%
 v
ir
al
 t
it
re
 r
el
at
iv
e 
to
 L
ac
Z
24h
48h
72h
96h
  
 151 
with 1MOI of 5′ONNVic-eGFP.  Conditioned media containing virus was collected at 
24, 48, 72 and 96h post infection, and viral RNA genome copy number/ml was 
calculated using qrt-PCR.  Three biological replicates were carried out.  Figure 33 A 
shows the viral RNA copy number/ml for each of the 5 gene knock downs.  In order 
to view the differences in viral load within replicates, the viral RNA copy number/ml 
was normalised to the LacZ (non-specific RNA control) removing the variation in 
overall level of infection from replicate to replicate (figure 33B).  The results show 
great levels of variation (as experienced with infection in vivo), however ML1 and 
HOP both show increased viral titres at multiple time points.  Curiously no difference 
in viral genome copy number was observed in AGO2 depleted mosquitoes.  The 
effectene transfection protocol was specifically optimised for use with L35 cells, and 
further transfections were carried out with dsRNA complimentary to the ML1 and 
HOP and GALE8 genes.  Higher, although not significantly so, levels of 5′ONNVic-
eGFP infection were observed in both HOP and ML1 KD cells (see figure 34).  GALE8 
KD had no effect on viral infection.    
 
7.2.1 Treatment of A. gambiae cells with non-specific exogenous RNA 
dramatically impairs the ability of 5′ONNVic-eGFP to infect and/or 
replicate in A. gambiae cells 
 
With a view to developing a genome wide RNAi screen in A. gambiae cells, a second 
method of gene silencing that would increase throughput of analysis was tested.  In 
this method, cells are bathed in dsRNA for 48h prior to infection.  Initially 2 genes 
were silenced prior to infection; AGO2, a known ONNV antagonist was used as a 
positive control; HOP, the kinase in the JAK/STAT pathway.  Treatment of cells with 
exogenous dsRNA had a dramatic inhibitory effect on viral replication in all dsRNA 
treated conditions (see figure 35). 
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Figure 34.  Viral genome copy number in A) ML KD and B) HOP KD and C) GALE8 KD 
L35 cells.  Viral genome copy numbers/ml was calculated using qrt-PCR, and is 
represented as a % of the viral titre observed in the LacZ (non-specific dsRNA) 
control.  Four biological replicates were carried out for HOP KD, 2 biological 
replicates were carried out for ML1 and 3 biological replicates were carried out for 
GALE8.  Error bars represent standard error.     
 
 
Bathing cells in dsRNA resulted in a dramatic reduction in viral titre, importantly this 
phenotype was not reversed by silencing of the RNAi pathway.  To further 
investigate this cells were treated for 48 hours with non-specific LacZ dsRNA prior to 
infection with 1MOI of 5′ONNVic-eGFP.  Viral genome copy number/ml was 
calculated from conditioned media from treated and untreated cells, collected at 24, 
48, 72 and 96 hpi.  Fluorescent microscopy clearly showed a reduction in the number 
of GFP expressing cells in dsRNA treated compared to untreated cells (Figure 36A).  
Viral genome copy number was significantly lower in conditioned media from cells 
treated with dsRNA at 48 and 72hpi (T Test P values of * P<0.05 and ** P<0.001) 
(Figure 36B).                
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Figure 35.  Effect of ‘bathing’ method of gene silencing on 5′ONNVic-eGFP infection 
in L35 cells.  Cells were untreated or ‘bathed’ in dsRNA corresponding to LacZ, HOP 
or AGO2 for 48h prior to infection with 1MOI P1/P2V 5′ONNVic-eGFP.  Viral genome 
copy number/ml in conditioned media was ascertained using qrt-PCR at 24, 48, 72 
and 96 hpi.  Error bars represent standard error of 3 biological replicates.     
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Figure 36. Non-specific dsRNA inhibits viral infection in A. gambiae cells.  Cells were 
treated with LacZ dsRNA in conditioned media for 48h prior to infection with 1MOI 
5′ONNVic-eGFP A) GFP (white) in cells treated with LacZ dsRNA compared to 
untreated cells.  B) Viral genome copy number/ml from conditioned media of cells 
treated with dsRNA compared to untreated cells at 24, 48, 72 and 96 hpi. Error bars 
represent standard error of 3 biological replicates. *P<0.05, **P<0.001 using 
students T-test      
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7.2.2 Treatment of cells with ssRNA 
To see if the response to RNA was specific to dsRNA, the experiment was repeated 
using ssRNA.  ssRNA specific to the LacZ was generated from a linearised plasmid 
containing the full LacZ sequence.  Cells were bathed in ssRNA for 48h prior to 
infection with 1MOI 5′ONNVic-eGFP.  Viral RNA genome copy number/ml was 
ascertained using qrt-PCR of the viral E2 gene at 24, 48 and 72hpi (see figure 37).  A 
similar phenotype to dsRNA treatment was observed, with ssRNA treatment 
significantly reducing the viral titre of conditioned media (T test P values of * P<0.05 
and ** P<0.001).   
 
 
 
 
Figure 37.  Non-specific ssRNA inhibits viral infection in A. gambiae cells.  Cells 
were treated with LacZ ssRNA in conditioned media for 48h prior to infection with 
1MOI 5′ONNVic-eGFP.  Viral genome copy number/ml was calculated from 
conditioned media of cells treated with ssRNA compared to untreated cells at 24, 48, 
72 and 96 hpi. Error bars represent standard error of 3 biological replicates. * 
P<0.05, **P<0.001 using students T-test.       
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7.2.3 Transcriptional responses of A. gambiae cells to treatment with non-
specific dsRNA, and non-specific ssRNA 
 
To investigate the cause of the dramatic impairment of virus infection and/or 
replication in RNA treated cells, the transcriptional responses of A. gambiae cells to 
ds/ssRNA treatment were characterised.  Cells were treated for 48h with non-
specific LacZ dsRNA, ssRNA or water as a control.  Total RNA from treated cells was 
collected in TRIzol and extracted as described in material and methods.  Total RNA 
was used to generate labelled probes for hybridisation to the aglient 4 X 44K array 
(see section 3.15).  Hybridised slides were washed to remove unbound labelled RNA 
and were scanned using a GenePix semiconfocal microarray scanner (AXON 
Instruments, Foster city, CA).  Gene Pix Pro 6.1 was used to record feature signal 
intensity, to eliminate local backgrounds, for grid alignment and manual inspection 
of feature quality.  Average feature diameter was calculated and features lying 
outside two standard deviations of the mean were excluded from analysis.  The ratio 
of feature intensity verses local and global backgrounds were calculated and features 
not exceeding background intensities were excluded from analysis.  Features were 
normalised using Genespring 6.1 (AXON Instruments, Foster city, CA) by locally 
weighted linear regression methods (Lowess).  Feature intensities over the three 
biological replicates were averaged.  T-test p-values were calculated, and normalised 
data was filtered to exclude data with p-values greater than 0.05.  Data was further 
filtered to include only genes showing 2-fold and greater regulation. 
 
A. gambiae cells showed significant transcriptional responses to both ds and ssRNA; 
227 genes were differentially regulated by treatment with exogenous dsRNA and 
141 genes were differentially regulated by ssRNA.  Of these genes, 97 were regulated 
by treatment with both ds and ssRNA (figure 38).  These genes were clustered into 
three groups – those regulated by ssRNA alone, those regulated by dsRNA alone, and 
those regulated by both ds and ssRNA.      
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Figure 38.  Transcriptional responses to treatment of A. gambiae cells with ds or 
ssRNA compared to water. The transcriptional responses of A. gambiae cells to ss 
and dsRNA were profiled using 4X44K Agilent RNA microarrays.  Gene lists include 
only features that pass strict criteria outlined in figure 20.  Genes included the 
analysis are 2-fold or greater regulated, with T-test P values of <0.05.  Genes were 
categorised based on gene ontology and orthologs in other insects. Red arrows 
indicate direction of regulation. Mel, Melanisation; LRR, Leucine Rich Repeat.   
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7.2.4 Transcripts regulated by ssRNA only 
 
Fourty seven genes are differentially regulated specifically by ssRNA alone.  Nine 
genes associated with metabolism are regulated, 6 of which are associated with 
oxidation/reduction (5 of which are up-regulated).  Sixteen genes have no predicted 
gene architecture and/or putative function.  A putative RNA binding protein is up-
regulated; it contains a putative dsRNA binding domain, however its function is not 
known.  Nine immunity related genes are differentially regulated.  Of these only 4 
are up-regulated by ssRNA treatment; 2 LRR proteins, and 2 Clip domain serine 
proteases.  Down-regulated immunity genes include 2 Fibrinogen-like proteins 
(FREPs), a further 2 LRR proteins and a lysozyme.  Other differentially regulated 
genes have diverse putative functions including protein-protein interaction, sugar 
transport, DNA repair, and a cuticle constituent.  Appendix 2 Table 3 gives a full list 
of genes regulated by ssRNA treatment.   
 
7.2.5 Transcripts regulated by dsRNA only 
 
A much larger number of genes are transcriptionally regulated by dsRNA alone; 110 
genes, 67 of which are up-regulated, and 43 are down-regulated.  Thirty regulated 
genes have diverse putative functions in metabolism, 5 are involved in 
oxidation/reduction.  Two RNA binding genes are up-regulated.  One is a putative 
inhibitor of translation.  The other is a Vasa-like RNA helicase, which may function in 
unwinding of dsRNA.  Interestingly 7 genes with roles in signalling are differentially 
regulated, including a tyrosine phosphorylation-regulated kinase (up-regulated), a 
tyrosine phosphatase (down-regulated), a putative transcription factor (up-
regulated), a G-protein (up-regulated) and a protein with multiple predicted domains 
including the integrin beta subunit, and EGF-like region and a Von Williebrand factor 
domain (up-regulated).  Seventeen immunity regulated genes are differentially 
regulated, 10 of which are down-regulated.  The most highly up-regulated immunity 
related gene is an LRR protein that contains a predicted transmembrane domain 
(TM) and encodes 2 possible Immuno Tyrosine Activating Motifs (ITAMs) in the 
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cytoplasmic tail of the protein, indicating that it may be an immune receptor that 
can signal upon activation.  A further LRR gene is up-regulated, along with an MD-2 
like protein ML5, 2 serine protease inhibitors SRPN5/16, a peptidoglycan recognising 
protein (PGRP-LB1) and a sugar binding protein (CTLMA4).  D. melanogaster PGRP-LB 
is a Gram negative antibacterial protein that is regulated by the IMD pathway, and 
itself down-regulates the IMD pathway in a negative feedback to regulate immune 
responses[182].  CTLMA4 is a C-type lectin that has also been shown to play a role in 
defence against Gram negative bacteria in A. gambiae[183], indicating that dsRNA 
triggers the IMD pathway.  However, DEF1, ortholog of DmDefensin-1 (which is 
regulated by both the Toll and the IMD pathways in Drosophila) is down-regulated 
by dsRNA treatment.  Two prophenoloxidases and three FREPs are down-regulated.  
Additionally a lysozyme, a scavenger receptor, LRIM1 and SRNP6 are down-
regulated.  Appendix 2 table 2 gives a full list of genes differentially regulated by 
dsRNA.     
 
7.2.6 Transcripts regulated by ds and ssRNA 
 
Ninety seven genes are differentially regulated by ds and ssRNA.  Fifty seven of these 
are up-regulated and 40 are down-regulated.  Of the up-regulated genes, 20 have no 
putative function and/or predicted genes architecture.  Nineteen genes have 
putative functions in metabolism, nine with oxido-reductase activity including a 
glutathione-S-tranferases and two cytochrome P450s.  Eight putative immunity 
genes are up-regulated, 7 of which have roles in the melanisation cascade and 
regulation of melanisation; 5 clip domain serine proteases (CLIPs) are regulated 
(A4/A8/A14/B5/B13), a super-oxide dismutase (SOD1) (known to reduce 
melanisation of parasites in mosquitoes[184]), and CTLMA1.  The final immunity 
gene is GALE8.  The remaining up-regulated genes have diverse functions, including a 
nucleic acid binding protein with a Tudor domain (found in Tudor-SN, a component 
of the RNAi pathway in D. melanogaster).   
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Of the 40 down-regulated genes, the majority are putative immunity genes (31).  19 
of these are Fibrinogen-like proteins (FREPs).  Four TEPs are down-regulated, along 
with 2 anti-microbial peptides (CEC1/3) and three lysozymes (LYSC1/2/5).  Three pro-
phenoloxidases (PPOs; enzymes in a cascade that produces melanin during 
melanisation) are also down-regulated.  Appendix 2 Table 1 gives a full list of genes 
differentially regulated by ds and ssRNA.     
 
7.2.7 Overlap in gene expression between viral responsive genes and 
ds/ssRNA regulated genes 
 
The genes differentially regulated by ds and ssRNA were compared to virally 
responsive genes (Table 8).  Five genes are differentially regulated in the same 
direction by all 3 conditions, and 1 is differentially regulated by ssRNA and 5′ONNVic-
eGFP infection.  Two of these genes are putative immunity genes; SRPN5 and GALE8.  
GALE8 was found to be an antagonist of ONNV infection in G3 mosquitoes.  The 
other genes include a transport protein that putative functions in transporting 
ligands between membranes, a dehydrogenase-like hydrolase that has a putative 
function in metabolism, and a sugar transporter that belongs to the Major Facilitator 
Superfamily (MFS) (a family of transporter capable of moving small solutes in 
response to chemiosmotic ion gradient. 
 
Eleven genes are differentially regulated in the opposite direction by ds/ssRNA 
treatment and 5′ONNVic-eGFP (Table 8), including 7 immunity genes, indicating that 
viral infection triggers distinct signalling to RNA recognition.       
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Table 8.  Transcripts differentially regulated by ds/ssRNA treatment and 5′ONNVic-
eGFP infection.   
 
  Fold change ratio 
AGAP 
Common 
name/function dsRNA ssRNA 
ONNV Day 
1 
ONNV Day 
4 
ONNV Day 
9 
              
Genes regulated in the same direction       
       
AGAP003733 
Cellular 
retinaldehyde 
binding/alpha-
tocopherol 
transport 2.217 n/a  2.11  
AGAP004954 
Haloacid 
dehalogenase-like 
hydrolase 2.622 2.215  2.91  
AGAP009145 unknown 2.156 n/a  2.06  
AGAP009221 SRPN5 2.127 n/a  2.15  
AGAP012529 GALE8 4.57 3.866111  2.08  
AGAP007753 
sugar transporter 
integral to 
membrane  2.652  3.02  
              
Genes regulated in the opposite direction       
       
AGAP000694 CEC3 0.34633 0.398  2.04  
AGAP002198 
Glycine N-
methyltransferase 0.421 n/a  2.7  
AGAP006278 
Insect 
pheromone/odorant 
binding protein 
PhBP 0.489 n/a 2.4 2.1  
AGAP007343 LYSC2 0.3873 0.424  2.08  
AGAP008578 
Vasa-like ATP 
dependent RNA 
helicase 2.122 n/a  0.4  
AGAP006348 LRIM1 0.495 n/a 2.2835   
AGAP010814 TEP17 0.406 0.493 2.601   
AGAP010774 FREP27 0.415 n/a  2.13  
AGAP010819 TEP10 0.401 0.423  2.10  
AGAP010830 TEP9 0.345 0.41 2.3   
AGAP011333 
AMP dependent 
synthase and 
ligase  2.048  0.50  
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7.2.8 Confirmation of microarray analysis using qrt-PCR 
 
In order to confirm the results seen in the microarray analysis, an independent 
method was used to ascertain the differential regulation of several genes found to 
be 2-fold or greater regulated by ds and ssRNA treatment. Qrt-PCR was used to 
confirm the differential regulation of CLIPA8, CEC1, CEC3 and DEF1 in A. gambiae 
cells.  The two independent methods gave similar fold-changes in transcripts for all 
genes tested for dsRNA treatment (figure 39A) and ssRNA treatment (figure 39B). 
Additionally the transcriptional profile of three genes, (CEC1, CEC3 and DEF1) in 
response to dsRNA treatment, were confirmed using a different A. gambiae cell line 
(figure 39C).       
 
 
 
 
Figure 39. Confirmation of transcriptional responses to RNA using qrt-PCR. Relative 
transcripts levels (compared to controls) were calculated in cells A) treated with 
dsRNA  B) treated with ssRNA. C)  Conformation of transcriptional responses to 
dsRNA in 2 different A. gambiae derived cell lines.   
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7.2.9 Effect of non-specific dsRNA treatment in A. gambiae mosquitoes   
 
Considering the dramatic effect of non-specific dsRNA on viral infection in A. 
gambiae cell lines, the effect of non-specific dsRNA treatment in adult G3 
mosquitoes was investigated.  Mosquitoes were inoculated with dsRNA or sterile 
PBS 4 days prior to infection with 5′ONNVic-eGFP.  Viral RNA genome copy 
number/mosquito was calculated using qrt-PCR against the viral E2 gene (figure 40).  
Injection of LacZ dsRNA did not dramatically reduce viral infection as observed in the 
L35 cell line.  Viral titre was slightly decreased at 1 dpi, however infection in LacZ 
dsRNA treated mosquitoes at 3 and 6 dpi was higher than in PBS treated mosquitoes, 
although this was highly variable from between replicates and not statistically 
significant.   
  
 
 
 
Figure 40.  Effect of non-specific dsRNA treatment on 5′ONNVic-eGFP infection in 
adult mosquitoes.  Mosquitoes were injected with either PBS or dsRNA specific to 
the LacZ gene 4 days prior to infection with 5′ONNVic-eGFP.  Viral genome copy 
number per mosquito was calculated using qrt-PCR at 1, 3 and 6 dpi.  Error bars 
represent standard deviation of 3 biological replicates.     
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7.2.10  Summary 
This chapter has covered:  
 Silencing of ML1 and HOP but not GALE8 increases viral replication in A. 
gambiae cells 
 Treatment of A. gambiae cells with exogenous non specific RNA impairs the 
ability of 5′ONNVic-eGFP to infect and replicate 
 A. gambiae cells transcriptionally respond to both ds and ssRNA treatment 
 Qrt-PCR confirmation of microarray analysis;  transcriptional responses were 
confirmed using an independent method and additionally using a different A. 
gambiae derived cell line 
 Non-specific dsRNA does not inhibit viral replication in adult mosquitoes 
 
 
7.3 Discussion 
 
 
The development of a high throughput genome-wide RNAi screen would greatly 
facilitate the identification of genes with roles in regulating viral infection in A. 
gambiae.  Any method of silecing genes using the RNAi pathway must include the 
introduction of dsRNA against genes of interest into cells to initiate gene silencing.  
In mammalian systems dsRNA and ssRNA are potent danger signals.  They are 
recognised or sensed by multiple receptors and proteins (RIG-1, MDA5, LGP-2, TLR-
3), resulting in the activation of anti-viral mechanisms [185].  Non-self ds and ssRNA 
are believed to be viral specific PAMPs, and are recognised both intra- and extra-
cellularly.  The mammalian response to RNA PAMPs is highly discriminative; the 
cytoplasm of cells are full of host RNA, however signalling only occurs in infected 
cells [185].  Viral PAMPs recognised by RIG-1 include viral genomic RNA, Viral 
transcripts and replication intermediates, non-capped RNA and Pol III transcribed 
RNA [185].  Although RNAi is an established anti-viral mechanism in invertebrates, 
which recognises and destroys foreign dsRNA, other mechanisms for sensing 
ds/ssRNA, like those seen in mammalian systems, have not been described.  In this 
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section the development of RNAi screens in A. gambiae cells and the response of A. 
gambiae cells to foreign ds and ssRNA are discussed.   
           
7.3.1 Testing genes in A. gambiae derived cell lines; a view to developing a 
genome wide RNAi screen 
 
 
A secondary objective of this project was to develop protocols for carrying out a 
genome wide RNAi screen to identify viral antagonists/agonists utilising the GFP 
marker inserted into 5′ONNVic-eGFP, and A. gambiae cell lines.  During this study a 
method to assay the effect of gene knock down (via transfection of dsRNA) on viral 
titres in L35 cells was developed, however, experiments using a plate reader to 
quantify GFP expression as a marker for infection were unsuccessful in 
differentiating between high and low levels of infection (data not shown).  This is 
due to the nature of the marker – cells infected with 5′ONNVic-eGFP express GFP 
shortly after infection, however the GFP expression is a qualitative rather than a 
quantitative marker, and does not reflect the viral genome copy number generated 
during infection.  Thus, GFP can only be used to identify differences in very early 
infection i.e. if silencing a gene results in 100% of cells becoming infected compared 
to 20% of cells in a control, or blocks the entry of virus into cells, preventing 
infection.  However, silencing a gene that limits, but does not prevent, infection 
would show no/very little difference in GFP expression.  As such, in this study, the 
viral genome copy number in conditioned media was used as a measure of viral 
infection of L35 cells, and was calculated using qrt-PCR. 
 
Two genes were found to be viral antagonists in L35 cells, ML1 – an MD-2 like 
receptor discussed previously, and HOP – the Janus kinase in the JAK/STAT pathway.  
HOP KD in A. gambiae mosquitoes also showed some interesting, however 
inconsistent, results in vivo, and as such was not taken forward for detailed analysis 
by plaque assay.  In view of the effect on viral replication in cells, it would be 
interesting to carry out plaque assays of HOP KD mosquitoes to see if the function is 
maintained in vivo.  Due to the high variation between replicates observed in viral 
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infections, and the low number of replicates carried out, neither HOP nor ML1 KD 
resulted in statistically significantly increased viral titres using a students T-test, 
however carrying out T-tests with such a small number of data is not appropriate.  
Curiously silencing of AGO2 had no effect on viral replication in L35 cells.  This was 
unexpected seeing as AGO2 is a known viral antagonist in A. gambiae mosquitoes 
and A. gambiae L35 cells do have a functioning RNAi pathway.  It is possible that 
AGO2 is redundant and silencing this gene does not prevent RNAi in L35 cells.  To 
test if RNAi is capable of limiting viral infection in L35 cells, further members of the 
RNAi pathway would need to be silenced.   
 
In order to increase the throughput of gene KD assays in cells, a second method of 
gene silencing was investigated.  Cells were bathed in dsRNA for 48h prior to 
infection.  Treating cells with dsRNA, both mosquito specific and non-specific, led to 
a dramatic decrease in viral infection.  This reduction of viral infection was not 
reversed by silencing AGO2, indicating that the virus is suppressed by a mechanism 
independent of RNAi (however as previously mentioned, the ability of RNAi to limit 
viral infection in L35 cells has not been demonstrated to date).  The observation of 
this dramatic phenotype led to the question of whether non-specific dsRNA, and 
additionally ssRNA, can act as a danger signal in mosquito cells.   
 
In mosquitoes there are a wide variety of immune responses that vary in their 
specificity.  There are broad spectrum responses, for example LRIM1 and several 
TEPS transcriptionally respond to diverse pathogens (bacterial, fungal and parasitic) 
(Leanna Upton, unpublished data), and there are more specific responses to 
individual pathogens, such as the Toll pathway responding to gram positive bacteria 
and fungal infection, and the IMD pathway responding to gram negative bacteria.  
RNAi demonstrates a still more specific response, which targets individual and 
specific dsRNA sequences from a single virus.   
 
In mammalian cells, dsRNA and ssRNA are potent triggers of innate immune 
responses, with multiple mechanisms for sensing ds/ssRNA and downstream 
signalling.  Unlike RNAi, the induction of innate immune signalling by ds/ssRNA in 
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mammalian cells is a non-specific response to foreign RNA, where foreign RNA is 
acting as a danger signal.  Intracellular dsRNA can be recognised by Protein kinase R 
(PKR), binding of which induces the phosphorylation of the eukaryotic translation 
initiation factor eIF2 and the inhibition of translation [186].  dsRNA is also recognised 
by 2’5’Oligoadenlyate synthetase, leading to the activation of RNAse L, which cleaves 
dsRNA [187].  Intracellular ds/ssRNA is recognised by RIG-1 and the RIG-1 like 
helicases (RLHs), MDA5 and Lgp2, all of which lead to signalling via CARD-CARD 
interactions and trigger NF-kB signalling, regulating the expression of a plethora of 
cytokines, interferon and potent anti-viral innate immune responses [185].  Lastly 
dsRNA is also recognised within endosomal vesicles of cells by Toll-like receptor 3 
(TLR-3).  TLR-3 signals through intracellular TIR domains, recruiting TRIF, and 
culminating in the activation of NF-kB, IRF3 and IRF7 signalling [188].  The ligands, or 
PAMPs, that are recognised by these proteins can be derived from viral transcripts 
and replication intermediates, viral genomic RNA, uncapped transcripts and Pol III 
transcribed RNA [185]. 
     
It has been suggested that in D. melanogaster, Dicer-2, despite lacking CARD 
domains, may still have a signalling function downstream of RNAi.  Vago is a gene 
expressed in a Dicer-2 dependent manner in D. melanogaster, and has an anti-viral 
function in the fat body against Drosophila C virus (DCV) infection [189].  The 
helicase domain of Dicer-2 is required for Vago expression [189], and may have a 
secondary function in Dicer-2 downstream signalling, mimicking the function of the 
RLH’s to which it’s helicases domain is closely related [190].  The signalling events 
leading to Vago expression remain uncharacterised.  In mosquitoes, the RNAi 
response is known to respond to non-self dsRNA, however, alternative mechanisms 
for sensing foreign RNA are little known.  Whether mechanisms exist that can sense 
RNA PAMPs through pathways other than RNAi in invertebrates, is not clear.           
 
The transcriptional responses of an A. gambiae cell line, 4a3A, to dsRNA and ssRNA 
were profiled using microarrays analysis.  Both ds and ssRNA elicited a significant 
transcriptional response in A. gambiae cells, including a large number of putative 
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immunity genes.  Ninety seven of these genes were regulated by both ds and ssRNA, 
however distinct groups of genes are regulated by dsRNA alone, and ssRNA alone.        
 
7.3.2 Genes regulated by ds and ssRNA 
 
The treatment of L35 cells with both dsRNA and ssRNA dramatically impairs the 
ability of ONNV to infect and/or replicate within cells.  This suggests that the genes 
involved in limiting viral infection are responsive to both ds and ssRNA.  These genes 
are discussed below.   
7.3.2.1 Melanisation  
 
Of the immunity genes up-regulated by both dsRNA and ssRNA, nearly all have roles 
in the melanisation cascade.  Five CLIPs are up-regulated.  The CLIPs are serine 
proteases, so called because of a ‘paper-clip’-like fold formed by disulphide bridges 
present in the protein family [191].  In A. gambiae there are 54 CLIPs, divided into 
several sub-families.  The CLIPAs are serine protease homologs (SPHs) where the 
catalytic triad of the enzyme has been mutated and is no longer functional [124].  
The CLIPBs are functional serine proteases.  The CLIPs have functions in hemolymph 
coagulation, anti-microbial peptide synthesis and melanin synthesis in invertebrates 
[192].  In D. melanogaster CLIPs are known to activate the Toll pathway; Eater, Snake 
and Persephone (3 CLIPs) are involved in the cleavage of Spatzle, the cleaved form of 
which is the ligand for the Toll pathway [191].  Additionally CLIPs have a role in 
regulating the melananotic cascade.  Melanisiation is an important immune reaction 
in invertebrates.  It involves a cascade of serine proteases that culminates in the 
cleavage of pro-phenoloxidase (PPO) into phenolxidase (PO).  PO is the first enzyme 
in a cascade that produces melanin: a compound that is deposited on the surface of 
pathogens & foreign objects, or around damaged tissue during wound healing [193].  
During the production of melanin, highly reactive and toxic intermediates are 
produced [193]; as such tight regulation of the melanotic cascade is required.  In A. 
gambiae, CLIPA8 (up-regulated by both ds and ssRNA) is a known positive regulator 
of melanisation of P. berghei ookinetes [67] and is also required for PPO activation 
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after bacterial infection [194].  The other up-regulated CLIPs do not have described 
roles in A. gambiae, however it seems that ds/ssRNA alters the regulation of 
melanisation.  CTLMA1 is also up-regulated; CTLMA2 inhibits the melanisation of P. 
berghei parasites [62], however if CTLMA1 has a similar function it is unknown.  In 
addition to the differential regulation of several CLIPs, three PPOs are down-
regulated by ds/ssRNA treatment, indicating that the melanisation cascade is 
inhibited by ds/ssRNA treatment.  Considering the poor characterisation of the 
majority of the CLIPs and other components of the melanisation cascade, it is not 
clear how ds/ssRNA treatment is altering the regulation of melanisation.                       
 
7.3.2.2 Redox status 
 
Nine genes up-regulated by ds/ssRNA have oxido-reductase activity, including a 
glutathione-S transferase, two cytochrome P450s and a flavin containing mono-
oxygenase (FMO).  Two aldo-keto reductase-like enzymes are up-regulated; these 
enzymes are NADPH dependent, catalyse the reduction of a variety of carbonyl 
compounds and have diverse cellular functions [195].  Another NAD(P) binding 
enzyme with oxido-reductase activity is also up-regulated.   
 
Gluathione-S transferases are a family of enzymes that have a wide variety of 
functions.  Much of the work on mosquito glutathione-S transferases has focused on 
insecticide resistance, demonstrating glutathione-s transferases to have an import 
role in maintaining the redox status of cells, and protecting against harmful reactive 
oxygen species [196].  FMOs are flavo-enzymes that require FAD, NADPH and oxygen 
for catalysis [197].  They function within a catalytic redox cycle much like the 
cytochrome P450s.  FMOs catalyse the oxidation of nitrogen, sulphur, phosphorous 
or selenium in normal metabolism, and in the metabolism of xenobiotics [197].  
Cytochrome P450s similarly catalyse the oxidation of a variety of compounds, 
including xenobiotics such as sulphur and nitrogen containing insecticides [197] and 
are known to be involved in resistance to insecticides in a variety of insects [198].  
The up-regulation of several enzymes capable of detoxifying xenobiotics and reactive 
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oxygen species indicates that ds/ssRNA treatment may be inducing oxidative stress 
in cells.  A further detoxifying exzyme, superoxide dismutase (SOD) is also up-
regulated by both ds/ssRNA, further supporting this idea.   
 
The respiratory burst is a well characterised immune response in mammalian 
systems that is triggered in activated macrophages; during phagocytosis a large 
number of ROS are released by macrophages that are toxic to invading 
microorganisms.   In D. melanogaster the oxidative burst has been shown to be 
indispensable for protection against microbes in the gut [199].  The redox status of 
mosquitoes has a known effect on the immune reactions to parasite infection; a 
strain of A. gambiae that is refractory to P. berghei infection (L35) has been shown to 
be in a state of heightened oxidative stress compared to susceptible strains [184].  
This strain of A. gambiae melanises all ookinetes as they cross the midgut.  
Microarray analysis identified several genes involved in redox metabolism as being 
up-regulated in the refractory strain.  Additionally the refractory stain was a) seen to 
have higher levels of reactive oxygen species (ROS) after blood feeding than 
susceptible mosquitoes, b) that treatment with anti-oxidants reversed the 
melanisation of ookinetes and c) that SOD expression was higher than in susceptible 
mosquitoes [184].  It is not clear whether the heightened oxidative stress directly 
targets the invading parasites, which are then melanised, or whether it speeds up 
the immune responses of the mosquito.         
 
There is limited evidence that viruses stimulate the respiratory burst; incubation of 
human neutrophils with the influenza virus stimulates the production of ROS and 
increased oxygen metabolism [200]; DENV infection in mouse spleen induces the 
production of hydrogen peroxide and superoxide anion [201]; in plants, infection of 
Tobacco with tobacco mosaic virus (TMV) stimulates the release of ROS [202], and 
additionally previous infection of Tobacco with TMV leads to higher levels of SOD 
during a second infection resulting in resistance to infection[203].  ds/ssRNA may be 
recognised as a viral PAMP, triggering oxidative stress, which in turn may target viral 
infection in cells.  It would be interesting to test susceptibility to viral infection in the 
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strain of A. gambiae that has been shown to be in a state of heightened oxidative 
stress.     
 
7.3.2.3 Fibrinogen-like proteins (FREPs) 
 
Of the genes down-regulated by ds/ssRNA treatment, almost half (19) are FREPs.  
The FREPs are a family of PRRs common to vertebrate and invertebrates.  In A. 
gambiae there has been significant species specific expansion of the family, with 59 
FREPs, compared to 14 in D. Melanogaster [204].   In invertebrates the FREPs have 
been implicated in innate immunity [134, 205-207].  A comprehensive study of the 
protein family in A. gambiae revealed strong correlation between expansions and 
chromosome location with immune responsiveness of the FREPs [204].  Different 
FREPs respond to bacterial, fungal and parasitic infection, demonstrating a wide 
repertoire of recognition capability.   
 
There are five different clusters of FREPs on several chromosomes [204] – the FREPs 
down-regulated by ds/ssRNA are from all 5 clusters, and represent genes 
differentially regulated by E.coli, S.aureus, P. berghei, B.bassiana and P. falciparum, 
in both directions i.e. there does not seem to be any immune responsive specificity 
in the FREPs that are down-regulated by ds/ssRNA.  Why such a broad range of 
FREPs are down-regulated by ds/ssRNA treatment is not clear.           
 
 
7.3.3 Genes regulated by dsRNA only 
 
There are 110 dsRNA specific responsive genes.  Just less than half the genes have no 
known putative function, or have very diverse functions.  Those with putative 
functions can be divided into several categories.   
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7.3.3.1 Signalling 
 
Six genes with functions in cellular signalling are differentially regulated – five of 
these are up-regulated.  Additionally an interesting LRR protein that appears to have 
signalling capability is the most highly regulated gene that is dsRNA responsive.  This 
LRR is a transmembrane protein with two possible immuno tyrosine-based activation 
motifs (ITAMs) in the intracellular portion of the protein (a ‘classical’ ITAM is 
YxxI/Lx(6-12)YxxI/L [208], the two possible ITAMs are YxxLx(14)YxxI and YxxxLx(8)YxxL).  
These two possible ITAM motifs are highly conserved between A. gambiae, Ae. 
aegypti and D. melanogaster.  The extracellular portion contains 18 leucine rich 
repeats (LRRs) that are also well conserved across the three species.  ITAMs are used 
by the classical immunoreceptors; T cell receptors (TCRs), B cell receptors (BCRs), 
FcRs, activating NK cell receptors, TREM1 and 2 all signal through ITAMs, activating 
the Scr family of kinases [208].  ITAMs are also utilised by a variety of non-immune 
receptors for signalling via the Scr family of kinases [208].  LRRs are structural motifs 
of 20-29 residues containing a conserved pattern of leucine residues.  Typically each 
LRR forms a β strand and an α helix connected by loops, with each LRR structural 
unit being arranged on a parallel axis and so forming a horseshoe structure [209].  
From surveys of LRR containing proteins, it is believed that the main function of LRRs 
is to provide a structural framework for protein-protein recognition[209].  
Importantly, although the leucines are highly conserved, the residues between the 
patterns of leucines  can be highly variable [210].  LRRs are found in many immune 
related genes; the TLRs have tandem LRRs, which deviate in sequence in the LRR 
domains, conferring the ability to bind a wide variety of PAMPs[210]; the LRIM 
family of proteins in A. gambiae all contain LRR domains, and have roles in anti-
plasmodium immunity [126]; the variable lymphocyte receptors (VLRs) in the jawless 
vertebrates contain highly diverse LRRs generated from a VLR locus with banks of 
LRR cassettes that can be inserted into incomplete germline VLR genes, thus 
individual lymphocytes express unique arrangements of LRRs for recognition of a 
variety of pathogens [211].  Examples of PAMPs recognised by LRR containing 
proteins are bacterial DNA (TLR7/8) [210],  dsRNA (TLR3) [212], LPS (TLR4) [213], 
flagellin (TLR5) [210] and fungal effectors [214].                               
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In addition to this receptor, a dual specificity tyrosine phosphorylation regulated 
kinase is up-regulated, a tyrosine phophatase is down-regulated, and a possible 
transcription factor is up-regulated.  The tyrosine phosphatase is an ortholog of D. 
melanogaster TRAM1; TLR4 induces signalling via two sets of adaptor proteins, one 
of which is the TRAM/TRIF pair of adaptor proteins[168].     It is temping to speculate 
that they may belong to a pathway that recognises exogenous dsRNA.  However, due 
to the wide variety of PAMPs recognised by LRR proteins, and the huge diversity in 
LRR sequences, it is impossible to theorise what is the ligand of this receptor.                             
 
7.3.3.2 Immunity genes 
 
The immune genes regulated by dsRNA treatment have a variety of predicted 
functions.  Several genes associated with defence against Gram negative bacteria are 
up-regulated; PGRP-LB1 is the ortholog of a Gram negative anti-bacterial protein 
regulated by the IMD pathway in D.melanogaster [182]; CTLMA4 has a role in 
defence against Gram negative bacteria in A.gambiae [183]; ML5 (an MD2-like 
receptor) may bind to the same substrate as the MD2 receptor (LPS found in the wall 
of Gram negative bacteria).  Several immune genes are down-regulated; DEF1 is an 
antimicrobial peptide that is regulated by both the Toll and the IMD pathway in A. 
Gambiae [135] and is predominantly active against Gram positive bacteria [49]; 
LRIM1, SCRC1 and three FREPs are all putative recognition proteins that respond to a 
wide variety of pathogens, but it is noteworthy that all three FREPs have been shown 
to be down-regulated in response to E.coli (a Gram negative bacteria) in A. Gambiae 
[204]. 
 
The differential regulation of the above immune genes by dsRNA indicates that 
pathways triggered by Gram negative bacteria are activated and/or modulated.  
However, the gene expression induced by the Toll and IMD pathways in A. gambiae 
are not as clear as they are in D. melanogaster, with several AMPs responding to 
signalling by both pathways [135].  The remaining immunity genes have roles in the 
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regulation of melanisation; SRNP6 and PPO2/4 are down-regulated (SRPN6 inhibits 
melanisation in A. Gambiae [215] and PPOs are the precursor to the enzyme at the 
start of the cascade that produces melanin), but SRPN5/16 are up-regulated.  Due to 
poorly defined roles of most of these genes, it is not possible to speculate how 
melanisation is being altered by dsRNA treatment.     
7.3.4 Genes regulated by ssRNA 
 
A smaller number of genes are regulated by ssRNA alone, however (as will be 
discussed in limitations of the microarray study) the majority of fold change ratios 
for the corresponding genes in the dsRNA microarray are missing, and as such it is 
difficult to say that these genes are specifically regulated by ssRNA alone.  Two 
groups of genes are ssRNA responsive; Redox status - A group of 5 genes with 
functions in maintaining the redox status of cells, including a glutathione-S 
transferase, are up-regulated by ssRNA.  As discussed previously this may be part of 
a respiratory burst response to a danger signal triggered by non-self RNA.  Immune 
genes – a smaller number of immunity genes are ssRNA responsive (9).  The majority 
of differentially regulated immune genes have uncharacterised functions and belong 
to gene families with diverse pathogen recognition capability (four LRRs and two 
FREPs) or diverse functions in modulating immune signalling (two CLIPs).  Their 
differential regulation suggests that ssRNA is also recognised as a PAMP by A. 
gambiae cells.      
 
 
7.3.5 Overlap of RNA responsive genes with other gene lists 
 
The genes differentially regulated by ss/dsRNA were compared with virally 
responsive genes.  Only a small number of genes are differentially regulated by 
ss/dsRNA and viral infection; 6 genes are up-regulated by both ss/dsRNA and viral 
infection, and 11 genes are regulated in opposite directions by ds/ssRNA and viral 
infection.  This very small overlap indicates that 5′ONNVic-eGFP infection triggers 
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different signalling pathways to ss/dsRNA, suggesting that the virus is not recognised 
through foreign ss/dsRNA.  It is perhaps not surprising that the two data sets do not 
overlap considering that ss/dsRNA treatment was extracellular, and is taken up into 
cells, as seen in Drosophila cells [151, 216].  Infection of mosquito cells with 
5′ONNVic-eGFP does not appear to trigger apoptosis, and so we would not expect 
extracellular foreign ss/dsRNA to be present.  The transcriptional responses to 
exogenous ss/dsRNA may be triggered by receptors that recognise extracellular RNA, 
whereas viral infection may be recognised through a variety of PAMPs, such as the 
coat proteins of the virus, viral genomic RNA, dsRNA replication intermediates or 
secondary structure of RNA and viral transcripts.  ss/dsRNA represents only a single 
PAMP compared to the many present during a natural viral infection.  However the 
observation that recognition of foreign RNA leads to gene regulation that can target 
viral infection supports the idea that foreign RNA is recognised as a viral PAMP.  
Considering that viruses utilise host cells to produce and post translationally modify 
their proteins and use host membranes to form new virions, foreign RNA is possibly 
one of the most accessible and recognisable PAMPs.        
 
Interestingly none of the genes differentially regulated by RNA are putative 
members of the RNAi pathway.  It is possible that components of the pathway are 
already sufficiently expressed in the cell line, and so differential expression of these 
genes is not required for efficient RNAi.  The dataset of RNA responsive genes was 
also compared to those identified in a dsRNA uptake pathway in D.melanogaster 
[151, 216]; again none of the RNA responsive genes are involved in the dsRNA 
uptake pathway in D.melanogaster, however whether this pathway is conserved 
between D. melanogaster and A.gambiae is not clear.                   
 
7.3.6 Limitations of the microarray study 
 
The first limitation of this microarray study involves an issue already discussed in 
section 6.1.8.  When attempting to compare differentially regulated genes from two 
separate microarray experiments, there is often data ‘missing’ from one of the 
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arrays for a number of reasons – data can be missing because it is flagged as ‘absent’ 
before analysis in Genespring software.  This includes features that have diameters 
outside two standard deviations of the mean of all features, features that do not 
exceed local and/or global backgrounds (i.e. are low intensity) and features removed 
due to scratches, dust, dirt or patches that have dried out during hybridisation on 
the array.  Data can also be missing because of high variability between biological 
replicates: T-test p values greater than 0.05 are excluded from analysis.  In order to 
compare between gene lists, the ‘missing’ data that can be retrieved (in this case 
those with inconsistent ratios and thus high P values) have been added into tables of 
regulated genes for comparison (see Appendix 2, text in red), however data removed 
before analysis in Genespring software cannot be retrieved, due to the fact that any 
data retrieved would be in a raw format prior to normalisation.  Considering that 
Lowess normalisation takes into account each feature from the array, un-normalised 
data cannot be directly compared with normalised data.  During this microarray 
study, the hybridisation for ssRNA was considerably better than for dsRNA, and as 
such, much of the data found to be differentially regulated by ssRNA does not have 
an equivalent value in the dsRNA analysis.  This means it is difficult to say accurately 
that a gene regulated by ssRNA is exclusively regulated by ssRNA alone.  The same 
problem does not occur in the opposite direction, where data for both genes 
regulated by dsRNA and ssRNA are present.  As a technical problem with microarray 
analysis this is difficult to overcome.     
 
The second limitation in this study occurs when we try to compare the experiment to 
a natural situation that occurs during viral infection.  During the experiments short 
(~500bp) fragments of ss/dsRNA were used to treat cells.  In a natural system, viral 
RNA and viral RNA transcripts are much longer than ~500bp, and may be recognised 
and processed using different mechanisms.  Also, cells were treated exogenously 
with ss/dsRNA; the majority of virally derived RNA is expected to be intracellular 
considering that their replication cycle takes place within the cytoplasm of host cells, 
and in the case of ONNV infection of A. gambiae, does not cause apoptosis, thus 
limiting the exposure of cells to exogenous foreign RNA.  This does not detract from 
the finding that recognition of foreign RNA and subsequent signalling results in the 
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dramatic impairment of ONNV infection and/or replication, however it is likely that 
natural viral infection is recognised through different mechanisms, as highlighted by 
the very small overlap between virally responsive and RNA responsive genes.     
7.3.7 Final comments 
 
This study has revealed that ss and dsRNA trigger immune mechanisms in A. 
gambiae cells that can inhibit the infection and/or replication of ONNV.  Both ds and 
ssRNA were shown to alter the transcriptional profile of a large number of genes, 
including immune related genes.  Both ds and ssRNA appear to regulate genes 
mainly associated with regulation of the melanisation cascade, and a number of 
genes involved in detoxification of ROS indicating that ds and ssRNA induce an 
oxidative burst in A. gambiae cells.  In addition to responding to both ds and ssRNA, 
groups of genes are also dsRNA specific and ssRNA specific.  dsRNA induces the 
regulation of a number of interesting signalling genes that may be involved in dsRNA 
recognition and subsequent signalling.  ssRNA triggers the differential regulation of a 
smaller number of genes, the immune category of which primarily have 
uncharacterised or diverse functions.  It is not clear which of the immune genes 
differentially regulated are responsible for the dramatic decrease in virus in 
ds/ssRNA treated cells, however the oxidative burst that appears to be induced has 
been shown in other systems to be active against viral infection.  The oxidative burst 
may be another immune mechanism employed by A. gambiae to tackle viral 
infection.  These observations lead further work in the direction of identifying the 
molecular basis of ds/ssRNA recognition, and identifying the responses to foreign 
RNA that are anti-viral.   
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8 Final discussion and future perspectives 
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8.1 Final discussion 
 
The invertebrate immune system was long considered to be archaic and simple 
compared to its mammalian counterpart, however over the past 20 years, the 
complexity of invertebrate innate immunity has been revealed.  Several distinct 
immune signalling pathways respond to a variety of pathogens, resulting in the 
differential regulation of potent anti-microbial peptides (considered to be the 
hallmark of invertebrate immunity), the activation of complement-like signalling 
cascades that recognise and kill pathogens, the activation of white blood cell-like 
hemocytes that can phagocytose or melanotically incapsulate pathogens, and 
activation of the melanisation cascade.  Although it lacks the adaptive capability of 
the mammalian immune response, the invertebrate immune system is far from 
simple.  Much research has been carried out into the responses of A. gambiae to 
malaria parasites and bacterial infections, however it is only in recent years that anti-
viral immunity has been in the spotlight.  Mosquito-borne viruses are responsible for 
huge numbers of human infections every year, including DENV, YFV, WNV and 
CHICKV to name but a few.  Just as mosquitoes have been shown to respond to 
bacterial, fungal and parasitic infections, they also respond to viral infection, with 
recent evidence implicating three signalling pathways as key in invertebrate anti-
viral immunity – the JAK/STAT pathway, the Toll pathway, and most importantly the 
RNAi pathway.  The majority of studies carried out to date on anti-viral immunity in 
mosquitoes have focused on the Aedes genus (one of the most important group of 
vectors of human viruses).  Mosquito-borne arboviruses are almost exclusively 
transmitted by Aedes or Culex mosquitoes, with one exception – ONNV, which is 
transmitted by Anopheline mosquitoes.  The ONNV-A. gambiae combination offers a 
unique opportunity to study the interactions occurring in a natural infection of A. 
gambiae mosquitoes with an important human pathogen, possibly giving insights 
into the poor viral vectorial capacity of Anopheline mosquitoes.  One of the 
advantages of studying A. gambiae mosquitoes is the variety of tools available in the 
laboratory, including DNA microarrays with full genome coverage of A. gambiae, and 
a selection of cell lines derived from several strains of A. gambiae.     
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The main objective of this study was to identify genes involved in the anti-viral 
immune response of A. gambiae, using 2 approaches; the first based on the 
literature currently available to select candidates that may have a role in anti-viral 
immunity; and a second using forward genetics to identify viral responsive genes 
through transcriptional profiling.  A secondary objective of the project was to 
develop a reverse genetic approach to rapidly identify genes for functions in ONNV 
infection using RNAi, a GFP-encoding ONNV infectious clone and A. gambiae cell 
lines, with a view to conducting a genome wide RNAi screen.   
 
The study was successful in indentifying immune responses to ONNV infection, and 
in demonstrating that some of these responses are involved in limiting viral infection 
in A. gambiae mosquitoes.  Four genes were identified with novel functions in anti-
viral immunity in invertebrates.  The study also clearly demonstrated that 
development of a cell-based genome wide RNAi screen approach to identify viral 
antagonists may not be feasible with the current tools available in A. gambiae.  It 
was observed that even non-specific RNA triggers a response in cells that 
dramatically reduced viral infection. This result although discouraging with regards 
to the development of a high-throughput reverse genetic approach, triggered 
another very interesting question: whether non-specific foreign RNA acts as a PAMP, 
as seen in mammalian systems. Transcriptional profiling of responses to ds and 
ssRNA were conducted revealing that non-specific foreign RNA induces immune 
gene expression and triggers oxidative stress in A. gambiae cells and opening new 
avenues for the study of mosquito anti-viral defence.  An additional inherent 
problem with the development of a cell-based assay for viral infections was the use 
of GFP expression as a readout, which did not allow accurate quantification of the 
viral infection or monitoring the different phases of the infections. It was concluded 
that different quantitative readouts tightly linked to the presence of the virus must 
be developed. 
 
The main findings of this study can be divided into four sections discussed below, 
each of which adds to our understanding of the interactions between A. gambiae 
and ONNV, and opens up new areas of research to build upon these findings.  
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8.1.1 Susceptibility of Anopheles spp to ONNV   
 
The results obtained in this study support the idea that A. gambiae may not be the 
main vector of ONNV, with low rates of infection, slow replication rates and poor 
dissemination compared to many other vector-virus combinations. Testing ONNV 
infection in several Anopheline mosquitoes revealed large differences in 
susceptibility to viral infection.  A. quadriannulatus is more susceptible to ONNV 
infection than A. gambiae or A. arabiensis.  Interestingly the reverse is true for 
infection with Plasmodium parasites.  A. quadriannulatus is refractory to 
Plasmodium infection, whilst A. gambiae and A. arabiensis are susceptible [63].  It 
has been shown that KD of immune genes in A. quadriannulatus reverses the 
refractory phenotype of the mosquito rendering it a capable vector of malaria [63].  
This demonstrates that differences in immune status determine the vectorial 
capacity of a mosquito spp for Plasmodium infection.  A. gambiae can be infected 
with ONNV, but frequently limits viral infection, and restricts tissue tropism of 
infection.  Silencing immune genes, such as AGO2, in A. gambiae leads to 
widespread infection of mosquitoes demonstrating that most tissues in A. gambiae 
can be infected with ONNV [80] i.e. restricted tissue tropism is not caused by the lack 
of a receptor necessary for infection, but that most tissues are not infected, possibly 
due to immune responses to infection.  The differences in vectorial capacity of A. 
gambiae and A. quadriannulatus for malaria transmission are hypothesised to be 
caused by evolutionary co-adaptation of mosquito species frequently exposed to 
malaria parasites, thus A. gambiae, which is frequently exposed to malaria parasites, 
has an attenuated immune response to parasite, whereas A. quadriannulatus, which 
has limited exposure to malaria parasites, retains the ability to kill invading parasites 
[63].   
 
Just as A. quadriannulatus receives limited exposure to Plasmodium, epidemics of 
ONNV have occurred in areas where A. gambiae and A. arabiensis are abundant, but 
A. quadriannulatus is scarce.  It is possible that the continual exposure of A. gambiae 
and A. arabiensis to ONNV has resulted in the evolution of anti-viral mechanisms in 
A. gambiae, however this has not occurred in A. quadriannulatus due to 
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geographical isolation.  Indeed if ONNV infection of A. gambiae/arabiensis caused 
mortality as observed in A. quadriannulatus, there would be significant pressure to 
evolve mechanisms to cope with viral infection.   
 
After invasion of the midgut wall, Plasmodium parasites are exposed to the 
hemolymph of the mosquito, which contains a multitude of immune proteins that 
can recognise pathogens and regulate an appropriate immune response.  Co-
infections of ONNV and P. berghei revealed that viral infection shifts the humoral 
immune response away from melanisation and towards lysis or opsonization of 
pathogens.  Parasites entering the hemocoel of mosquitoes infected with ONNV 
showed reduced melanisation and increased parasite losses through lysis.  
Conversely A.quadrinnaulatus melanises large numbers of invading P. berghei 
parasites compared to A. gambiae, suggesting that its immune system is skewed 
towards melanisation of invading pathogens.  This shift in immune responses may 
account for the increased susceptibility to viral infection, where genes that can 
target viral infection through lysis or opsonisation are inhibited and genes that 
promote melanisation are activated.  This implies that the same immune responses 
that lyse parasites may be targeting viral infection, such as the mosquito 
complement system.  Indeed ML1, a gene found to be antagonistic to viral infection, 
is also a P. falciarum antagonist, KD of which increases live oocyst number, indicating 
a role in the lysis of parasites [134].    
 
8.1.2 A. gambiae can recognise and respond to viral infection through a 
combination of conserved anti-viral mechanisms and other spp specific 
immune responses 
 
Transcription profiling of A. gambiae responses to ONNV infection demonstrated 
that A. gambiae differentially regulates many immunity related genes, presumably 
to cope with viral infection.  Indeed several of these genes were shown to 
antagonise viral infection.  Interestingly some key differences between A. gambiae-
ONNV interactions compared to other vector-virus combinations were observed.   
  
 183 
 
Gene silencing experiments confirmed that RNAi has a central role in limiting viral 
infection, as previously demonstrated in A.gambiae and a variety of other 
invertebrate systems including Aedes mosquitoes and D.melanogaster.  However it 
was demonstrated that other immune signalling pathways known to be involved in 
anti-viral immunity in insects do not appear to function in modulating ONNV 
infection in A.gambiae.  The Toll pathway, an established anti-viral pathway in D. 
melanogaster and known to regulate DENV2 infection in Ae.aegypti [72],  does not 
modulate ONNV infection in A.gambiae.  Activating or inhibiting the pathway had no 
effect on viral titres in adult mosquitoes.  Also, genes known to be regulated by the 
Toll pathway in A.gambiae, such as CEC1 (personal communication, G K 
Christophides), were not identified in transcriptional profiling of infected 
mosquitoes.  This suggests that ONNV infection does not trigger Toll signalling, and 
the Toll pathway does not up-regulate genes involved in regulating ONNV infection.           
 
The JAK/STAT pathway is also an established anti-viral pathway in D.melanogaster 
and Ae.aegypti.  Although inhibition of the JAK/STAT pathway by silencing of HOP led 
to a moderate increase in ONNV infection in L35 cells, A.gambiae mosquitoes show a 
small and inconsistent increase in viral titre when the JAK/STAT pathway is inhibited 
(through silencing of HOP, STAT1 and STAT2).  Activation of the pathway through KD 
of PIAS, an inhibitor of the JAK/STAT pathway, does not decrease viral infection (as 
demonstrated in Ae.aegypti infected with DENV2 [75]).  Additionally infection of L35 
cells with ONNV does not induce translocation of STAT1 into the nucleus, implying 
that there is no activation of the JAK/STAT pathway by ONNV infection.  These 
results suggest that the JAK/STAT pathway may have a limited role in regulating 
ONNV infection but is not triggered by viral infection.  A.gambiae has two described 
STAT genes [100].  It is possible that STAT2, rather than STAT1, is translocated to the 
nucleus following pathway activation by viral infection.  Also PIAS has not been 
shown to inhibit the JAK/STAT pathway in A.gambiae: its function has been inferred 
by the role of orthologous genes in D.melanogaster and Ae.aegypti.  As such, 
silencing PIAS may not induce JAK/STAT signalling.  To date, no markers of JAK/STAT 
activation in A.gambiae have been identified, and so determining if the pathway has 
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indeed been activated is challenging.  Although the data presented here suggest that 
the JAK/STAT pathway does not respond to viral infection, to confirm this, direct 
evidence that PIAS silencing activates the JAK/STAT pathway, and whether STAT2 
translocates to the nucleus upon ONNV infection would be required.  The IMD 
pathway also appears to have no effect on ONNV when inhibited through REL2 KD, 
despite the indications from transcriptional profiling that ONNV infection triggers 
IMD signalling.   
 
In addition to the major immune signalling pathways, mosquitoes have a humoral 
branch of the immune system, consisting of complement-like proteins, serine 
proteases and enzymes that can recognise invading pathogens and target them for 
melanisation, lysis or opsonisation.  The proteins that regulate these processes 
circulate in the hemolymph, and through the recognition of pathogens, lead to the 
activation of signalling cascades that can tip the balance of an immune response 
towards melanisation, lysis or opsonisation.  Recently a complex of complement-like 
proteins that recognise invading Plasmodium parasites and target them for lysis was 
described in A.gambiae [126].  Transcriptional profiling of ONNV infected 
mosquitoes showed that several complement-like proteins are up-regulated 
following infection, including a member of this complex, LRIM1.  Although viral 
particles are difficult to visualise during an infection, Plasmodium parasites are easily 
visible and can be used to visualise the responses of the mosquito immune system: 
melanisation is clearly visible as invading ookinetes are coated in black melanin and 
lysis of parasites can be inferred from changes in the number of live oocysts 
observed during infection compared to controls.  Co-infections, designed such that 
ookinetes invading the midgut come into contact with hemolymph proteins at 4 dpi 
with ONNV, reveal that melanisation is inhibited by ONNV infection, diverting 
immune responses towards lysis and/or opsonisation (as demonstrated by a 
decrease in the number of melanised parasites and an overall decrease in the 
number of live parasites in ONNV infected mosquitoes).  This is consistent with the 
up-regulation of two genes that have roles in melanisation inhibition in A. gambiae: 
CTLMA2 and CLIPA2 [62, 183].  Interestingly the L35 cell line (which is highly 
susceptible to ONNV infection) is derived from a strain of A. gambiae that melanised 
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all invading Plasmodium parasites, and A. quadriannulatus (also highly susceptible to 
ONNV infection) melanises large numbers of invading Plasmodium parasites.  This 
suggests that diversion of immune responses towards melanisation and away from 
lysis or opsonisation increases susceptability to ONNV infection. 
 
The overall number of live parasites was decreased in ONNV infected mosquitoes, 
indicating that some parasites are lysed after invasion of the midgut.  Four LRIMs 
and five TEPs are up-regulated by ONNV infection, and may form the basis of 
recognition and targeted lysis of viral particles in a similar mechanism to the 
LRIM1/APL1C/TEP1 complex.  Interestingly, although LRIM1 is up-regulated, APL1C 
and TEP1 are not, suggesting that LRIM1 may interact with other binding partners in 
response to different PAMPS.  Although the number of live parasites decreased in 
ONNV infected mosquitoes, the reduction in oocyst number was not dramatic, 
suggesting that other mechanisms including opsonisation may be triggered by viral 
infection.  Two scavenger receptors with putative roles in opsonisation are up-
regulated, along with three Galectins that may act as opsonins.     
 
The finding that two pathways with known anti-viral roles in other invertebrate-virus 
systems do not extensively modulate ONNV infection indicates that A. gambiae may 
use other immune mechanisms to recognise and fight viral infections.  
Transcriptional profiling of infected mosquitoes and co-infections with Plasmodium 
parasites suggests these mechanisms involve the complement-like proteins of the 
humoral immune response functioning in lysis and opsonisation of pathogens.  The 
anti-viral immune response in A. gambiae is thus composed of some key conserved 
mechanisms to target viral infection including RNAi, but also other diverse and 
possibly species-specific mechanisms.  Four genes found to be anti-viral in A. 
gambiae have novel roles in invertebrate anti-viral immunity, pointing to A. 
gambiae-specific recognition of viral PAMPs and mechanisms for targeting viral 
infection.   
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8.1.3 Four genes were discovered to have novel anti-viral functions in A. gambiae 
 
The four novel viral antagonists identified in this study are all predicted to be 
secreted proteins and are not known to function in the described immune signalling 
pathways in A. gambiae.  ML1, an MD2-like receptor was found to be an antagonist 
of ONNV infection in both mosquitoes and L35 cells.  Interestingly when looking at 
the pattern of GFP expression in per os infected ML1 KD mosquitoes, no difference in 
infection prevalence is observed but a skew towards higher numbers of cells being 
infected is seen.  This indicates that ML1 does not function in preventing initial 
infection, but does limit the spread of virus from cell to cell.  ML1 may act as a 
recognition protein that binds to a receptor on cells inducing signalling that regulates 
anti-viral effectors, as seen in LPS recognition in mammalian systems where LPS 
binds to heterodimers of MD2 and TLR4 [168].  ML1 may act as part of an 
extracellular surveillance system to detect viral infection.  In contrast AGO2 KD has 
no effect on the number of cells that become infected, but does increase the 
prevalence of infection, indicating that RNAi is important for preventing the 
establishment of infection.  This is consistent with the intracellular role of the RNAi 
pathway, where RNAi can prevent the virus from replicating within an initially 
infected cell, and thus occasionally clearing infection before it is established.  When 
RNAi is inhibited initial infection is more often successful, thus increasing the 
prevalence of infection.  RNAi is an established intracellular surveillance mechanism 
for detecting viral infection, confirmed in this study as being key in regulating viral 
infection in A. gambiae.   
 
GALE8 was shown to be a viral antagonist in A. gambiae mosquitoes, and is up-
regulated by both ONNV infection, and RNA treatment of cells.  GALE8 is a prototype 
galectin; prototype galectins contain a single CRD and often form homodimers.  It is 
one of three GALEs that transcriptionally respond to ONNV infection, all of which are 
part of a mosquito specific expansion of the GALE family.  One possible mechanism 
of action is suggested by evidence from galectin-virus interactions observed in 
mammalian systems; GALE8 may bind and cross-link the envelope glycoproteins of 
virus particles, blocking the ability of the virus to infect cells.  The differential 
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regulation of GALE8 during mid-infection suggests that GALE8 functions downstream 
of initial recognition of viral infection.  Galectins also have reported roles in immune 
signalling, induction of cytokines, and driving proliferation of immune cell 
populations [164].  As such, GALE8 may have diverse roles in anti-viral immunity, 
including activation of hemocytes or inducing proliferation of hemocytes.  Two 
lysozymes were also demonstrated to have anti-viral roles in this study; LYSC4/6.  As 
classical anti-bacterial proteins, the mechanism of anti-viral immunity is unclear.     
 
The four genes discovered to have novel anti-viral functions in A. gambiae suggest 
new mechanisms of viral recognition and subsequent inhibition of viral infection 
through the recognition protein families ML and GALEs and the effector protein 
family of the lysozymes, with multiple members of each family responding 
transcriptionally to ONNV infection.  Although speculative modes of action are 
outlined in figure 41, much work must be carried out to begin identifying the actual 
mechanism of action of each of these interesting proteins.       
 
8.1.4 Foreign RNA acts as a PAMP in A. gambiae cells 
 
This study has demonstrated that RNA acts as a PAMP in A. gambiae cells and 
triggers transcriptional responses that can limit viral infection.  In invertebrate 
immunity there are numerous PAMPs recognised as danger signals.  Some of these 
PAMPs are very specific, and will trigger equally specific immune responses.  For 
example, ML1 is regulated in response to P. falciparum infection and is an antagonist 
of parasite development, however it has no function in limiting P. berghei parasite 
development.  Immune responses can be species specific (as just described), 
structure specific, such as the Toll pathway responding to Gram positive bacteria, 
and the IMD pathway responding to Gram negative bacteria, and pathogen specific, 
such as the Toll pathway responding to fungal infection.  The PAMPs that trigger 
these responses can equally be species-specific or broad spectrum.  Experiments in 
this study sought to answer if foreign RNA can act as a broad spectrum PAMP in 
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Figure 41.  Possible mechanisms of anti-viral immunity in A. gambiae mosquitoes.  
Putative functions of immune genes that regulate ONNV infection in A. gambiae.  
Modes of action have been inferred from the function of orthologous genes in other 
organisms.  ML1 may directly or indirectly recognise extracellular virus, and bind to a 
TLR-like receptor inducing dimerisation and signalling.  The JAK/STAT pathway, 
although not activated by viral infection, regulates the transcription of unknown 
anti-viral genes.  GALE8 may bind glycoproteins in the coat of circulating virus 
directly preventing infection of cells or acting as an opsonin.  Alternatively GALE8 
may induce proliferation of, or activate, hemocytes circulating in the hemolymph.  
The RNAi pathway limits viral infection through the destruction of viral specific 
transcripts within infected cells.  LYSC4/6 may perturb the membrane of circulating 
viruses.       
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A. gambiae, as seen in mammalian immune systems.  Intra- and extra-cellular ss and 
dsRNA are recognised by a number of mechanisms in mammalian cells, and trigger a 
variety of immune responses, in particular those targeting viral infection.  Foreign 
RNA indeed does illicit immune responses in A. gambiae derived cells, and the 
transcriptional responses induced by foreign RNA dramatically limit viral infection.  
This is, to date, the first demonstration of non-specific RNA as a PAMP in 
mosquitoes, and opens an interesting new avenue to study the mechanisms of RNA 
recognition, RNA uptake and subsequent triggering of signalling, and to try and 
identify the mechanism of viral suppression downstream of RNA recognition.                     
 
8.1.5 Differences in responses between adult A. gambiae and A. gambiae 
derived cells to ONNV infection 
 
Some interesting differences were observed between adult mosquitoes and the L35 
A. gambiae cell line.  Identified antagonists through gene silencing experiments in 
L35 cells were ML1, HOP and non-specific ds/ssRNA.  AGO2 and GALE8 KD showed 
no effect on viral titre.  In contrast in adult mosquitoes, ML1, AGO2 and GALE8 were 
identified as antagonists, but HOP KD and non-specific dsRNA had no effect on viral 
titre.  Additionally the L35 cell line is highly susceptible to ONNV infection, in 
contrast to adult mosquitoes where infection patterns are restricted.  The 
observation that AGO2 silencing has no effect on viral titre in L35 cells, coupled with 
the high susceptibility to infection suggests that L35 cells do not have a functioning 
RNAi pathway.  However, silencing of genes using dsRNA has been achieved in L35 
cells, demonstrating that they are capable of RNAi (data not shown).  In fact, the 
efficiency of gene silencing of a single gene was tested in all 7 A. gambiae cell lines, 
and no correlation between the efficiency of gene silencing and susceptibility to 
5′ONNVic-eGFP infection was observed (data not shown).  Although it has been 
demonstrated that AGO2 is required for RNAi in the Sua1B cell line [217], it is 
possible that AGO2 is redundant in L35 cells, and is not required for RNAi.     
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The A. gambiae cell lines were derived from minced neonates; newly hatched larvae 
were used for primary culture from three A.gambiae strains (Suakoko 2La, 4a r/r and 
L-35).  These primary cell lines have not been immortalised or cloned and contain a 
mixed population of cells that is assumed to be continually changing.  Each cell line 
has varying properties, for example the 4a3A cell line does not express PPOs 
(enzymes involved in the melanisation response) in comparison to the 4a3B cell line 
which expresses 6 PPOs [99] despite both cell lines being derived from the same 
initial pool of newly hatched larvae.  The cell lines currently used in the laboratory 
were selected for immuno-responsiveness (for example to bacterial challenge) and 
are described as hemocyte-like from immune gene expression patterns, making 
them appropriate for use in studies of immune responses to pathogens [99, 218].  
Little characterisation of the L-35 derived cell line used in this study has been carried 
out.  Microarray analysis of cell line responses to pathogen challenge compared to 
adult mosquito responses to pathogen challenge showed similar patterns of gene 
expression (Dr G christophides, personal communication) and as such the cells have 
been considered a useful model for experiments.  However the due to the 
heterogeneous population of cells within these cultures, properties including gene 
expression may change over time decreasing the accuracy of modelling mosquito-
arbovirus interactions.         
 
Although A.gambiae derived cells will not represent the complex responses of 
multiple tissues to viral infection, and we can expect that through changes in cell 
populations during passage different cells lines will respond to viral infection in 
different ways, the use of cell lines for high throughput analysis is still invaluable.  
The disparity between cell culture and whole mosquitoes is a problem common to all 
in vitro systems and underlies the importance of carrying out research in vivo where 
possible.  However, some genes have similar functions in vitro and in vivo, for 
example ML1, and cell lines offer a practical solution for the rapid identification of 
genes with interesting functions.  Continuing to develop a high throughput method 
for screening genes for functions in ONNV infection warrants further investment and 
will greatly facilitate the identification of anti-viral mechanisms in A. gambiae 
mosquitoes.                         
  
 191 
This series of experiments is the start of the process of understanding the 
interactions between A. gambiae and a natural viral pathogen of this mosquito.  It is 
clear that Anopheline mosquitoes are poor vectors of viral disease, although they are 
efficient vectors of malaria parasites.  The genetic differences that determine the 
vectorial capacity of mosquitoes for different groups of pathogens are just beginning 
to be dissected, including immune responses to infection.  This study has revealed 
that not all of the immune signalling pathways with known anti-viral roles in 
invertebrates are utilised by A. gambiae mosquitoes to fight ONNV infection.  The 
novel anti-viral genes identified in this study indicate that other uncharacterised 
immune responses can limit viral infection and may be important in defining the 
ability of mosquito spp to harbour and spread arboviral disease.     
 
8.2 Future perspectives 
 
The results of this study point to several avenues for further research in anti-viral 
immunity in A. gambiae.  Much of the work conducted in this series of experiments 
represents the first steps, in a relatively young field of study.  There is much work 
that can be carried out, building upon the results found here, which will broaden our 
understanding of the interactions between mosquitoes and their viral pathogens.   
 
During this study it was noted that there is a large level in variation between 
individual mosquitoes to support ONNV infection.  Some individuals were highly 
susceptible to viral infection, showing high viral titres when infected intrathoracically 
or showing broad patterns of midgut infection after per os infection.  In contrast 
some individuals appear to be refractory to infection, showing very low titres after 
intrathoracic inoculation, or no infection in the gut after per os infection.  The 
question arises if there are genetic differences between the individuals within these 
populations that confer susceptibility or refractoriness to infection? One way to 
investigate this is to identify any single nucleotide polymorphisms (SNPs) that exist 
between groups of highly susceptible verses refractory individuals using a SNP chip.  
Genes that confer susceptibility or refractoriness will have a higher density of SNPs 
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compared to other genes, and so these genes can be identified through finding areas 
of dense SNPs typically within a single gene.  SNP chip analysis has been used to 
identify genes involved in insecticide resistance and in disease resistance, for 
example, SNPs have been identified in immune genes that are associated with P. 
falciparum infection [219].  During this study, large numbers of N’gousso strain A. 
gambiae (a recently colonised strain of A. gambiae that still retains a relatively large 
amount of genetic diversity within the colony) were per os infected with ONNV, and 
individuals demonstrating refractoriness to infection, or demonstrating high 
susceptibility to infection were collected and genomic DNA was extracted.  In a 
collaboration with the Broad Institute, the DNA samples are currently being used for 
SNP analysis using an array containing 400,000 SNPs in A. gambiae.  The results of 
this project are pending, but will hopefully give some insight into the genes that may 
confer the ability of A. gambiae mosquitoes to act as vectors of ONNV. 
 
In addition to the high levels in variation observed between individuals of the same 
species, large differences in the ability to host ONNV infection were observed 
between different species of Anopheline mosquitoes.  It would be interesting to 
investigate the transcriptional responses of A. quadriannulatus to ONNV infection 
and to contrast this with the transcriptional responses of A. gambiae.  As previously 
discussed, in a study conducted by a colleague in the laboratory differences in gene 
copy number between A. gambiae and A. quadriannulatus were determined (Dr T 
Habtewold, unpublished data), and revealed large differences in gene copy number 
for apoptosis related genes.  Apoptosis may be responsible for the mortality 
observed in ONNV infected A. quadriannulatus mosquitoes, which could be 
confimed using a number of fluorescent markers of apotosis in A. quadriannulatus.  
Additionally positive and negative regulators of apotosis could be silenced in A. 
quadriannulatus to see if this has any effect on viral infection or mortality.               
 
During this study a small scale RNAi screen of 19 genes was carried out in A. gambiae 
mosquitoes to identify genes with roles in anti-viral immunity.  The transcriptional 
profiling of infected mosquitoes revealed a large number of genes to be responsive 
to viral infection, many of which have no putative function.  It would be important to 
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continue screening these genes for functions in anti-viral immunity, as they may 
identify A. gambiae specific mechanisms for targeting viral infection.  The 
development of a high throughput cell based assay to screen genes would greatly 
assist this process, but has to date been unsuccessful.  Methods to develop these 
assays should continue to be investigated.   
 
This study identified four genes as being novel anti-viral genes in A. gambiae, 
however the mechanism by which each of these genes targets viral infection is not 
clear.  Identifying these mechanisms is the next challenge in this field.  Firstly it 
would be important to show if there is any direct interaction between the genes 
identified and invading virus.  Localisation studies using antibodies against these 
genes may give insight into their function.  For example can GALE8 bind to the 
glycosylated coat proteins of ONNV and/or does ML1 act as a recognition receptor 
that can bind virus or perhaps binds to receptors on immune/other cells.  It would be 
interesting to see if these proteins bind not only to virus, but also what other 
proteins may be involved in viral recognition complexes, or signalling receptors that 
may be activated by these proteins.  Producing tagged proteins and using techniques 
including immunoprecipitation assays could identify such proteins.  Whether ML1 
has a role as a signalling receptor could be investigated: determining the 
transcriptional profile of ML1 KD mosquitoes may identify genes with anti-viral 
functions.  A possible function of GALE8 may be to activate/and or recruit hemocytes 
- proliferation of hemocyte populations after viral infection could be identified using 
markers of hemocyte activation (however these remain poorly characterised in A. 
gambiae) and markers of cellular proliferation.  Each of the four genes belongs to a 
protein family with several predicted members in A. gambiae.  There are 15 
predicted MLs (two of which are up-regulated by ONNV infection), 11 predicted 
GALEs (3 of which are up-regulated by ONNV infection) and 8 predicted LYSCs (three 
of which are up-regulated by ONNV infection) in A. gambiae.  It would be interesting 
to screen the other members of these protein families to see if they also have roles 
in anti-viral immunity. 
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Foreign RNA ellicits the transcriptional regulation of hundreds of genes in A. 
gambiae derived cells.  Work now must begin to elucidate which of these genes is 
responsible for the inhibition of viral infection and/or replication of cells exposed to 
foreign RNA.  Initially an RNAi screen could be carried out, to see if silencing any of 
the differentially regulated genes reverses the phenotype observed.  Additionally, 
the mechanisms for recognition and uptake of exogenous foreign RNA remain to be 
characterised in A. gambiae.  Silencing genes with putative roles in the mechanisms 
identified through the transcriptional analysis carried out in this study, for example 
the signalling genes that are differentially regulated by dsRNA may reveal functions 
in recognition and signalling in response to dsRNA recognition.     
 
8.3 Concluding comments 
 
In summary this study has attempted to identify components of the anti-viral 
immune system of A. gambiae mosquitoes.  Through transcriptional profiling of 
virally infected mosquitoes, it was demonstrated that A. gambiae responds to viral 
infection through the differential regulation of a number of putative immunity 
genes, in addition to many genes with non-immune or uncharacterised function.  
Further to this, an RNAi based screen identified several virally responsive genes as 
being antagonistic to viral infection.  One of these genes is a component of the RNAi 
pathway and has previously been described as a viral antagonist in A. gambiae.  The 
other 4 genes have novel roles in anti-viral immunity, and do not appear to belong to 
the classical invertebrate anti-viral immune signalling pathways i.e. the Toll and the 
JAK/STAT pathways.  Additionally the Toll pathway has no effect on ONNV infection 
and the JAK/STAT does not appear to activated by ONNV infection.  Thus it appears 
that A. gambiae mosquitoes utilise a combination of key conserved anti-viral 
mechanisms to target viral infection, such as RNAi, with other mosquito specific, and 
possibly even species specific anti-viral immune mechanisms.  Transcriptional 
profiling of infected mosquitoes and co-infections with P. berghei suggests these 
mechanisms involve the complement-like proteins and lysis and/or opsonisation.  
This study also revealed non-specific RNA to be a broad spectrum PAMP in A. 
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gambiae derived cells, triggering transcriptional responses that antagonise viral 
infection.   
 
The study of the interactions between the mosquito immune system, and viral 
pathogens is not only interesting in terms of the fascinating cell biology but is 
important for the development of novel approaches to prevention of arboviral 
disease transmission.  Viruses have very different lifestyles compared to many other 
pathogens, being obligate intracellular pathogens that rely on host cells to complete 
their lifecycles.  They represent a unique challenge to the immune system, and 
require sophisticated mechanisms of recognition and targeting.  Completing their 
replication cycle within host cells enables viruses to ‘hide’ from conventional 
recognition from the immune system, and their use of the host cell membrane to 
form new viral particles reduces the number of PAMPs that the immune system can 
recognise.  The mechanisms immune systems have evolved to detect these stealthy 
pathogens are not only ingenuous, but provide us with novel targets for the 
development of disease prevention methods, for example rendering mosquitoes 
refractory to viral infection through genetic engineering, using transmission blocking 
vaccines or chemical modification of immune responses.  Although many years away 
from realisation, each of these theoretical disease prevention methods requires a 
detailed understanding of the interactions between mosquitoes and their viral 
pathogens.  This study is one of the first steps towards elucidating the unique ways 
in which A. gambiae mosquitoes respond to and fight viral infection.  
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“To the reader who asks, ‘What can you possibly see to interest you in these 
miserable creatures?’ or ‘So you work on mosquitoes, so what?’ (according to 
what side of the Atlantic he is on) I would say I find it sobering to reflect that 
mosquitoes have at times played a more effective part in determining the 
course of human history than the generals and other leaders who set 
themselves up to guide our fortunes.  But when the inevitable question is 
asked, I can only ask in return, ‘What use is a man?’ 
 
“I think the present time may well go down in history as the period when man 
sought to conquer and control nature as if he himself were something apart, 
when the ignorance of the nineteenth century was replaced by the arrogance 
of the twentieth.  But I question the whole present-day attitude that defines 
progress and civilisation as conquests over nature.  Progress can come only 
from an understanding of and attempt to co-operate with the forces of 
nature in the full realisation that we ourselves as well as the mosquitoes that 
bite us are moulded by these very forces and are as inseparable from them as 
the clouds from the sky.” 
 
J.D. Gillett, 1971 
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Appendix 1  
 
Table 1.  Genes regulated by 5’ONNVic-eGFP infection in A.gambiae 
mosquitoes.Two-fold or greater fold change ratios are shown in black text for 
one day postinfection (D1), 4 days post infection (D4) and nine days post 
infection (D9).  Fold change ratios less than 2-fold regulated that have passed all 
filters outlines in figure 20 excluding filtering on fold change ratio, are shown in 
grey text.  Putative functions/functional domains were derived from Gene 
ontology terms, Interpro domains and functions of orthologous genes 
(www.vectorbase.org).   
 
AGAP D1 D4 D9 
Common 
name Functional group Putative function 
Early onset       
AGAP001899 2.03    Fatty acid synthesis Fatty acid synthase 
AGAP000260 2.08    Housekeeping 
ATPase, F1 complex, epsilon 
subunit, mitochondrial 
AGAP010814 2.60   TEP5 Immunity Thioester containing protein   
AGAP006348 2.28   LRIM1 immunity Leucine rich repeat protein 
AGAP004248 2.27   GPXH3 Immunity peroxidase, GPX sub familiy 
AGAP002848 2.01   ML9 Immunity MD2-like receptor 
AGAP005901 0.48    immunity/apoptosis? 
Sterile alpha and TIR motif 
containing protein (d.mel ortho), 
also had Armadillo repeats 
AGAP001116 2.02    metabolism FAD dependent oxidoreductase 
AGAP006009 2.49   CPR30 Misc insect cuticle protein,structural 
AGAP006958 0.48    Misc Heat shock protein 
AGAP010895 0.46 0.51   Misc 
D.mel ortho beta spectrin, 
cytoskeletal protein with diverse 
function 
AGAP005913 0.45    Signalling G-protein with WD-40 repeats 
AGAP005912 0.45    Signalling G-protein with WD-40 repeats 
AGAP005911 0.39    Signalling G-protein with WD-40 repeats 
AGAP002171 0.48    Translation 
Nucleolar protein nop5 (d.mel 
ortho), rRNA processing factor 
AGAP003773 4.37    unknown unknown 
AGAP003778 4.12    unknown unknown 
AGAP003777 4.06    unknown unknown 
AGAP003939 2.83  1.85  unknown protein binding, unknown 
AGAP003775 2.65    unknown unknown, PA fragment 
AGAP001078 2.28    unknown unknown 
AGAP009974 2.12    unknown unknown 
AGAP008447-
RA 
AGAP008444-
RA 2.11    unknown unknown 
 23.00      
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Early to mid 
onset       
AGAP008118-
RA 0.48 0.35   Cell division 
Cell cycle checkpoint kinase, d.mel 
ortho grp 
AGAP004556-
RA 0.46 0.32   Cell division 
d mel ortho peter pan (ppan), 
required for larval growth, roles in 
mitosis and cell growth (mutants 
show reduced growth) 
AGAP009176-
RA 2.21 2.19 1.27  Fatty acid synthesis Fatty acid synthase 
AGAP003196-
RA 2.17 2.01   Fatty acid synthesis 
GNS1/SUR4 membrane protein - 
unknown function/poss fatty acid 
elongation 
AGAP005620 2.02 3.60 1.66 DPT Immunity Dipteracin, anti-microbial peptide 
AGAP004845 2.01 3.42  SCRB8 Immunity Scavenger receptor, cell adhesion,  
AGAP012352 2.31 2.86 1.61 ML1 Immunity MD2-like lipid recognition 
AGAP009556 2.10 2.82  FREP50 Immunity Fibrinogen-like 
no AGAP 2.47 2.77 1.44 CLIPA9 Immunity Clip domain serine protease 
AGAP010812-
RA 2.88 2.73 1.61 TEP4 Immunity Thioester containing protein 
AGAP008654 2.15 2.58 1.68 TEP12 immunity Thioester containing protein 
AGAP007457 2.10 2.38   Immunity LRR protein 
AGAP004455 2.10 2.55  GNBPB1 Immunity 
Gram negative binding protein 
subgroup B 
AGAP011790 2.09 2.36  CLIPA2 Immunity Clip domain serine protease 
AGAP003247 2.14 2.17  CLIPB19 Immunity Clip domain serine protease 
AGAP010819 2.53 2.15  TEP10 Immunity Thioester containing protein 
AGAP010830 2.23 2.06  TEP9 Immunity Thioester containing protein 
AGAP007315 2.04 2.69   metabolism nitrogen compound metabolism 
AGAP005372 3.15 3.01  COEBE3D Misc Carboxylesterase, type B 
AGAP012320-
RA 2.32 2.48  OBP25 Misc oderant binding protein 
AGAP006278 2.05 2.18 1.85  Misc 
insect pheromone/odorant 
binding protein 
AGAP008311-
RA 2.46 2.12   Misc 
acylphophatase, unknown 
function 
AGAP007160 2.12 2.06   Misc HSP20 domain 
AGAP000930-
RA 0.47 0.36   Misc 
WD40 repeats - protein-protein 
interactions, D.mel ortho pod1 
(actin/microulue binding) 
AGAP006904 0.39 0.48 0.61  Misc 
Matrix metalloproteinase (MMP1 
d.mel ortho) functions in digestion 
of ECM, release of apoptotic 
ligands, diverse functions in cell 
proliferation, angiogensis, 
apoptosis and immune defence 
AGAP010548-
RA 2.21 2.85 1.61  signalling 
Laminin B (cell adhesion, EM), 
EGF-like domain (epidermal-
growth factor-like) 
AGAP001589-
RA 0.49 0.32   Translation 
initiation factor 2b-related 
(translation) 
AGAP008306-
RA 2.76 3.58   unknown 
hypothetical protein, unknown 
function 
AGAP008011-
RA 2.10 3.48   unknown Unknown 
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AGAP006504 2.51 3.24   unknown Unknown 
AGAP006507 2.67 3.00   unknown Unknown 
AGAP005611 2.15 2.89   unknown Unknown 
AGAP011317-
RA 2.05 2.79   unknown 
General oderant binding precursor 
familiy 
AGAP010066-
RA 2.34 2.70   unknown Peroxisomal membrane protein 
AGAP008307-
RA 2.44 2.59   unknown 
hypothetical protein, unknown 
function 
AGAP007711 2.03 2.44   unknown Unknown 
AGAP003239-
RA 2.42 2.31 1.26  unknown Unknown 
AGAP004208 0.46 0.43   unknown unknown  
       
 38.00      
Mid onset       
AGAP009792-
RA 0.68 0.49   Cell division 
d.mel ortho pendulin, needed for 
cell proliferation, comains 
armadillo repeats, and an 
importing domain 
AGAP003742-
RA  0.47   Cell division 
regulator of chromosome 
condensation 
AGAP005800  0.47   Cell division 
DNA replication licensing factor 
MDM7, part of a complex required 
for initialtion and elongation of 
replicative forks during S-phase 
AGAP006165  0.45   Cell division 
ortho d.mel domino; hemocyte 
proliferation, mRNA splicing, DNA 
helicase activity 
AGAP007874-
RA 0.58 0.45   Cell division 
Initiation factor eIF-4 gamma, 
MA3, or cell cycle control 
AGAP007477  0.40   Cell division 
ATP dependent DNA helicase, DNA 
replication, mitosis, DNA repair 
(from d.mel ortho Replication 
Factor C40, RfC40) 
AGAP002440-
RA  0.34  
CDC42_A
NOGA Cell division 
CDC42 - cell division control 42; 
Rho GTPase, diverse functions 
including regualtion of the cell 
cycle, also Miro-like - ribosomal 
homeostasis and apoptosis 
functions 
AGAP007112 0.50 0.27   Cell division 
Cell cycle checkpoint (BRCT dmain) 
and cell proliferation (pescadillo 
domain) 
AGAP010150-
RA 1.94 2.45 1.79  Fatty acid synthesis 
Cytochrome b5 related, fattcy acid 
desaturase domains 
AGAP010695-
RA  2.31   fatty acid synthesis 
GNS1/SUR4 membrane protein - 
unknown function/poss fatty acid 
elongation 
AGAP008468-
RA 1.88 2.06 1.57  fatty acid synthesis Fatty acid synthase 
AGAP010461-
RA 0.81 0.47   Histone Histone H1 ortho 
no AGAP 1.87 2.86 1.55 CLIPC9 Imminuty Clip domain serine protease 
no AGAP 1.65 2.45  CLIPE4 Immunity Clip domain serine protease 
  
 212 
AGAP003058 1.64 2.44 1.99 CLIPB9 Immunity Thioester containing protein 
AGAP008368  2.44  TEP14 Immunity Clip domain serine protease 
AGAP010774  2.30  FREP27 Immunity Fibrinogen-like 
AGAP004806  2.28  GALE6 Immunity galectin, sugar binding 
AGAP009221 1.82 2.27  SRPN5 Immunity Serpin 
AGAP005334 1.57 2.25  CTLMA2 Immunity C-type lectin, sugar binding 
AGAP012529  2.21  GALE8  Immunity galectin, sugar binding 
AGAP004807 1.54 2.20  GALE7 Immunity galectin, sugar binding 
AGAP010360-
RA 1.47 2.19   Immunity peritrophin-A chitin binding 
AGAP007343  2.19  LYSC2 Immunity Lysozymes 
AGAP005717 1.94 2.18  LYSC6 Immunity lysozyme   
no_AGAP  2.15  FREP10 Immunity Fibrinogen-like 
AGAP004920  2.14  CASPS6 Immunity Caspase, apoptosis 
AGAP003246 1.50 2.12 1.90 CLIPB2 Immunity Clip domain serine protease 
AGAP000694-
RA 1.60 2.11 1.76 CEC3 Immunity AMP 
AGAP012945-
RA 1.58 2.07   Immunity Caspase (d.mel Decay) 
AGAP000443 1.73 2.07  CTL5 Immunity C-type lectin, sugar binding 
AGAP009166 0.50 0.48  IKK1 Immunity 
part of IKK complex required for 
IMD signalling 
AGAP004036  0.48  HXP7 Immunity Peroxidase 
AGAP007294 0.68 0.46  IAP1 Immunity inhibitor of apoptosis 
AGAP004038 0.80 0.45  HXP8 Immunity Peroxidise 
AGAP008354  0.35  HOP Immunity Janus kinase, Hopskotch 
AGAP010363-
RA  4.23   Immunity? Chitin binding,peritrophin-A 
AGAP010364-
RA  4.08   Immunity? peritrophin-A chitin binding 
AGAP006707  3.23   metabolism Chymotrypsin 
AGAP005752  2.89   metabolism 
Metabolic, transferase activity, 
transferring hexosyl groups 
AGAP010530-
RA 1.77 2.63   metabolism chymotrypsin/Hap 
AGAP012034-
RA 
AGAP012035-
RA  2.32   metabolism 
chymotrypsin/Hap domain, 
unknown gene family 
AGAP007142  2.29   metabolism 
Peptidase S1A, chymotrypsin, 
trypsin activity, digestion, 
metabolism 
AGAP006926  2.22   metabolism alcohol dehydrogenase 
AGAP012843-
RA 1.84 2.19 1.54  metabolism Chymotrypsin/Hap 
AGAP005124 1.51 2.18   metabolism Aldehyde dehydrogenase 
AGAP002721-
RA  2.16   metabolism 
tryptophan oxygenase - 
tryptophan metabolism 
AGAP010243-
RA  2.04   metabolism 
chymotrypsin (aedes ortho of 
trypsin), complement activation? 
AGAP007505  0.47   metabolism serine carboxypeptidase activity 
AGAP011948-
RA  0.44   metabolism Threonine dehydrogenase 
  
 213 
AGAP002208-
RA 0.57 0.38   Metabolism 
cytochrome P450 family, 
monooxygenase activity, iron 
binding 
AGAP008296-
RA 1.32 0.34  
TRY1_AN
OGA Metabolism 
Peptidase S1A, chymotrypsin, 
trypsin activity, digestion, 
metabolism 
AGAP007753-
RA  3.13   Misc 
Major facilitator family. Sugar 
transporter 
AGAP007601  3.08   Misc 
Major facililtator family, general 
substrate transporter 
AGAP008052-
RA  2.85  
Q6H8Z3_
ANOGA Misc 
Putative sensory appendage 
protein SAP-2 precursor 
AGAP006076 1.44 2.80  OBP50 misc oderant binding protein 
AGAP002198-
RA  2.73 1.96  Misc 
Methyltransferase, gene/protein 
regulation? 
AGAP010409-
RA  2.43  OBP22 Misc oderant binding protein 
AGAP005837  2.37   Misc 
Juvenile hormone esterase, d mel 
ortho 
AGAP007918-
RA  2.37  
Q8I9N3_A
NOGA Misc 
aldehyde oxidase/xanthine 
dehydrogenase 
AGAP011426-
RA  2.32   Misc 
Sodium dependent phosphate 
transported (D.m and Aedes 
ortho's), part of MIP familoy of 
transporters 
AGAP004433-
RA 1.67 2.31  OBP19 Misc oderantbinding protein19 
AGAP002826-
RA 
AGAP002827-
RA  2.27   Misc 
Major facilitator family, 
transporter 
AGAP008404-
RA  2.20 1.57  Misc 
N-6 Adenine-specific DNA 
methylase 
AGAP003733-
RA 1.70 2.18 1.45  Misc 
Cellular retinaldehyde 
binding/alpha-tocopherol 
transport 
AGAP008182-
RA 1.38 2.13   Misc oderant binding protein 
AGAP001966-
RA  2.10   Misc Sodium solute symporter 
AGAP009464-
RA 1.36 2.08 1.53  Misc 
ABC transporter (import/exportof 
a wide variety of substrates) 
AGAP005918 1.70 2.06   Misc cation diffusion 
AGAP006249  0.48   misc transport of aa's 
AGAP001514-
RA  0.48   misc Kv3.4 voltage-gated K+ channel 
AGAP002622-
RA 0.61 0.48   misc 
Sodium/substrate sympoter - 
imports substrates against the 
concentration gradient using 
sodium gradients 
AGAP012089-
RA 0.72 0.48   Misc 
negative regulation of protein 
amino acid dephosphorylation 
AGAP004274-
RA 0.56 0.47   misc Zinc finger, CCHC type 
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AGAP000889-
RA 0.68 0.46   misc 
Actin-binding, cofilin/tropomyosin 
type 
AGAP005174 0.81 0.45   Misc 
Nucleoporin, WD-40 repeat 
containing 
AGAP002284-
RA  0.44   misc 
Tetratricopeptide region, found in 
a wide variety of proteins, 
mediates protein-protein 
interactions/formation of 
multiunti complexes 
AGAP011178-
RA 0.61 0.44   Misc Zinc/iron permease 
AGAP011250-
RA 0.63 0.43   Misc calmodulin binding 
AGAP003279-
RA 0.60 0.43   misc 
TPR (tetratrico peptide repeat 
region) protein-protein 
interactions, assembly of 
mutliprotein complexes 
AGAP009507-
RA 0.66 0.43   Misc deubiquitinating-like enzyme 
AGAP009659-
RA  0.42   Misc 
TPR (tetratrico peptide repeat 
region) protein-protein 
interactions, assembly of 
mutliprotein complexes 
AGAP008136-
RA 0.65 0.42   Misc 
RNA binding, cyclophillin-like 
(protein folding?) 
AGAP006925 0.64 0.42   misc 
n-acetylgalactosaminyltransferase, 
oligosaccharide biosynthetic 
process 
AGAP006949 0.85 0.41   misc Metalloendopetidase activity 
AGAP002387-
RA 0.60 0.40   Misc Histidine acid phosphatise 
AGAP011742-
RA  0.39   Misc GCN5-related N-acetyltransferase 
AGAP001423-
RA 0.73 0.38   Misc 
BIFUNCTIONAL PURINE 
BIOSYNTHESIS 
AGAP002409-
RA 0.55 0.36   Misc 
pseudouridylate synthase activity, 
pseudouridine is a modefied 
nucleoside found in RNA, may 
offer protection from radiation 
AGAP001522-
RA 0.68 0.35   Misc 
Chaperonin clpA/B, AAA ATPase - 
core, Peptidase S16, Lon protease, 
aedes ortho thyroid hormone 
receptor interactor 
AGAP012005-
RA  0.27   Misc 
ABC transporter (import/exportof 
a wide variety of substrates) 
AGAP010303-
RA 1.45 2.23   protein degradation 
ubiquitin activating enzyme, 
autophage associated (orthologs) 
AGAP007721  2.57   
protein 
transport/secretion 
Synaptobrevin, membrane protein 
from vesicles, part of the SNARE 
complex involved in exocytosis 
AGAP003576-
RA  0.43   
Protein 
transprot/secretion 
Transportin, transport of protein 
into the nucleus 
AGAP002836-
RA  0.49  
Q86MA9_
ANOGA 
(Dicer-1) RNA degradation 
Dicer-1 (RNAi pathway, miRNA 
generation for gene expression 
regulation 
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AGAP011627-
RA 0.71 0.45   RNA degradation RNA metabolic process 
AGAP005672 0.61 0.34  TSN RNA degradation 
Tudor-SN d.mel ortho, RNAi 
pathway 
AGAP011204-
RA 0.57 0.18   RNA degradation 
PIWI, contains PIWI and PAZ 
domains, and PRO rich - d.mel 
ortho of PIWI, diverse roles but 
not classical siRNA 
AGAP006941  0.44   RNA helicase 
Probable ATP dependent RNA 
helicases 
AGAP011145-
RA 0.65 0.42   RNA helicase 
DEAD box ATP dependent RNA 
helicases 
AGAP012655-
RA  0.42   RNA helicase helicase? 
AGAP011084-
RA 0.51 0.40   RNA helicase 
DEAD box ATP dependent RNA 
helicase   
AGAP009600-
RA 0.51 0.37   RNA helicase 
ATP-dependent RNA/DNA 
helicase, DEAD box 
AGAP003508-
RA  0.34   RNA helicase 
ATP-dependent RNA/DNA 
helicase, DEAD box 
AGAP011322-
RA  2.82   Signalling 
Fibulin like - EGF-like calcium 
binding domains (ECM associated) 
AGAP010766-
RA  2.51   signalling 
protein serine/threonine kinase 
activity, nucleotide binding, 
transferase activity, unknown 
function 
AGAP012666-
RA  2.20   Signalling C-type lectin, sugar binding 
AGAP005719 0.58 0.48 0.61  Signalling Transcription initiation factor 
AGAP002035-
RA 0.65 0.47   Signalling Putative transcription factor   
AGAP007050 0.69 0.46   Signalling 
GTP binding, porbable nucleolar 
GTP binding protein 
AGAP005289  0.45   Signalling 
Transforming growth factor 
ortholog, inhibitin beta unit 
AGAP003121-
RA 0.68 0.45   Signalling PI-4 kinase/cadherin 
AGAP001953-
RA 0.71 0.42   Signalling Rab GTPase activator activity 
AGAP000627-
RA 0.67 0.42   Signalling 
Ser/thre or tyrosine kinase, ortho 
Casein kinase 1 isoform alpha 
(d.mel)(though to phos 
desheivilled in the WNT signalling 
pathway) 
AGAP007118  0.42   Signalling 
Tyrosine specific protein 
phosphatise 
AGAP005362 0.64 0.39   Signalling 
Nuclear Transcription factor, X-box 
binding 
AGAP002902-
RB 0.54 0.36  
Q6PUC1_
ANOGA 
(medea) Signalling 
Regulator of transcription in the 
dpp signalling pathway in 
drosophila (when bound to 
another Smad) 
AGAP002123-
RA 0.55 0.36   Signalling 
negative regulator of the WNT 
pathway (D.mel Axin) 
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AGAP008149-
RA 0.58 0.35   Signalling Protein phosphatase 2C 
AGAP010984-
RA 0.65 0.33   Signalling Transcription factor Tfb2 
AGAP010118-
RA  2.32   Transcription 
Histone acetyltransferase, 
promotes transcription 
AGAP001900-
RA  0.49   Transcription 
negative regulation of 
transcription 
AGAP009024-
RA 0.63 0.28   Transcription 
RNA polymerase I specific 
transcription initiation factor RRN3 
AGAP001879-
RA 0.66 0.49   Translation 
Regulation of alternative splicing? 
D.mel ortho crokked neck protein 
AGAP005640 0.60 0.49   Translation 
Pre mRNA spicing factor, RNA 
processing 
AGAP007326 0.76 0.47   Translation 
Part of the splicosome, regulation 
of mRNA maturation/splicing 
AGAP000325-
RA 0.84 0.46   Translation 
Catalyss attachement of aa to 
tRNA during translation 
AGAP002337-
RA 0.68 0.43   Translation 
Eukaryotic translation initiation 
factor 3, subunit 7 
AGAP004336-
RA 0.51 0.40   Translation rRNA processing 
AGAP012283-
RA 0.64 0.34   Translation Cysteinyl-tRNA synthetase, class Ia 
AGAP006200  4.28   unknown Unknown 
AGAP003083-
RA 1.31 2.98   unknown 
Alpha-beta hydrolasefold-1 - 
common fold in hydrolytic 
enzymes 
AGAP006506 1.97 2.82   unknown Unknown 
AGAP010365-
RB  2.82   unknown Unknown 
AGAP004784 1.69 2.80   unknown 
Male sterility domain, function 
unknown 
AGAP007946-
RA  2.64   unknown Unknown 
AGAP002582-
RA 1.35 2.60   unknown PA fragment 
AGAP010111-
RA  2.52   unknown Unknown 
AGAP002853-
RA  2.46   unknown Unknown 
AGAP005614 1.90 2.34   unknown unknown 
AGAP012432-
RA 1.37 2.30   unknown 
membrane protein of unknown 
function 
AGAP004549-
RA  2.29   unknown major royla jelly protein domain 
AGAP010502-
RA  2.29   unknown unknown 
AGAP010385-
RA  2.27   unknown unknown 
AGAP003095-
RA 1.92 2.26  
Q8MZM5
_ANOGA unknown 
major royla jelly/calcium binding 
EF-hand domains 
AGAP008013-
RA 1.67 2.25   unknown unknown 
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AGAP005247  2.24   unknown unknown 
AGAP004695 1.48 2.24   unknown unknown 
AGAP006259 1.77 2.23   unknown unknown 
AGAP011784-
RA 1.80 2.22   unknown unknown 
AGAP008301-
RA  2.22   unknown 
Cystine knot, c-terminal, growth 
factor? (common motif in several 
growth factors) 
AGAP004674-
RA 1.51 2.13   unknown conotoxin 
AGAP003636-
RA  2.11   unknown unknown 
AGAP009145-
RA 1.48 2.09   unknown PA fragment 
AGAP001989-
RA  2.07   unknown unknown 
AGAP012436-
RA  2.05   unknown PA fragment 
AGAP006275 1.54 2.04   unknown unknown 
AGAP005259 0.62 0.48   unknown unknown, antifreeze domain 
AGAP011333-
RA  0.48   unknown 
AMP-dependent synthetase and 
ligase 
AGAP003086-
RA 0.73 0.47   unknown unknown, TM 
AGAP002014-
RA 0.65 0.46   unknown unknown 
AGAP003646-
RA 0.62 0.46   unknown unknown 
AGAP005033 0.62 0.46   unknown unknown 
AGAP004468-
RA 0.65 0.45   unknown Phosducin-like, unknown function 
AGAP012103-
RA 0.57 0.45   unknown RNA binding 
AGAP009424-
RA  0.44   unknown tubby domain, unknown function 
AGAP012281-
RA  0.42   unknown protein binding, function unknown 
AGAP009307-
RA  0.40   unknown 
bromodomain, KV14 domain, 
functin unknwon 
AGAP008879-
RA  0.39   unknown PA fragment, unknown function 
AGAP004463-
RA 0.56 0.34   unknown unknown 
AGAP000270-
RA 0.63 0.32   Unknown 
Tropomyosin (mucle contaction in 
muscle cells, unknown function in 
other cells), P60-like (protein 
found to interact with hereps virus 
proteins, funtion unknown) 
 170.00      
Mid to late 
onset       
AGAP005693  5.88 2.76  Immunity LRR protein 
AGAP001768-
RA  3.16 2.35  metabolism 
Gamma interferon inducible 
lysosomal thiol reductase GILT 
domain 
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AGAP008141-
RA  3.25 2.03  Misc Fumerate lyase 
AGAP003776-
RA  8.33 2.81  unknown unknown 
 5.00      
Late onset       
AGAP003502 1.45  2.53 HPX6 Immunity Peroxidase 
AGAP012037   2.26 CLIPB20 Immunity Clip domain serine protease 
AGAP003246   2.18 CLIPB2 Immunity Clip domain serine protease 
AGAP004316 1.91  2.72  immunity? CLIP   
AGAP004880   3.43  metabolism L-lactate dehydrogenase 
AGAP012561 1.62  2.98  misc iron binding, peroxidase 
AGAP009551   2.26  misc 
Sulfotransferase, transfers 
sulphate groups to specific 
compounds 
AGAP005458   0.43  misc 5'nucleotidase, putative 
AGAP008862   0.50  RNA degradation 
Piwi and Paz domain containing 
(not d.mel Piwi) 
AGAP007965   0.49  RNA degradation 
tudor/maternal tudor domain 
containing (not d.mel Tudor-SN) 
AGAP005079 1.43 1.66 2.20 
AOEJE7_A
NOGA Signalling G protein alpha subunit, q2 
AGAP001610  1.83 2.44  unknown unknown 
AGAP004133   2.41  unknown unknown 
AGAP012604   2.41  unknown unknown 
AGAP001096 1.21 1.59 2.38  unknown unknown 
       
 16.00      
Early and 
late onset       
AGAP005848 2.05 1.85 2.59 FREP44 Immunity Fibrinogen-like 
AGAP010781 2.64  2.46  unknown unknown 
AGAP000183 2.45  2.07  unknown unknown 
 3.00      
Broadly 
responsive       
AGAP007385 2.03 2.54 2.07 LYSC4 Immunity Lysozyme 
 1.00      
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 Figure S1.   Immunity probe set plots for all immunity related genes identified as 
being differentially regulated 
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Figure S1.  Immunity probe set plots for all immunity related genes identified as 
being differentially regulated.  For all immunity genes where at least one immunity 
probe passed all the filtering criteria outlined in figure 20, the entire probe-set, 
including data with poor P-values, was plotted.      
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Appendix 2 
 
Tables of genes differentially regulated by ds/ssRNA.  Red text denotes a P value of 
>0.05.  ‘Lost’ denotes no data for the probe due to low intensity or flagged as absent 
in GeneSpring.  ssRNA/dsRNA denotes the fold change ratio for ss/dsRNA treated 
compared to a water control.  Genes have grouped based on functional groups 
Immunity, Metabolism – general, Metabolism – Redox, Other, Unknown.  Genes are 
ordered by fold change ratio within each functional group.     
 
Table 1.  Genes regulated by ds and ssRNA 
 
AGAP Name ssRNA  dsRNA Putative function 
Immunity         
AGAP011780 CLIPA4 3.525 4.988 Serine protease homolog 
AGAP005234 SOD2 3.289 4.7045 superoxide dismutase 
AGAP004148 CLIPB5 2.741 4.61 Serine protease 
AGAP012529 GALE8 3.866 4.57 galectin (sugar binding) 
AGAP004855 CLIPB13 2.611 4.059 Serine protease 
AGAP010731 CLIPA8 2.303 3.423 CLIP-SPH 
AGAP007411 CTLMA1 2.165 2.631 sugar binding 
AGAP011788 CLIPA14 2.176 2.149 Clip domain serine protease 
AGAP002825 PPO1 0.377 0.496 prophenoloxidase 
AGAP004917 FREP12 0.454 0.464 FREP 
AGAP012539 FREP15 0.461 0.419 FREP 
AGAP011224 FREP57 0.43 0.41633 FREP 
AGAP011197 FREP13 0.384 0.41171 FREP 
AGAP010775 FREP26 0.415 0.41133 FREP 
AGAP010814 TEP5 0.493 0.406 TEP5 
AGAP012616 PPO5 0.479 0.4025 prophenoloxidase 
AGAP010819 TEP10 0.423 0.401 Thioester containing protein 
AGAP004975 PPO3 0.445 0.398 prophenoloxidase 
AGAP011225 FREP28 0.409 0.391 FREP 
AGAP011231 FREP59 0.421 0.3898 FREP 
AGAP000693 CEC1 0.428 0.38922 ceropin 
AGAP011230 FREP58 0.4625 0.3889 FREP 
AGAP007343 LYSC2 0.424 0.3873 lysozyme 
AGAP011276 FREP29 0.407 0.3676 FREP 
AGAP011226 FREP5/61 0.402 0.363 FREP 
AGAP010763 FREP35/21 0.406 0.354 FREP 
AGAP007346 LYSC5 0.42 0.35325 lysozyme 
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AGAP010815 TEP1 0.427 0.353 Thioester containing protein 
AGAP000694 CEC3 0.398 0.34633 Cecropin 
AGAP010830 TEP9 0.4095 0.345 Thioester containing protein 
AGAP010773 FREP22 0.427 0.342 FREP 
AGAP010762 FREP4 0.375 0.3346 FREP 
AGAP009184 FREP7 0.396 0.3296 FREP 
AGAP006743 FREP65 0.435 0.3265 FREP 
AGAP007347 LYSC1 0.374 0.3005 Lysozymes 
AGAP007041 FREP39 0.374 0.254 FREP 
AGAP010760 FREP32 0.322 0.317 FREP 
AGAP010811 FREP19 0.37 0.297 FREP 
AGAP011239 FREP60 0.345 0.279 FREP 
Metabolism - 
general         
AGAP010733  6.724 8.65 Vanin-like (nitrogen metabolism) 
AGAP011750  3.53 4.187 n-acetylglucosaminidase 
AGAP006121  3.063 3.704 carboxylic ester hydrolase 
AGAP012400  2.231 3.372 amino acid transporter/Glycosyl hydrolase 
AGAP012818  2.112 3.2 ATPase, V0/A0 complex, 116-kDa subunit 
AGAP005846  3.144 3.124 Carbohydrate metabolic process 
AGAP004954  2.215 2.622 Haloacid dehalogenase-like hydrolase 
AGAP006821  2.014 2.238 Thiolase (acetyltransferase activity) 
AGAP004399  2.089 2.074 phosphoglycerate mutase 
AGAP008837  0.459 0.411 ubiquitin-dependent protein catabolic process 
AGAP003350  0.429 0.373 Phosphoenolpyruvate carboxykinase (GTP) 
Metabolism - 
redox         
AGAP006576  4.028 4.9445 Oxidoreductase activity 
AGAP003408  3.309 4.627 Oxidoreductase activity 
AGAP010255  2.785 3.666 Oxidoreductase activity 
AGAP011051  3.088 3.6 Oxidoreductase activity 
AGAP011325  2.424 3.567 Chymotrypsin 
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AGAP010400  2.576 3.478 Flavin-containing monooxygenase FMO 
AGAP002866  2.693 3.035 Cytochrome P450 (oxidoreductase activity) 
AGAP009197 GSTE3 2.442 3.007 Glutathione s transferase   
AGAP002867 CYP6P4 3.322 2.737 Cytochrome P450 (oxidoreductase activity) 
AGAP009225  2.001 2.372 Oxidoreductase  
AGAP003030  2.052 2.103 dehydrogenase E1 - oxidoreductase activity 
Other         
AGAP010361  6.581 10.79 Chitin binding 
AGAP004785  4.394 7.105 Transport - carrier protein? 
AGAP002810  3.618 4.975 Calcium binding - supercoiling factor? 
AGAP000628  2.569 3.792 tudor - RNA binding/ssDNA binding? 
AGAP012197  2.277 3.777 Histone H3 
AGAP001823  2.166 2.692 Vacuolar (H+)-ATPase G subunit 
AGAP000740  2.503 2.667 Histidine triad protein (HIT) 
AGAP008403  2.106 2.303 serine-type endopeptidase activity 
AGAP006669  2.879 2.094 
multiple domains - DNA 
binding/atrophin/antifreeze/proline 
rich/eggshell protein/voltage gated K 
channel/ELM2 
AGAP006948  0.393 0.5 P25-alpha tubulin polymerisation (?) 
AGAP007237  0.484 0.462 Peroxidasin (with LRR repeats) 
AGAP012029  0.495 0.45 WD-40 repeat containing protein 
AGAP012067  0.463 0.435 calcium ion binding 
AGAP001392  0.487 0.388 Enhanser of split-like 
AGAP007349  0.435 0.348 Tropoelastin/annexin  
AGAP000279 OBP8 0.461 0.337 oderant binding protein 
Unknown         
AGAP003358  6.674 9.718 Unknown 
  
 225 
AGAP008923  7.193 7.605 Unknown 
AGAP003713  4.086 6.599 Twist protein family - unknown function 
AGAP004787  2.568 5.295 Unknown 
AGAP006207  2.879 4.814 Unknown 
AGAP010266  2.615 4.207 Unknown 
AGAP003764  3.683 3.997 Unknown 
AGAP012536  2.167 3.606 Unknown 
AGAP006398  3.279 3.507 Unknown 
AGAP006449  2.413 3.467 Unknown 
AGAP012127  2.801 3.372 Unknown 
AGAP007021  2.394 3.326 Unknown 
AGAP007641  2.164 3.251 unknown  
AGAP008192  2.381 3.104 Unknown 
AGAP004587  2.489 2.895 Unknown 
AGAP011518  2.43 2.714 ATP binding cassette 
AGAP007149  2.585 2.706 Unknown 
AGAP003834  2.119 2.662 Unknown 
AGAP000103  2.206 2.486 Unknown 
AGAP000669  2.104 2.183 Unknown 
 
Table 2.  Genes regulated by dsRNA 
 
AGAP Name dsRNA 
ssRNA 
ratio 
ssRNA p 
value Putative function 
Immunity           
AGAP006645  4.22 2.11006667 
poor P 
value LRR 
AGAP011503  3.662 1.558 0.412 LRR 
AGAP002857 ML5 2.629 1.489 0.094 MD-2-related lipid-recognition 
AGAP009213 SRPN16 2.179 1.432 0.110 serine protease inhibitor 
AGAP009221 SRPN5 2.127 1.384 0.258 serine protease inhibitor 
AGAP007407 CTLMA4 2.117 1.69311111 
good p 
value sugar binding 
AGAP001212 PGRPLB1 2.032 1.406 0.409 
peptidoglycan recognition 
protein 
AGAP006348 LRIM1 0.495 0.642 0.063 LRR 
AGAP011294 DEF1 0.4945 0.71425 
poor P 
value Defensin 
AGAP009212 SRPN6 0.45125 0.65211111 
poor P 
value inhibitory serine protease 
AGAP010869 FREP30 0.44375 0.46216667 
poor P 
value Fibrinogen-like 
AGAP004981 PPO4 0.441 lost #N/A prophenoloxidase 
AGAP011974 SCRC1 0.4342 0.65988889 
good p 
value Scavenger receptor 
AGAP010774 FREP27 0.415 0.84757143 
poor P 
value Fibrinogen-like 
AGAP006258 PPO2 0.387 0.671 0.320 prophenoloxidase 
AGAP011307 FREP3  0.206 0.318 0.066 Fibrinogen-like 
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Signalling           
AGAP010233  2.691 1.995 0.068 
multiple domains - integrin beta 
subunit/EGF-like region/von 
Williebrand factor, Type A 
AGAP007654  2.658 lost #N/A GTPase (Ras/Rab/Rho) 
AGAP002119  2.336 1.948 0.058 
Dual specificity tyrosine-
phosphorylation-regulated 
kinase 
AGAP008235  2.284 1.584 0.003 Zinc-finger, DNA binding 
AGAP006355  2.281 1.642 0.020 
transcription initiation factor IIE, 
alpha subunit 
AGAP000107  2.063 1.473 0.155 ion transport/ankyrin domains 
AGAP008708  0.474 0.592 0.051 
tyrosine phosphatase (de-
phosphorylation) 
Metabolism - general         
AGAP000219  3.238 1.852 0.193 
microtubule cytoskeletal 
organisation 
AGAP010229  4.968 4.237 0.061 
nitrogen metabolism  - aliphatic 
nitrilase 
AGAP006962  4.556 3.408 0.097 acid phosphatase activity 
AGAP001600  3.61 2.643 0.065 
5'nucleotidase / hydrolyase 
activity 
AGAP003664  3.293 2.673 0.063 metalopeptidase activity 
AGAP007028  2.943 2.377 0.071 
transferase activity, transferring 
glycosyl/hexosyl groups 
AGAP006670  2.421 2.168 0.062 gamma-glutamyl hydrolase 
AGAP012399  2.283 1.728 0.212 
carbohydrate metabolism, 
cation binding 
AGAP008686  2.275 1.873 0.084 
epoxide hydrolase 
activity/response to 
toxin/microsome/membrane 
AGAP003688  2.226 1.905 0.005 
Aromatic amino acid beta-
eliminating lyase/threonine 
aldolase 
AGAP010164  2.188 1.967 0.008 
CARNITINE O 
PALMITOYLTRANSFERASE 
AGAP011061  2.167 1.704 0.028 
Phosphotriesterase-related 
protein  
AGAP007590  2.124 1.841 0.003 carbohydrate kinase 
AGAP002055  2.124 1.841 0.003 
BETA GALACTOSIDASE 
PRECURSOR 
AGAP011183  2.101 1.585 0.039 
OXYSTEROL BINDING RELATED 
11 
AGAP003148  2.083 1.966 0.024 
peptide-modifying enzyme 
component 
AGAP005750  2.066 1.431 0.061 
UDP-glucuronosyl/UDP-
glucosyltransferase 
AGAP006371  2.059 1.37 0.061 
Glycoside hydrolase/Alpha-
amylase  
AGAP003730  2.035 1.458 0.099 
Neutral/alkaline nonlysosomal 
ceramidase (phospholipid 
generation (?)) 
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AGAP011859  0.49 0.626 0.012 Glycoside hydrolase, family 2 
AGAP005066 Q6WLH5_ANOGA 0.484 0.566 0.018 
Carbonic anhydrase (carbonate 
dehydratase activity) 
AGAP012656  0.48 0.686 0.123 
Carbonic anhydrase (carbonate 
dehydratase activity) 
AGAP000162  0.469 0.607 0.035 cysteine synthase 
AGAP011939 Q17032_ANOGA 0.454 0.644 0.065 
Glycosyl hydrolase, family 13, 
catalytic region 
AGAP008596  0.422 0.564 0.005 
AMP-dependent synthetase and 
ligase 
AGAP002198  0.421 0.548 0.064 Glycine N-methyltransferase 
AGAP011569  0.41 0.517 0.032 Phospholipase_A2_met 
AGAP011984  0.391 0.505 0.026 Glycosyl transferase, family 2 
Metabolism - 
redox           
AGAP002865  3.667 2.246 0.082 
Cytochrome P450 
(oxidoreductase activity) 
AGAP004383 GSTD10 2.275 1.873 0.084 Glutathione S-transferase 
AGAP005948  2.171 1.871 0.015 kynurenine 3-monooxygenase 
AGAP006132  2.006 1.431 0.061 
Glutathione S-transferase, N-
terminal 
AGAP012291  0.47 0.606 0.010 
Cytochrome P450, E-class, 
CYP3A 
Other           
AGAP010861  2.918 1.975 0.009 
neurotransmitter 
transport/sodium dependent aa 
transporter 
AGAP008335  2.846 2.401 0.065 general substrate transporter 
AGAP005653  2.496 1.561 0.191 
amino acid transmembrane 
transporter 
AGAP003295  2.352 1.942 0.070 DNAse II 
AGAP008738  2.231 1.55 0.099 
(from drosophila) RNA 
binding/inhibition of translation 
AGAP003733  2.217 1.448 0.029 
Cellular retinaldehyde 
binding/alpha-tocopherol 
transport 
AGAP006934  2.196 1.98 0.002 
Tropomyosin/voltage gated K 
channel domains 
AGAP009381  2.162 1.857 0.017 
Cellular retinaldehyde 
binding/alpha-tocopherol 
transport 
AGAP008578  2.122 1.82 0.014 
Vasa-like ATP dependent RNA 
helicases 
AGAP005776 PDH 2.034 1.722 0.104 pigment dispersing hormone 
AGAP007119  2.03 1.4 0.258 sideroflexin/ion carrier 
AGAP000633  2.023 1.691 0.034 testis specific protein 
AGAP010344  2.006 1.431 0.061 sulphate transporter 
AGAP012107  2.052 1.495 0.013 unbiquitin conjugating enzyme 
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AGAP000793  2.044 2.331 0.065 
E3 UBIQUITIN LIGASE SHPRH 
EC_6.3.2.- EC_3.6.-.- 1 SNF2 
HISTONE LINKER PHD AND RING 
FINGER DOMAIN CONTAINING 
HELICASE 
AGAP005064  2.012 1.419 0.057 
protein family - E3 UBIQUITIN 
LIGASE EC_6.3.2.- RING FINGER 
AGAP009182  0.489 0.513 0.071 Sec61 protein (Fragment) 
AGAP006278  0.489 0.513 0.071 
Insect pheromone/odorant 
binding protein PhBP 
AGAP011870  0.481 0.618 0.018 
Extracellular matirx 
metalloproteinase 
AGAP003703  0.48 0.686 0.123 actin/microtubule binding 
AGAP009791  0.478 0.594 0.026 metallopeptidase, neprilysin-like 
AGAP002248  0.478 0.594 0.026 
microtubule motor (kinesin-
motor region containing), in 
Drosophila meiotic/meitotic 
spindle associated 
AGAP010386  0.474 0.592 0.051 
transmembrane, TRAM1-like, in 
drosophila 
phagocytosis/engulment 
AGAP000376  0.467 0.577 0.019 Transferrin - Iron transport 
AGAP001242  0.462 lost #N/A Immunoglobulin subtype 2 
AGAP012391  0.445 lost #N/A Unknown 
AGAP006718  0.407 0.512 0.005 
sodium:dicarboxylate symporter 
activity 
Unknown           
AGAP004988  3.54 2.553 0.055 Anti-freeze/unknown 
AGAP009473  3.52 2.093 0.155 Unknown 
AGAP007049  3.398 2.357 0.229 Defensin? 
AGAP006067  3.233 2.351 0.087 unknown  
AGAP006102  2.852 2.234 0.249 Unknown 
AGAP007663  2.689 2.164 0.062 Unknown 
AGAP010032  2.678 1.885 0.032 Unknown 
AGAP007529  2.669 2.285 0.055 Unknown 
AGAP001974  2.523 1.843 0.015 Unknown 
AGAP010640  2.318 lost #N/A Anti-freeze/unknown 
AGAP009146  2.245 1.61 0.003 Unknown 
AGAP009145  2.156 1.376 0.461 PA fragment 
AGAP007159  2.125 1.476 0.142 Unknown 
AGAP008410  2.065 1.566 0.167 Unknown 
AGAP005397  2.011 1.282 0.002 Unknown 
AGAP010736  0.5 0.629 0.240 Unknown 
AGAP000014  0.493 0.682 0.107 Unknown 
AGAP005732  0.492 0.602 0.009 Unknown 
AGAP012878  0.491 0.64 0.019 Unknown 
AGAP010839  0.484 0.566 0.018 Unknown 
AGAP000268  0.479 lost #N/A PA-fragment, unknown 
AGAP002034  0.474 0.592 0.051 PA-fragment, unknown 
AGAP010523  0.471 0.611 0.031 Unknown 
AGAP004753  0.467 0.577 0.019 Unknown 
AGAP007997  0.452 0.696 0.052 Unknown 
AGAP012423  0.398 0.6 0.106 Unknown 
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Table 3.  Genes regulated by ssRNA 
 
AGAP Name ssRNA 
dsRNA 
ratio 
dsRNA p 
value Putative function 
Immunity           
AGAP006647  3.71 lost   #N/A LRR 
AGAP000572 CLIPC10 3.09 1.25 
poor p 
value Clip domain serine protease 
AGAP004318 CLIPC3 2.99 lost   #N/A Clip domain serine protease 
AGAP012425  2.09 lost   #N/A LRR 
AGAP004918 Frep63 0.46 0.51 0.01290 Fibrinogen-like 
AGAP009728 FREP42 0.44 lost   #N/A Fibrinogen-like 
AGAP012384  0.42 lost   #N/A LRR 
AGAP007758  0.37 lost   #N/A LRR 
AGAP007345 LYSC3 0.35 lost   #N/A lysozyme 
Metabolism - 
redox           
AGAP005645  3.76 lost   #N/A Oxidoreductase  
AGAP010250  3.03 lost   #N/A Aldo/keto reductase 
AGAP010399  2.68 lost   #N/A 
oxidoreductase activity/FAD 
binding 
AGAP004639  2.67 lost   #N/A Peptidase S1A, chymotrypsin 
AGAP009196 
GSTE3/7 (probe 
maps to both 
genes) 2.20 lost   #N/A Glutathione S-transferase 
AGAP010966 Q5XNS9_ANOGA 0.45 lost   #N/A Cytochrome P450 
Other           
AGAP003168  2.14 1.99 0.04140 
Isocitrate/isopropylmalate 
dehydrogenase 
AGAP006400  2.12 lost   #N/A alkaline phophatase 
AGAP011333  2.05 1.99 0.07260 
Disco-interacting 
protein/catalytic activity 
metabolism 
AGAP004642 NPF 4.62 lost   #N/A 
neuropeptide hormone 
activity 
AGAP004281  3.30 lost   #N/A dsRNA binding 
AGAP010579  3.25 lost   #N/A 
Tyrosyl-DNA 
phosphodiesterase/DNA 
repair 
AGAP004018  2.75 lost   #N/A protein binding 
AGAP007753  2.65 lost   #N/A 
sugar transporter integral to 
membrane 
AGAP011026 Q9UB34_ANOGA 2.46 lost   #N/A 5'nucleotidase, putative (?) 
AGAP012462 CPR147 2.31 1.85 0.01510 
structural constituent of 
cuticle 
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AGAP007588  2.31 1.81 0.01330 
glucosyl/glucuronosyl 
transferases 
AGAP007645  2.25 lost   #N/A protein binding 
AGAP004169  0.50 lost   #N/A Collagen triple helix repeat 
AGAP001537  0.48 lost   #N/A DEAD-like DNA (?) helicases 
AGAP007631  0.46 lost   #N/A adenylate cyclise 
AGAP001657  0.30 lost   #N/A 
hemocyanin oxygen 
transport? 
Unknown           
AGAP006093  5.09 lost   #N/A unknown 
AGAP001661  2.72 lost   #N/A unknown 
AGAP009955  2.70 lost   #N/A unknown 
AGAP008478  2.31 lost   #N/A unknown 
AGAP005492  2.30 lost   #N/A unknown 
AGAP007425  2.28 1.23 0.11700 unknown 
AGAP002160  2.10 1.58 0.00233 unknown 
AGAP005890  2.04 lost   #N/A unknown 
AGAP007365  2.03 lost   #N/A unknown 
AGAP010651  2.01 0.88 0.35500 unknown 
AGAP007081  0.50 lost   #N/A unknown 
AGAP000944  0.50 lost   #N/A PA fragment 
AGAP010838  0.50 lost   #N/A unknown 
AGAP001104  0.47 0.50 0.01190 unknown 
AGAP008878  0.44 lost   #N/A unknown 
AGAP011605  0.41 lost   #N/A PA fragment 
    
 
